Jak kinases and regulations of cytokine signal transduction

ABSTRACT

The invention relates generally to the Jak family of kinases. This includes the DNA and amino acid sequences for Jak 3 kinases. Additionally, the invention concerns expression vectors comprising DNA sequences encoding a Jak 3 kinase and host cell containing such expression vectors.

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY-SPONSORED RESEARCH AND DEVELOPMENT

Part of the work performed during development of this invention utilized U.S. Government funds under Grant No. RO1 DK42932 from the National Institute of Diabetes and Digestive and Kidney Diseases; Grant No. P30 CA21765 from the National Cancer Institute Center Support (CORE); Grant No. RO1 DK42932 from the National Institute of Diabetes and Kidney Diseases; and Grant No. CA58223 from the National Cancer Institute Specialized Program of Research Excellence in Breast Cancer (SPORE). The U.S. Government has certain rights in this invention.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a division of application Ser. No. 08/282,012, filed Jul. 29. 1994, abandoned which is a continuation-in-part of application Ser. No. 08/097,997, filed Jul. 29, 1993 U.S. Pat. No. 5,728,536 which is a continuation-in-part of application Ser. No. 08/118,968, filed Sep. 9, 1993 (abandoned).

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates generally to the Jak family of kinases and their role in the cellular response to the binding of cytokines to their respective receptors. The invention relates more specifically to the cytokine-induced activation of at least one member of a Jak kinase family, to the identification of interactions between specific cytokines and members of the Jak kinase family, and to compounds, compositions and methods relating to the regulation of this interaction.

2. Description of the Background Art

The growth, differentiation and function of eukaryotic cells is regulated in large part by extracellular factors, referred to generally as cytokines herein. These cytokines induce cellular responses by binding to their respective receptors. The receptors for cytokines fall into two major families, the cytokine receptor superfamily and the tyrosine kinase receptor superfamily.

Receptors belonging to the tyrosine kinase receptor superfamily are characterized by the presence of an identifiable cytoplasmic tyrosine kinase domain involved in the transduction of the cytokine-receptor binding signal. Members of this receptor family have been further classified into three structural subgroups (Yarden et al., Ann. Rev. Biochem. 57: 443-478 (1988). Members of the first subgroup are characterized as monomeric with two cysteine rich sequence repeat regions within their extracellular domains and include, e.g., the receptor for epidermal growth factor (EGF) and TGF-α (see, e.g., Ullrich et al., Nature 309: 418-425 (1984)). Members of the second subgroup are characterized as functioning as heterotetramers and include the receptors for insulin (Ullrich, supra, (1985); Ebina et al., Cell 40. 747-758 (1985)) and insulin-like growth factor-1 (IGF-1) (Ullrich et al., EMBO J. 5:2503-2512 (1986)). Members of the third subgroup are characterized by the presence of conserved repeat structures and the interruption of their catalytic domains by long (77-107 amino acids) insertion sequences. This third subgroup includes, e.g., receptors for platelet-derived growth factor (PDGF-R) (Yarden et al., Nature 323:226-232 (1986)) and the colony stimulating growth factor (CSF-1) (Sherr et al., Cell 41: 665-676 (1985)).

Receptors belonging to the cytokine receptor superfamily are characterized by the presence of four positionally conserved cysteines and a WSXWS (SEQ ID No. 1) motif in the extracellular domain The family is also characterized by variably sized cytoplasmic domains that show very limited sequence similarity and which do not contain identifiable motifs that might indicate the signal transducing mechanisms. Members of the cytokine receptor superfamily include the hematopoietic growth factor receptors, receptors for growth hormone, the prolactin receptor, ciliary neurotrophic factor and others (Bazan, Science 257:410-413 (1992)). The receptors for interferon, although more distantly related, have been speculated to have evolved from a progenitor common to this receptor superfamily.

In spite of the lack of catalytic domains, considerable evidence suggests that signal transduction of members of the cytokine receptor superfamily involves tyrosine phosphorylation (Miyajima et al., Annu. Rev. Immunol. 10:295-331 (1992); Metcalf, Nature 339:27-30 (1989)). There is also some evidence that members of this receptor superfamily may utilize common tyrosine phosphorylation pathways for signal transduction. Specifically, binding of hematopoietic growth factors to their respective receptors have been found to induce comparable patterns of tyrosine phosphorylation (Ihle, in Interleukins: Molecular Biology and Immunology, Kishimoto, ed., Karger, Basel, pp. 65-106 (1992)).

While it is widely appreciated that cytokine receptors from both families described above play a key role in cellular growth regulation, little is known about the biochemical cascades triggered by the binding of cytokines to these receptors. An understanding of the steps involved in the transduction of the cytokine signal through these receptors would be useful for identifying molecules which play a critical role in signal transduction and which can serve as targets for regulating the activity of these cytokines.

A model for the study of receptor signal transduction has been developed for the erythropoietin receptor (EPOR), one of the hematopoietic growth factor receptors and a member of the cytokine receptor superfamily. Introduction of the EPOR into interleukin-3 (IL-3) dependent cell lines confers on the cells the ability to proliferate in response to EPO (D'Andrea et al., Cell 57:277-285 (1989); Miura et al., Mol. Cell Biol. 11:4895-4902 (1991)). In transfected cells, EPO induces the expression of a series of immediate early genes including c-myc, c-fos, c-pim-1 and egr-1 (Miura et al., Mol. Cell. Biol. 13:1788-1795 (1993)). In addition, EPO induces the rapid tyrosine phosphorylation of a series of cellular substrates (Linnekin et al., Proc. Natl. Acad. Sci. USA 89:6237-6241 (1992); Dusanter-Fourt et al., J. Biol. Chem. 267:10670-10675 (1992); Quelle and Wojchowski, J. Biol. Chem. 266:609-614 (1991); Miura et al., Mol. Cell Biol. 11:4895-4902 (1991); Yoshimura and Lodish, Mol. Cell. Biol. 12:706-715 (1992); Damen et al., Blood 80:1923-1932 (1992)), suggesting that EPOR may function by coupling ligand binding to the activation of a protein tyrosine kinase.

Although the importance of protein tyrosine phosphorylation for biological activities associated with EPO-EPOR binding has been clearly demonstrated, very little has been known concerning the kinases that might be involved. The rapid induction of tyrosine phosphorylation of the carboxyl region of EPOR (Miura et al., Mol. Cell Biol. 11:4895-4902 (1991): Yoshimura and Lodish, Mol. Cell. Biol. 12:706-715 (1992); Dusanter-Fourt et al., J. Biol. Chem. 267:10670-10675 (1992)) suggests that the receptor is closely associated with a kinase, either constitutively or following ligand binding. One study (Yoshimura and Lodish, Mol. Cell Biol. 12:706-715 (1992)) identified a non-glycosylated protein of 130 kDa that could be cross-linked with the receptor and which was tyrosine phosphorylated either in vivo or in in vitro kinase assays as assessed by its ability to be detected by an anti-phosphotyrosine antibody. Whether the 130 kDa protein was a kinase could not be determined. Recent studies (Linnekin et al., Proc. Natl. Acad. Sci. USA 89:6237-6241 (1992)) also identified a 97 kDa substrate of tyrosine phosphorylation which could be radiolabeled with an azido derivative of ATP, suggesting that it was a kinase. Whether the 130 kDa or 97 Kda potential kinases are previously characterized kinases was not determined.

Tyrosine phosphorylation has also been observed in response to the cytokine interferon gamma (IFNγ). Recent studies (Shuai et al., Science 259:1808-1812 (1992)) have demonstrated that IFNγ induces tyrosine phosphorylation of a 91 kDa protein, and that this 91 kDa protein migrates to the nucleus and binds a γ-activated site.

Tyrosine phosphorylation has further been associated with the response to the cytokine growth hormone (GH). Studies in 3T3-F442A cells showing rapid GH-dependent tyrosyl phosphorylation of multiple proteins, tyrosyl phosphorylation of microtubule-associated protein kinases, and stimulation of microtubule-associated protein kinase activity, as well as the inhibition of these actions by inhibitors of growth hormone receptor (GHR)-associated tyrosine kinase (Campbell et al., J. Biol. Chem. 268:7427-7434 (1993)), suggest a central role for a GHR-associated tyrosine kinase activity in signaling by GH. In addition, the presence of a tyrosine kinase activity in a complex with GH receptor (GHR) prepared from GH-treated fibroblasts has been reported (Carter-Su. et al., J. Biol. Chem. 264:18654-18661 (1989); Stred et al., Endocrinol. 130:1626-1636 (1992); Wang et al., J. Biol. Chem. 267:17390-17396 (1992)). More recently, a nonreceptor tyrosyl phosphorylated 122 kd protein was identified in a kinase-active GH-GHR preparation (Wang et al., J. Biol. Chem. 268:3573-3579 (1993)).

To identify the spectrum of protein tyrosine kinases that are expressed in IL-3-dependent cells which might be involved in signal transduction, polymerase chain reactions (PCR) have been done with degenerative oligonucleotides to conserved protein tyrosine kinase domains (Wilks, Methods Enzymol. 200:533-546 (1991)). Using this approach and Northern blot analysis, IL-3 dependent cells have been shown to express the genes for a number of protein tyrosine kinases including lyn, Tec, c-fes, Jak1 and Jak2 (Mano et al., Oncogene 8:417-424 (1993)). Whether these tyrosine kinases, or other as yet unidentified tyrosine kinases, are involved in cytokine signal transduction is largely unknown.

The potential involvement of lyn kinase in signal transduction was indicated by a recent studies that indicated that IL-3 stimulation increased lyn kinase activity in immune precipitates (Torigoe et al., Blood 80:617-624 (1992)).

Two of the other tyrosine kinases expressed in IL-3dependent cells, Jak1 and Jak2, belong to the Jak family of kinases. The Jak (Janus kinase; alternatively referred to as just another kinase) family of kinases were initially detected in PCR amplification of tyrosine kinase domains in hematopoietic cells (Wilks, Proc. Natl. Acad. Sci. USA 86:1603-1607 (1989)). These studies identified two closely related genes (FD17 and FD22; later termed Jak2 and Jak1) from which the major PCR amplification products were derived. The complete structure of the human Jak1 gene has been reported (Wilks et al., Mol. Cell. Biol. 11:2057-2065 (1991)) and, recently, a partial sequence of the murine Jak2 gene was published (Harpur et al., Oncogene 7:1347-1353 (1992)). Independently a third member of the family (Tyk2) was isolated by screening a cDNA library with a tyrosine kinase domain probe from the c-fms gene (Firmbach-Kraft et al., Oncogene 5:1329-1336 (1990)). The family is characterized by the presence of two kinase domains, one of which is a carboxyl domain that has all the hallmarks of protein kinases. The second domain is immediately amino terminal and bears all the hallmarks of a protein kinase but differs significantly from both the protein tyrosine and serine/threonine kinases. Amino terminal to the kinase domains, there are no SH2 and SH3 domains that characterize most of the non-receptor tyrosine kinases. However, there is extensive similarity in this region among the Jak family members and a number of homology domains have been defined (Harpur et al., Oncogene 7:1347-1353 (1992)).

A link between one member of the Jak family of kinases and the signal transduction of interferon alpha (IFNα) has been recently reported (Velazquez et al., Cell 70:313-322 (1992); Fu, Cell 70:323-335 (1992); Schindler et al., Science 257:809-813 (1992)). Using a genetic approach, the Tyk2 gene was cloned by its ability to functionally reconstitute the cellular response to IFNα in a mutant human cell line that was unresponsive to IFNα. No other link between Tyk2, or any other member of the Jak kinase family, and the signal transduction of any cytokine other than IFNα has been reported.

Ciliary neurotrophic factor (CNTF), as its name implies, is a protein that is specifically required for the survival of embryonic chick ciliary ganglion neurons in vitro (Manthorpe et al., J. Neurochem. 34:69-75 (1980)). CNTF has been cloned and synthesized in eukaryotic as well as bacterial expression systems, as described in International Application No. PCT/US90/05241, filed Sep. 14, 1990 by Sendtner et al., incorporated by reference in its entirety herein.

Over the past decade, a number of biological effects have been ascribed to CNTF in addition to its ability to support the survival of ciliary ganglion neurons. CNTF is believed to induce the differentiation of bipotential glial progenitor cells in the perinatal rat optic nerve and brain (Hughes et al., Nature 335:70-73 (1988)). Furthermore, it has been observed to promote the survival of embryonic chick dorsal root ganglion sensory neurons (Skaper and Varon, Brain Res. 389:39-46 (1986)).

Several novel activities of CNTF have also been discovered, including its ability to support the survival and differentiation of motor neurons and hippocampal neurons, and to increase the rate of hippocampal astrocyte proliferation (International Application No. PCT/US 90/05241, supra).

The CNTF receptor (CNTFR or CNTFRα) has been cloned and expressed in eukaryotic cells, as described in International Application No. PCT/US91/03896, filed Jun. 3, 1991, incorporated herein by reference in its entirety.

The sequence of CNTFR reveals that, unlike most receptors which contain an extracellular domain, a hydrophobic transmembrane domain, and a cytoplasmic domain, CNTFR does not appear to have a cytoplasmic domain. Additionally, the transmembrane hydrophobic domain is proteolytically processed, with the mature form of CNTFR becoming anchored to the cell surface by an unconventional linkage, referred to as a glycophosphatidyl inositol (GPI) linkage (Id.). GPI-linked proteins such as CNTFR may be released from the cell surface through cleavage of the GPI anchor by the enzyme phosphatidylinositol-specific phospholipase C. Of other known receptor sequences, CNTFR is related to a number of receptors, referred to herein as the CNTF/IL-6/LIF receptor family, including IL-6, LIF, G-CSF and oncostatin M (OSM) (Bazan, Neuron 7:197-208 (1991); Rose and Bruce, Proc. Natl. Acad. Sci. 88:8641-8645, (1991)), but appears to be most closely related to the sequence of the receptor for IL-6. However, IL-6 has not been shown to be a GPI-linked protein (e.g., Taga et al., Cell 51:573-581 (1989); Hibi et al., Cell 63:1149-1157 (1989)).

The cloning, sequencing and expression of the CNTF receptor (CNTFR) led to the discovery that CNTFR and CNTF may for a complex that interacts with a membrane bound, signal transducing component, thus suggesting therapeutic activity of a soluble CNTF/CNTFR receptor complex.

One such signal transducing component involved in high affinity binding of CNTF and the subsequent functional response of the cell has been identified as gp130, a β component common to the IL-6, OSM, LIF family of receptors (Fukunaga et al., EMBO J. 10:2855-2865 (1991); Gearing et al., EMBO J. 10:2839-2848 (1991); Gearing et al., Science 255:1434-1437 (1992); Ip et al., Cell 69:1121-1132 (1991)). A further β component identified as being involved in binding and signal transduction in response to LIF (LIFRβ) appears to be the same or similar to a β component necessary for response to CNTF. (As a consequence of the identification of β components necessary for binding and signal transduction of CNTF, what was originally generally termed CNTFR is currently referred to as CNTFRα).

IL-6 is a pleiotropic cytokine which acts on a wide variety of cells, exerting growth promotion and inhibition and specific gene expression sometimes accompanied by cellular differentiation; it has been implicated as being involved in several diseases including inflammation, autoimmunities and lymphoid malignancies Kishimoto et al., Science 258:593 (1992)). LIF, G-CSF and OSM are all broadly acting factors that, despite having unique growth-regulating activities, share several common actions with IL-6 during hemopoiesis as well as in other processes. For example, all can inhibit the proliferation and induce the differentiation of the murine myeloid leukemia cell line, M1 (Rose and Bruce, Proc. Natl. Acad. Sci. 88:8641-8645 (1991)). LIF and OSM induced tyrosine phosphorylations and gene activation in neuronal cells which are indistinguishable from responses induced by CNTF (Ip et al., Cell 69:1121-1132 (1992)).

Although the events surrounding CNTF binding and receptor activation have recently been elucidated (Davis et al., Science 253:59-63 (1991); Ip et al., Cell 69:1121-1132 (1992); Stahl et al., Cell 74:587-590 (1993); Davis et al., Science 260:1805-1018 (1993)), the mechanism by which signal transduction is initiated inside the cell is more poorly understood. Like the other distantly related receptors for the extended cytokine family--which includes Interleukin (IL)-3, IL-5, GM-CSF, G-CSF, EPO, GH, and the interferons ((Bazan, J. F., Proc. Natl. Acad. Sci. USA 87:6934-6938 (1990); Bazan, J. F., Neuron 7:197-208 (1991))--the CNTF receptor β subunits gp130 and LIFRβ do not have protein tyrosine kinase domains in their cytoplasmic regions (Hibi et al., Cell 63:1149-115 (1990); Gearing et al., EMBO J. 10:2839-2848 (1991)). In spite of this, CNTF-induced dimerization of the β subunits somehow result in the rapid accumulation of a set of tyrosine phosphorylated proteins called the CLIPs (Ip et al., Cell 69:1121-1132 (1992)).

Although, as described above, two of the more prominent CLIPs were identified as the β subunits themselves, most of the others have yet to be characterized. The activation of cytoplasmic tyrosine kinase(s) appears to be essential for CNTF action since inhibitors that block the tyrosine phosphorylations also block subsequent downstream events such as gene inductions (Ip et al., Cell 69:1121-1132 (1992)).

A possible clue to the identity of the cytoplasmic tyrosine kinase(s) activated by the CNTF family of factors came from the finding that other distantly related cytokines resulted in the activation of the Jak/Tyk family of kinases (Firmbach-Kraft et al., Oncogene 5:1329-1336 (1990); Wilks et al., Mol. Cell. Biol. 11:2057-2065 (1991); Harpur et al., Oncogene 7:1347-1353 (1992)). This family of nonreceptor cytoplasmic protein tyrosine kinases consists of 3 known members--Jak1, Jak2, and Tyk2--which are all equally related to each other and share the unusual feature of having two potential kinase domains and no Src homology 2 (SH2) domains. Elegant studies involving complementation of a genetic defect in a cell line unresponsive to IFNa resulted in the identification of Tyk2 as a required component of the IFNα signaling cascade ((Velazquez et al., Cell 70:313-322 (1992)). More recently, the receptors for cytokines such as EPO, GM-CSF, and GH were shown to associate with and activate Jak2 (Argetsinger et al., Cell 74:237-244 (1993); Silvennoinen et al., Proc. Nat. Acad. Sci. USA (1993, in press); Witthuhn et al., Cell 74:227-236 (1993)). The kinase was shown to bind to the membrane proximal cytoplasmic region of the receptor, and mutations of this region that prevented Jak2 binding also resulted in the loss of EPO induced proliferation, suggesting that Jak2 plays a critical role in EPO signaling. Jak1 has not been reported to be significantly activated by any of these receptor systems.

The identification of hemopoietic factors that share receptor components with CNTF would enable the utilization of CNTF and its specific receptor components for activation of targeted cells that are normally responsive to such hemopoietic factors.

Citation of any document herein is not intended as an admission that such document is pertinent prior art, or considered material to the patentability of any claim of the present application. Any statement as to content or a date of any document is based on the information available to applicant at the time of filing and does not constitute an admission as to the correctness of such a statement.

SUMMARY OF THE INVENTION

The present invention is based in part upon the discovery that the cellular response to several cytokines, particularly those cytokines which function by binding to members of the cytokine receptor superfamily, is mediated by the activation (i.e. phosphorylation) of a member of the Jak kinase family. According to the present invention, Jak kinases mediate cytokine activity through their tyrosine phosphorylation (i.e. activation) in response to cytokine-receptor binding.

The present invention is also directed to methods for regulating cytokines whose activity is mediated by the activation of a Jak kinase.

The present invention provides methods for inhibiting the cellular response to cytokines whose activity is mediated by activation of at least one Jak kinase activity.

The present invention also provides methods for treating disease conditions caused by an excessive response to a cytokine whose activity is mediated by the activation of a Jak kinase, such as cytokine induced excessive proliferation of eukaryotic cells.

The present invention also provides assays for identifying compositions capable of inhibiting the biological response of a eukaryotic cell to a cytokine whose activity is mediated by the activation of a Jak kinase.

The present invention also provides methods for enhancing the biological response of a eukaryotic cell to a cytokine whose activity is mediated by the activation of a Jak kinase activity.

The present invention further provides antibodies useful for detecting and extracting a particular Jak protein without interfering with its kinase activity.

Particular cytokines are also provided by the present invention whose activity is mediated by at least one Jak kinase.

The present invention is also based on the elucidation of the complete DNA and amino acid sequence for particular Jak kinases, as described herein Accordingly, the present invention also furnishes oligonucleotide probe sequences, and gene sequences coding, for the Jak kinases, expression vehicles containing the gene sequence capable of expressing a portion of, or a full-length sequence of, a Jak kinase, and hosts transformed therewith

Other utilities, features, embodiments and methods of the present invention will be apparent to skilled artisans from the following detailed description and non-limiting examples relating to the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1H

The nucleotide sequence of the Jak2 open reading frame and flanking non-coding regions is shown (SEQ ID No. 8). The single letter amino acid sequence is shown below (SEQ ID No. 9). Nucleotide and amino acid sequence information from the published partial Jak2 cDNA sequence (Harpur et al., Oncogene 7:1347-1353 (1992)) is shown above and below the sequences provided where that information is different. The ATG codons are indicated (*). The arrow (>) above nucleotide 522 designates the 5' end of the reported Jak2 sequence. The arrow ( ) at nucleotide position 2226 indicates the location of a 7 amino acid insert, detected in previous studies (Harpur, supra, (1992)). The nucleotides in parenthesis in the 3' non-coding region were present in the previous studies (Harpur, supra (1992)) and not detected in our studies.

FIGS. 2A-2D

The published amino acid (SEQ ID No. 11) and DNA coding sequence (SEQ ID No. 10) for human Jak1 kinase is shown (Wilks et al., Mol. Cell. Biol. 11: 2057-2065 (1991)). Nucleotide numbering is retained from the published sequence, with the coding sequence beginning at nucleotide 76 and ending at nucleotide 3504.

FIGS. 3A-3E

The published amino acid (SEQ ID No. 13) and DNA coding sequence (SEQ ID No. 12) for human Tyk2 kinase is shown (Firmbach-Kraft et al., Oncogene 5: 1329-1336 (1990)). Nucleotide numbering is retained from the published sequence, with the coding sequence beginning at nucleotide 307 and ending at nucleotide 3867.

FIG. 4

DA-3 cells were removed from growth factors and were either unstimulated (-) or stimulated (+) with IL-3 for 10 min as described in Materials and Methods. Cell extracts were then immunoprecipated with normal rabbit serum (NRS) or the antipeptide antiserum specific for Jak2 in the absence of competing peptide (αJak2) or in the presence of the peptide (30 μgl/ml) to which the antiserum was raised (αJak2+Jak2 peptide) or in the presence of an equivalent amount of the peptide that corresponds to the comparable region of Jak1 (αJak2+Jak1 peptide). The immunoprecipitates were used for in vitro kinase assays as described in Methods and Materials (Example 1). The products of the reactions were resolved by SDS-PAGE, transferred to nitrocellulose and detected by autoradiography (top panel). The blots were subsequently probed with the antiserum against Jak2 (bottom panel).

FIGS. 5A-5E

An alignment of the amino acid sequences of Jak1 (line 1; SEQ ID NO:14)), Tyk2 (line 2; SEQ ID NO:13), and Jak2 (line 3; SEQ ID NO:9)), along with the consensus sequence (line 4) generated using the Intelligenetics computer program "Pileup" is shown (Plurality=2.00; Threshold=1.00; AveWeight=1.00; AveMatch=0.54; AvMisMatch=-0.4).

FIGS. 6A-6C

Amino acid sequence comparisons of the Jak family kinases. The amino sequences of murine Jak1 (SEQ ID NO: 14) (O. Silvennoinen, J. H. Ihle, unpublished data), murine Jak2 (SEQ ID NO. 14)(Silvennoinen, Proc. Natl. Acad. Sci. USA 90:8429-8433 (1993)) and human Tyk2 (SEQ ID NO: 13) (Firmbach-Kraft, et al. Oncogene 5:1329-1336 (1990)) are compared with the murine Jak3 (SEQ ID NO: 16) sequence. Alignments were initially made by computer analysis with an intelligenetics program and were subsequently aligned by inspection. Gaps were introduced to optimize alignment. The consensus alignment indicates positioning in which 3 or 4 of the sequences have an identical amino acid. PCR amplification with degenerate kinase domain primers and cDNA from primary breast cancer tissue was used to identify novel kinases as previously described (Cance et al., Int. J. Cancer 54:571-577 (1993)). The PCR fragment (TK5) was used to screen a mouse pre-B cell cDNA library (Schatz et al., Cell 59:1035-1048 (1989)) by standard techniques. Four cDNA clones were obtained, one of which was near the size of the transcript detected by Northern blots. The nucleotide sequence was determined by dideoxynucleotide, chain termination sequencing (Sanger et al., Proc. Natl. Acad. Sci. USA 74:5463-5467 (1977)) in both directions.

FIGS. 7A-B

In vitro translation of cDNAs for Jak family members and characterization of antisera. FIG. 7A: cDNAs for murine Jak1, Jak2 and Jak3 and human Tyk2 were transcribed and translated in vitro utilizing the Promega (Madison, Wis.) TNT T3 coupled reticulocyte system and labeled with (³⁵ S) methionine as previously described (Silvennoinen, et al., Proc. Nat. Acad. Sci. USA 90:8429-8433 (1993)). The reaction products were subsequently resolved by SDS-PAGE and the proteins detected by autoradiography. FIG. 7B: Characterization of antisera against Jaks. The (³⁵ S) labeled Jak3 protein from the in vitro translation reactions with a preimmune serum (lane 1), an antipeptide antiserum against Jak3 (lane 2), the antiserum against Jak3 in the presence of excess peptide (100 μg/ml) to which the antiserum was raised (lane 3) or an irrelevant peptide (lane 4). The antipeptide antiserum was raised against the peptide AKLLPLDKDYYVVREPG (SEQ ID NO: 15) derived from a region of the kinase domain of Jak3 by previously described techniques (Silvennoinen, Proc. Natl. Acad. Sci. USA 90:8429-8433 (1993)). The cross-reactive, antipeptide antiserum was made against a synthetic peptide derived from Tyk2 (SPSEKEHFYQAQHRLPEPS (SEQ ID NO:7).

FIG. 8

Jak3 expression in murine cell lines. RNA was prepared from the indicated cells by previously described techniques 1. Approximately 15 μg of total RNA was resolved by electrophoresis and blotted to filters for hybridization. The RNAs included (lane 1) an IL-3 dependent myeloid cell line (DA3); (lane 2) an IL-3 dependent myeloid cell line, 32D(Epo1), that expresses the endogenous EPO receptor and expresses differentiated functions in response to EPO (Migliaccio et al., J. Cell Biol. 109:833-841 (1989)); (lane 3) an IL-3 dependent myeloid cell line, 32Dc13, that can differentiate along the granulocytic pathway in response to G-CSF (Migliaccio et al., J. Cell Biol. 109:833-841 (1989)); (lane 4) NIH 3T3 fibroblasts transfected with the wild-MV EPO receptor; and (lane 5) a clone of an IL-2 dependent cytotoxic T cell line that was stably transfected with the EPO receptor, CTLLpoR. The position of migration of RNA standards are shown. The single Jak3 transcripts migrates with an apparent size of 4.0 kb. RNA samples were obtained from cells by standard procedures. The RNA samples were electrophoresized on 2.2 M formaldehyde-1% agarose gels and transferred to Zeta bind (NEN) membranes. The probe consisted of a 1 kb SstI fragment of the CDNA, labeled by random priming. The filters were hybridized at 65° in 750 mM NaCl, 1 mM EDTA, 10 mM Tris-HCL pH 7.5, 10% ficoll, 1% polyvinylpyrrolidone, 0.1% SDS and 100 μg/ml salmon sperm DNA. The filters were washed to a final strigency of 15 mM NaCl at 65° and exposed for 14 hours.

FIGS. 9A-D

IL-2 and IL-4 stimulation of Jak1 and Jak3 tyrosine phosphorylation and activation of Jak3 in vitro kinase activity. FIG. 9A: CTLL cells were deprived of growth factors for 14 hr and were either left unstimulated (lanes 1, 4, 7 and 10), were stimulated with 100 U/ml with IL-2 (Cetus) for 10 min (lanes 2,5,8 and 11) or were stimulated with 100 ng/ml of IL-4 (R&D) for 10 min (lanes 3, 6, 9 and 12). Extracts were prepared as previously described (Witthuhn et al., Cell:227-236 (1993)) and used for immunoprecipitation with the indicated antisera. The immunoprecipitates were resolved by SDS-PAGE, electrophoretically transferred to nitrocellulose and the membranes were probed with the 4G10 monoclonal antibody (UBI) against phosphotyrosine. FIG. 9B: CTLL cells were deprived of growth factors for 14 hr and were either unstimulated (lane 1), stimulated with IL-2 (lane 2) or stimulated with IL-4 (lane 3) as above. Extracts were prepared and used for immunoprecipitation with the Jak3/Jak1 cross-reactive antipeptide antiserum against Tyk2. The immunoprecipitates were used in in vitro kinase essays as previously described (Witthuhn et al., Cell:227-236 (1993)) and the products resolved by SDS-PAGE and visualized by autoradiography. FIG. 9C: 32Dcl3 cells transfected with the human IL-2 β receptor chain (32D/IL-2Rβ) were deprived of IL-2 for 14 hr and either not stimulated (lane 1 and 4) or stimulated with 100 U/ml of IL-2 (lanes 2 and 5) or 10 U/ml of IL-3 and 6). Extracts were made, resolved by SDS-PAGE and transferred to filters as above. The filters were probed with the 4G10 monoclonal antibody for phosphotyrosine. FIG. 9D: CTLL cells transfected with the EPO receptor were deprived of IL-2 for 14 hr and were either left unstimulated (lanes 1 and 5), were stimulated with 100 U/ml of IL-2 (lanes 21 and 6), 100 ng/ml of IL-4) or 10 U/ml of EPO (lanes 4 and 7). Extracts were prepared and blots obtained as above and probed with the 4G10 monoclonal antibody against phosphotyrosine. The positions of migration of standards are shown on the left. Cells were harvested and extracts prepared in 0.1% triton as previously described (Witthuhn et al., Cell:227-236 (1993)). Cell extracts from 2×10⁷ cells were used for immunoprecipitations with the designated antisera and the complexes collected with protein A SEPHAROSE. The immunoprecipitates were subjected to SDS-PAGE and electrophoretically transferred to nitrocellulose filters. Filters were probed with the 4G10 monoclonal antibody (Upstate Biologicals Inc.) against phosphotyrosine. Detection was done by enhanced chemiluminescence, ECL (Amersham) and exposure to film. The conditions for the in vitro kinase assays are as previously described (Witthuhn et al., Cell:227-236 (1993)).

DETAILED DESCRIPTION OF THE INVENTION

The present invention is in part directed to novel methods for regulating the cellular response to cytokines. These methods are based upon the general role of a Jak family of kinases in the cellular response to cytokines.

By "cytokine" is meant any polypeptide secreted by cells that affects the function, such as survival, mitosis, differentiation or metabolism, of other cells. Examples of cytokines include, but are not limited to, peptide hormones and growth factors.

By "cellular response to a cytokine" or "cytokine activity" is meant the general biological effect upon a eukaryotic cell or cell population which ultimately results from the association of a particular cytokine with its cellular receptor and typically involves the modification of gene expression within the cell. The invention relates to cytokine activity which is mediated by the activation of a Jak kinase. Examples of such activity include, but are not limited to, the proliferation and differentiation of hematopoietic progenitor cells in response to interleukin-3 (IL-3), the proliferation and differentiation of erythroid lineage cells in response to erythropoietin (EPO), somatic cell growth in response to growth hormone (GH), and other similar responses as known in the art, and/or as taught herein.

The methods taught by the invention apply to any cytokine whose activity is mediated by a member of the Jak kinase family, which includes, but is not limited to, Jak1, Jak2, Jak3 and Tyk2. Cytokines of this type include those which function by binding to members of the cytokine receptor superfamily, and also those which function by binding to members of the tyrosine kinase receptor superfamily. More specifically, these cytokines include, but are not limited to, at least one selected from the group consisting of interleukin-3 (IL-3), interleukin 2 (IL-2), interleukin 4 IL-4), interleukin 5 (IL-5), interleukin 6 (IL-6), interleukin 7 (IL-7), interleukin 9 (IL-9), interleukin 11 (IL-11), oncostatin M (OSM), leukemia inhibitory factor (LIF), granulocyte-macrophage specific colony stimulating factor (GM-CSF), erythropoietin (EPO), granulocyte colony stimulating factor (G-CSF), interferon-γ (IFN-γ), prolactin hormone and growth hormone.

According to the invention, Jak kinases mediate cytokine activity through their tyrosine phosphorylation (i.e. activation) in response to cytokine-receptor binding. Thus, cytokines susceptible to the methods of regulation provided by the present invention may be identified on the basis of their ability to cause the tyrosine phosphorylation (i.e. activation) of one or more members of the Jak kinase family. Tyrosine phosphorylation of a Jak kinase in a cell following cytokine stimulation may be detected, for example, by assaying for its ability to bind antiphosphotyrosine monoclonal antibody; only tyrosine phosphorylated Jak kinases will bind this type of antibody. Alternatively, in vitro kinase assays as described below may be used to determine the state of activation (tyrosine phosphorylation) of a Jak kinase in a cell following cytokine stimulation.

Jak Kinase Peptides (JKP). A Jak kinase peptide (JKP), according to the present invention, can refer to any subset of a Jak kinase (JK) having JK activity. A peptide fragment according to the present invention can be prepared by proteolytic digestion of the intact molecule or a fragment thereof, by chemical peptide synthesis methods well-known in the art, by recombinant DNA methods discussed in more detail below, and/or by any other method capable of producing a JKP and having a conformation similar to an active portion of JK and having Jak kinase activity, according to known Jak activity as screening assays, e.g., as described herein. The minimum peptide sequence to have activity is based on the smallest unit containing or comprising a particular region, consensus sequence, or repeating unit thereof of a JK having Jak kinase activity, i.e., ability to be phosphorylated at least one tyrosine by at least one cytokine.

Accordingly, a JKP of the present invention alternatively includes polypeptides having a portion of a JK amino acid sequence which substantially corresponds to at least one 15 to 400 amino acid fragment and/or consensus sequence of a known Jak kinase or group of JKs, wherein the JKP has homology of at least 80%, such as 80-99% homology, or any range or value therein, while maintaining Jak kinase biological activity, wherein a JKP of the present invention is not naturally occurring or is naturally occurring but is in a purified or isolated form which does not occur in nature. Preferably, a JKP of the present invention substantially corresponds to a Jak kinase domain of particular Jak kinase, or group of Jak kinases, as a consensus sequence, such as between Jak1 and Jak2.

Percent homology may be determined, for example, by comparing sequence information using the GAP computer program, version 6.0, available from the University of Wisconsin Genetics Computer Group (UWGCG). The GAP program utilizes the alignment method of Needleman and Wunsch (J. Mol. Biol. 48:443 (1970), as revised by Smith and Waterman (Adv. Appl. Math. 2:482 (1981). Briefly, the GAP program defines similarity as the number of aligned symbols (i.e., nucleotides or amino acids) which are similar, divided by the total number of symbols in the shorter of the two sequences. The preferred default parameters for the GAP program include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non-identities) and the weighted comparison matrix of Gribskov and Burgess, Nucl. Acids Res. 14:6745 (1986), as described by Schwartz and Dayhoff, eds., ATLAS OF PROTEIN SEQUENCE AND STRUCTURE, National Biomedical Research Foundation, pp. 353-358 (1979); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps.

In a preferred embodiment, the peptide of the present invention corresponds to an active portion of a sequence of FIG. 6.

A peptide of at least about 5-335 amino acids (or any range or value therein) that has the basic structure of the active portion of a JK can, in one embodiment, be characterized as having 80-99% homology (or any range or value therein) to the above JK sequences, which peptide can have JK activity and is contemplated within the scope of the present invention. Thus, one of ordinary skill in the art, given the teachings and guidance presented in the present specification, will know how to substitute other amino acid residues in other positions of a JK to obtain a JKP, including substituted, deletional or insertional variants.

A JKP of the present invention also includes a variant wherein at least one amino acid residue in the polypeptide has been conservatively replaced, inserted or deleted by at least one different ammo acid.

An amino acid or nucleic acid sequence of a JKP of the present invention is said to "substantially correspond" to another amino acid or nucleic acid sequence respectively, if the sequence of amino acids or nucleic acid in both molecules provides polypeptides having biological activity that is substantially similar, qualitatively or quantitatively, to the corresponding fragment of at least one JK domain having JK activity. Such "substantially corresponding" JKP sequences include conservative amino acid or nucleotide substitutions, or degenerate nucleotide codon substitutions wherein individual amino acid or nucleotide substitutions are well known in the art.

Accordingly, JKPs of the present invention, or nucleic acid encoding therefor, include a finite set of substantially corresponding sequences as substitution peptides or polynucleotides which can be routinely obtained by one of ordinary skill in the art, without undue experimentation, based on the teachings and guidance presented herein. For a detailed description of protein chemistry and structure, see Schulz, G. E. et al., Principles of Protein Structure, Springer-Verlag, New York, 1978, and Creighton, T. E., Proteins: Structure and Molecular Properties, W. H. Freeman & Co., San Francisco, 1983, which are hereby incorporated by reference. For a presentation of nucleotide sequence substitutions, such as codon preferences, see Ausubel et al., eds, Current Protocols in Molecular Biology, Greene Publishing Assoc., New York, N.Y. (1987, 1988, 1989, 1990, 1991, 1992, 1993, 1994) at §§ A.1.1-A.1.24, and Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1989), at Appendices C and D.

Amino Acid Substitutions of a Native JK for a JKP. Conservative substitutions of a JKP of the present invention includes a variant wherein at least one amino acid residue in the polypeptide has been conservatively replaced, inserted or deleted by at least one different amino acid.

Such substitutions preferably are made in accordance with the following list as presented in Table 1, which substitutions can be determined by routine experimentation to provide modified structural and functional properties of a synthesized polypeptide molecule, while maintaining JK biological activity, as determined by known JK activity assays. In the context of the-present invention, the term JKP or "substantially corresponding to" includes such substitutions.

                  TABLE 1                                                          ______________________________________                                         Original            Exemplary                                                                       Residue Substitution                                      ______________________________________                                         Ala                 Gly; Ser                                                     Arg Lys                                                                        Asn Gln; His                                                                   Asp Glu                                                                        Cys Ser                                                                        Gln Asn                                                                        Glu Asp                                                                        Gly Ala; Pro                                                                   His Asn; Gln                                                                   Ile Leu; Val                                                                   Leu Ile; Val                                                                   Lys Arg; Gln; Glu                                                              Met Leu; Tyr; Ile                                                              Phe Met; Leu; Tyr                                                              Ser Thr                                                                        Thr Ser                                                                        Trp Tyr                                                                        Tyr Trp; Phe                                                                   Val Ile; Phe                                                                 ______________________________________                                    

Accordingly, based on the above examples of specific substitutions, alternative substitutions can be made by routine experimentation, to provide alternative JKPs of the present invention, e.g., by making one or more conservative substitutions of JK fragments which provide JK activity.

Alternatively, another group of substitutions of JKPs of the present invention are those in which at least one amino acid residue in the protein molecule has been removed and a different residue inserted in its place according to the following Table 2. The types of substitutions which can be made in the protein or peptide molecule of the present invention can be based on analysis of the frequencies of amino acid changes between a homologous protein of different species, such as those presented in Table 1-2 of Schulz et al., infra. Based on such an analysis, alternative conservative substitutions are defined herein as exchanges within one of the following five groups:

                  TABLE 2                                                          ______________________________________                                         1.  Small aliphatic, nonpolar or slightly polar residues: Ala, Ser, Thr              (Pro, Gly);                                                                2.  Polar, negatively charged residues and their amides: Asp, Asn, Glu,         Gln;                                                                          3.  Polar, positively charged residues:                                            His, Arg, Lys;                                                             4.  Large aliphatic, nonpolar residues:                                            Met, Leu, IIe, Val (Cys); and                                              5.  Large aromatic residues: Phe, Tyr, Trp.                                  ______________________________________                                    

The three amino acid residues in parentheses above have special roles in protein architecture. Gly is the only residue lacking any side chain and thus imparts flexibility to the chain. This however tends to promote the formation of secondary structure other than α-helical. Pro, because of its unusual geometry, tightly constrains the chain. It generally tends to promote β-turn-like structures, although in some cases Cys can be capable of participating in disulfide bond formation which is important in protein folding. Note that Schulz et al. would merge Groups 1 and 2, above. Note also that Tyr, because of its hydrogen bonding potential, has significant kinship with Ser, and Thr, etc.

Conservative amino acid substitutions, included in the term "substantially corresponding" or "corresponding", according to the present invention, e.g., as presented above, are well known in the art and would be expected to maintain biological and structural properties of the polypeptide after amino acid substitution. Most deletions and insertions, and substitutions according to the present invention are those which do not produce radical changes in the characteristics of the protein or peptide molecule. "Characteristics" is defined in a non-inclusive manner to define both changes in secondary structure, e.g. α-helix or, β-sheet, as well as changes in physiological activity, e.g. in receptor binding assays.

However, when the exact effect of the substitution, deletion, or insertion is to be confirmed, one skilled in the art will appreciate that the effect of the substitution or substitutions will be evaluated by routine JK activity screening assays, either immunoassays or bioassays, to confirm biological activity, such as, but not limited to, Jak kinase.

Amino acid sequence insertions as included in JKP variant can also include amino and/or carboxyl-terminal fusions of from one residue to polypeptides of essentially unrestricted length, as well as intrasequence insertions of single or multiple amino acid residues. Intrasequence insertions can range generally from about 1 to 10 residues, more preferably 1 to 5. An example of a terminal insertion includes a fusion of a signal sequence, whether heterologous or homologous to the host cell, to a JKP to facilitate secretion from recombinant bacterial hosts.

One additional group of variants according to the present invention is those in which at least one amino acid residue in the peptide molecule, and preferably, only one, has been removed and a different residue inserted in its place.

For a detailed description of protein chemistry and structure, see Schulz et al., Principles of Protein Structure, Springer-Verlag, New York, 1978; Ausubel, infra, which are hereby incorporated by reference.

Most deletions and insertions, and substitutions of JKPs according to the present invention are those which maintain or improve the Jak kinase characteristics of the peptide molecule. However, when it is difficult to predict the exact effect of the substitution, deletion, or insertion in advance of doing so, one skilled in the art will appreciate that the effect will be evaluated by routine screening assays. For example, a variant made by site-specific mutagenesis of the peptide molecule-encoding nucleic acid and expression of the variant JKP in cell culture or, alternatively, by chemical synthesis, can be tested for Jak kinase activity (e.g., as is known or as described herein). The activity of the cell lysate or purified peptide variant can be screened in a suitable screening assay for the desired characteristic, for example Jak kinase activity in any of the several assays.

Modifications of peptide properties, such as redox or thermal stability, hydrophobicity, susceptibility to proteolytic degradation or the tendency to aggregate with carriers or into multimers, can also be assayed by methods well known to the ordinarily skilled artisan.

Also included in the scope of the invention are salts of the JKPs of the invention. As used herein, the term "salts" refers to both salts of carboxyl groups and to acid addition salts of amino groups of the protein or peptide molecule.

Amino acid sequence variants of a JKP of the present invention can also be prepared by mutations in the DNA. Such variants include, for example, deletions from, or insertions or substitutions of, residues within the amino acid sequence. Any combination of deletion, insertion, and substitution can also be made to arrive at the final construct, provided that the final construct possesses some Jak kinase activity. Preferably improved Jak kinase activity is found over that of the non-variant peptide. Obviously, mutations that will be made in the DNA encoding the variant must not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure (see, e.g., EP Patent Application Publication No. 75,444; Ausubel, infra; Sambrook, infra).

At the genetic level, these variants ordinarily are prepared by site-directed mutagenesis of nucleotides in the DNA encoding a JKP, thereby producing DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture. The variants typically exhibit the same qualitative biological activity as the naturally occurring JK (see, e.g., Ausubel, infra; Sambrook, infra).

Knowledge of the three-dimensional structures of proteins is crucial in understanding how they function. The three-dimensional structures of more than 400 proteins are currently available in the protein structure database (in contrast to around 200,000 known protein and peptide sequences in sequence databases, e.g., Genbank, Chemical Abstracts REGISTRY, etc.). Analysis of these structures shows that they fall into recognizable classes or motifs. It is possible to model the three-dimensional structure of protein based on homology to a related protein of known structure. Examples are known where two proteins that have relatively low sequence homology, but are found to have almost identical three dimensional structure. Such homologous variants are also included in JKPs of the present invention.

Once a Jak kinase structure or characteristics have been determined using the above analysis, JKPs can be recombinantly or synthetically produced, or optionally purified, to provide commercially useful amounts of JKPs for use in diagnostic or research applications, according to known method steps (see, e.g., Ausubel, infra, and Sambrook, infra, which references are herein entirely incorporated by reference).

Methods for Inhibiting Cytokine Activity Dependent Upon Jak Kinases

According to the invention, the activity of a cytokine may be inhibited by inhibiting the activity of the Jak kinase which mediates that cytokine's effect upon the cell.

One way of inhibiting Jak kinase activity within the scope of the present invention is by inhibiting Jak gene expression. Expression of Jak kinases may be inhibited using antisense molecules or ribozymes.

Antisense molecules and their use for inhibiting gene expression are well known in the art (see, for example, Cohen, J., Oligodeoxyribonucleotides, Antisense Inhibitors of Gene Expression, CRC Press (1989); Toole, WO 92/10590). Antisense molecules useful for inhibiting the expression of a Jak kinase contain nucleic acid sequences complementary to, and capable of binding to, the mRNA and/or DNA gene sequence of the Jak kinase desired to be inhibited. Such antisense molecules may be provided to the cell via genetic expression using DNA encoding the antisense molecule as taught by U.S. Pat. No. 5,190,931, issued Mar. 2, 1993 to Inoue, M. (incorporated by reference herein in its entirety). Alternatively, antisense molecules of the invention may be made synthetically and then provided to the cell. Synthetic antisense molecules contemplated by the invention include oligonucleotide derivatives known in the art which have improved biological activity compared to unmodified oligonucleotides (see, e.g., Cohen, J., supra; U.S. Pat. No. 5,023,243, issued Jun. 11, 1991 to Tullis, R. H. and incorporated by reference herein in its entirety).

Ribozymes and their use for inhibiting gene expression are also well known in the art (see, e.g., Cech et al., J. Biol. Chem. 267: 17479-17482 (1992); Hampel et al., Biochemistry 28: 4929-4933 (1989); Haseloff et al., Nature 334: 585-591 (1988); Eckstein et al., WO 92/07065; and U.S. Pat. No. 5,168,053 issued to Altman et al. and incorporated by reference herein in its entirety). Like antisense molecules, ribozymes contain target sequences complementary to the mRNA of the genes whose expression they are designed to inhibit. Ribozymes useful for inhibiting the expression of a Jak kinase may be designed by incorporating target sequences into the basic ribozyme structure which are complementary to the mRNA sequence of the Jak kinase desired to be inhibited. Ribozymes targeting a Jak kinase may be synthesized using commercially available reagents (Applied Biosystems) or they may be genetically expressed from DNA encoding them.

As will be recognized by the skilled artisan, antisense and ribozyme molecules may be designed to inhibit a specific member of the Jak kinase family by targeting sequences unique to that member. Alternatively, antisense and ribozyme molecules may be designed to inhibit more than one Jak kinase by targeting sequences shared by the Jak members desired to be inhibited.

Jak kinase activity may also be inhibited through the use of compounds or peptides which inhibit the ability of the Jak protein to function as a kinase. Such inhibitors include, but am not limited to, drugs, anti-Jak kinase antibody, Jak kinase agonists and antagonists, trans-dominant mutants of Jak kinase, and general inhibitors of tyrosine kinase activity such as GENESTEIN. These inhibitors may have a general inhibitory effect upon all Jak kinases or they may possess a more specific inhibitory effect upon a specific member or subset of the Jak kinase family.

The term "antibody", as used herein, refers both to monoclonal antibodies which are a substantially homogeneous population and to polyclonal antibodies which are heterogeneous populations. Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The term "antibody", as used herein, is also meant to include both intact molecules as well as fragments thereof, such as, for example, Fab and F(ab')₂, which are capable of binding antigen. Fab and F(ab')₂ fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody (Wahl et al., J. Nucl. Med. 24:316-325 (1983)). Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments). See, generally, Kohler and Milstein, Nature 256:495-497 (1975); U.S. Pat. No. 4,376,110; Ausubel et al., eds., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Greene Publishing Assoc. and Wiley Interscience, N.Y., (1987, 1992, 1993, 1994); and Harlow and Lane ANTIBODIES: A LABORATORY MANUAL Cold Spring Harbor Laboratory (1988); Colligan et al., eds., Current Protocols in Immunology, Greene Publishing Assoc. and Wiley Interscience, N.Y., (1992, 1993), the contents of which references are entirely incorporated herein by reference. Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, GILD and any subclass thereof.

Both monoclonal and polyclonal antibodies to Jak kinase may be made according to methods well known in the art (see, e.g., Harlow, supra; Colligan, supra; Ausubel, supra, at §§11.4.2-11.13.4). Antibodies may be generated against Jak kinase protein produced recombinantly or isolated from cells and tissues where the Jak kinase naturally occurs. Antibodies may be generated against the entire Jak kinase protein or, more preferably, antibodies are generated against peptide subfragments representing functional domains of the Jak kinase protein required for its cytokine-induced tyrosine kinase activity. Antibodies for specifically inhibiting a particular Jak kinase may be generated against peptide fragments unique to that Jak kinase. Alternatively, antibodies for generally inhibiting more than one member of the Jak kinase family may be generated against peptide fragments shared by the Jak kinases desired to be inhibited.

Another method for inhibiting Jak kinase activity taught by the invention is through the use of inhibitors of the cytokine-dependent activation of the Jak kinase. Prior to cytokine stimulation, cellular Jak kinase is present in an inactivated state. Inhibitors of Jak kinase activation may be identified by their ability to inhibit the conversion of the Jak kinase into its catalytically active state, which can be detected by in vitro kinase assay as described below and in the Examples.

As discovered by the present inventors, Jak kinases are activated by their cytokine-induced tyrosine phosphorylation. Accordingly, inhibitors may also be identified according to the invention as those compounds or peptides which block or significantly reduce the cytokine-induced tyrosine phosphorylation of the Jak kinase into its catalytically active form. The state of tyrosine phosphorylation of a Jak kinase following cytokine stimulation may be assayed, for example, by the ability of the Jak kinase to be detected with an antiphosphotyrosine monoclonal antibody.

Activation of a Jak kinase by a particular cytokine may require the physical association of the Jak kinase with the receptor for that cytokine (see Example 2). According to the invention, peptide antagonists mimicking those portions of the Jak kinase or cytokine receptor involved in this association are useful as inhibitors of Jak kinase activation. These peptides are contemplated by the invention to act as inhibitors by associating with either the cytokine receptor (for the Jak kinase peptides) or the Jak kinase (for the cytokine receptor peptides), thus blocking the association of the Jak kinase with the cytokine receptor.

In particular, the invention teaches that Jak2 activation by EPO requires the physical association of Jak2 with the EPO receptor (EPOR) and that this association requires a membrane proximal region of EPOR that is essential for mitogenesis. According to the invention, peptide antagonists mimicking this membrane proximal region and capable of blocking the EPOR-Jak2 interaction are useful as inhibitors of Jak2 activation by EPO.

Assays for Inhibitors of Jak Kinase Activity

The present invention also provides screening assays for identifying inhibitors of Jak kinase activity useful in the methods described herein above.

Jak tyrosine kinase activity can be assayed in vitro by combining catalytically active Jak kinase, a Jak phosphorylation substrate(s), and ATP with the phosphorous at the γ position detectably labelled with, for example, a radiolabel such as ³² P. In this assay, the Jak kinase catalyzes the transfer of the labelled phosphorous from ATP to the substrate and Jak kinase activity is detected by the generation of substrate containing detectably labelled phosphorous (i.e. labelled substrate). Inhibitors of Jak kinase activity are identified as those compounds or peptides which, when incorporated into the assay, significantly reduce or eliminate the generation of labelled substrate.

Catalytically active Jak kinase for use in this assay may be obtained from a variety of sources. Preferably, a catalytically active Jak kinase is obtained from insect cells transformed with a baculovirus vector capable of expressing the Jak kinase at high levels. Jak2 kinase produced in this way has been found to be catalytically active and useful in in vitro kinase assays. It is expected that other Jak kinases produced in large amounts in insect cells in a similar manner will also be catalytically active.

A catalytically active Jak kinase may also be obtained from cells carrying mutations which result in constitutive activation of the Jak kinase. For example, an EPOR mutation known as R¹⁹⁹ to C results in constitutive activation of the EPOR (Yoshimura et al., Nature 348:647-649 (1990)). In cells expressing this mutation, in the absence of EPO, Jak2 kinase is constitutively tyrosine phosphorylated and possesses in vitro kinase activity.

Catalytically active forms of each Jak kinase may also be obtained from cells stimulated with a cytokine which causes their activation. For example, catalytically active Jak2 kinase may be obtained from cells stimulated with EPO, growth hormone, IL-3, and other cytokines, while catalytically active Tyk2 may be obtained from cells stimulated with IFNα.

Any phosphorylation substrate of the Jak kinase whose activity is being determined may be used in the assay. For a Jak kinase which possesses autophosphorylation activity, a preferred substrate is the Jak kinase itself, or a subfragment thereof containing the autophosphorylation site. Tyrosine kinases such as the Jak kinases generally tend to possess autophosphorylation activity (see, for example, Hanks, S. K. et al., Science 241: 42-52 (1988). Moreover, autophosphorylation activity for Jak2 has been established and the autophosphorylation site has been found to reside on a peptide fragment containing amino acids 1000-1015 of Jak2 (see FIGS. 1A-1H; the sequence is VLPQDKEYYKVEPG (SEQ ID No. 2)). Similar peptides fragments exist in the Jak1 protein at amino acids 1015-1029 (see FIGS. 2A-2D; the sequence is AIETDKEYYTVKDDR (SEQ ID NO:3)) and in the Tyk2 protein at amino acids 1047-1061 (see FIG. 3; the sequence is AVPEGHEYYRVREDG (SEQ ID NO:4)). Based on structural and functional similarities among the Jak kinases, as well as functional similarities among tyrosine kinases in general, it is expected that the other members of the Jak kinase family also possess autophosphorylation activity.

The present invention also provides an assay for inhibitors of cytokine-induced activation of a Jak kinase. Cytokine-induced activation of a Jak kinase can be assayed by preparing Jak kinase extracts from cells following cytokine induction and assaying the extracts for in vitro kinase activity as described herein. Inhibitors of cytokine-induced activation of a Jak kinase are identified as those compounds or peptides which, when present in the cells before and/or during cytokine induction, significantly reduce or eliminate the in vitro kinase activity detected in the Jak kinase extracts prepared from the cells following cytokine induction.

The present invention also provides an assay for inhibitors of Jak kinase-cytokine receptor interactions which are potential inhibitors of cytokine-induced Jak kinase activation. For those cytokine receptors which are phosphorylated by an activated Jak kinase, the Jak kinase-cytokine receptor interaction may be detected using the in vitro kinase assay described above by incorporating the cytokine receptor into the assay as the phosphorylation substrate. For example, phosphorylation of the erythropoietin receptor EPOR) by Jak2 kinase may be detected using this assay. Inhibitors of the Jak kinase-cytokine receptor interactions are identified as those compounds or peptides which, when incorporated into this assay, significantly reduce or eliminate the generation of phosphorylated (labelled) cytokine receptor protein.

Cytokine receptor protein is preferably obtained for use in this assay by production and purification from a recombinant host suitable for such purposes as described herein for the production of Jak kinases. A preferable host is insect cells transformed with a baculovirus vector capable of expressing cytokine receptor at high levels. Alternatively, cytokine receptor protein may be isolated from natural sources.

Methods for Enhancing Cytokine Activity Dependent Upon Jak Kinases

In those situations where the biological response of a cell to a cytokine is deficient due to insufficient amounts of a Jak kinase, the present invention provides for enhancing this response by increasing the levels of the Jak kinase in the cell (see Example 4). This situation could be due to mutations which reduce the amount of the Jak kinase produced by the cell to sub-normal levels. This situation could also be due to mutations which reduce the rate or degree of cytokine-induced Jak activation such that the level of Jak kinase produced by the cell does not provide sufficient levels of activated Jak kinase following cytokine induction.

The levels of Jak kinase may be increased in a cell by adding Jak kinase protein to the cell, or by introducing a vector into the cell capable of expressing the Jak kinase. Vectors and methods for the expression of Jak2 are provided below. As will be readily apparent to one of skill in the art, these methods may also be applied to the production and expression of other members of the Jak kinase family.

Therapeutic Applications Of The Methods For Regulating Cytokine Activity

It is also contemplated by the invention that methods provided for regulating Jak kinase activity as described above may be applied to treating disease conditions caused by an abnormal cellular response to a cytokine whose activity is mediated by the activation of a Jak kinase. Thus disease conditions caused by an excessive cellular response to a cytokine whose activity is mediated by the activation of a Jak kinase may be treated by inhibiting Jak kinase activity. In particular, disease conditions caused by excessive proliferation of eukaryotic cells may be treated by inhibiting Jak kinase activity where this excessive proliferation occurs in response to a cytokine whose activity is mediated by the activation of a Jak kinase. Such disease conditions are caused by genetically acquired mutations or spontaneously acquired mutations.

For example, erythrocytosis is a genetically acquired disease that involves excess proliferation of erythrocytes from progenitor cells. The overproduction is dependent upon erythropoietin (EPO) and is caused by a mutation in the EPO receptor (EPOR) that results in the abnormal regulation of Jak2 kinase activity through EPO-EPOR binding. Comparable mutations may also occur spontaneously and give rise to this disease condition. In addition, analogous disease conditions may occur in other cell lineages that are regulated through a Jak kinase mediated cytokine response.

Alternatively, disease conditions caused by a deficient cellular response, or nonresponsiveness, to a cytokine whose activity is mediated by the activation of a Jak kinase may be treated by enhancing Jak kinase activity.

It is contemplated by the invention that administration of the compositions as described herein capable of inhibiting Jak kinase activity, including antisense molecules, ribozymes, Jak antibodies, antagonists, etc. may be accomplished by any of the methods known to the skilled artisan. For example, administration may be by parenteral, subcutaneous, intravenous, intramuscular, intra-peritoneal, or transdermal routes, administered in a pharmaceutically acceptable carrier by any means recognized as suitable by the skilled artisan.

It is understood that the dosage of a pharmaceutical compound or composition of the present invention administered in vivo or in vitro will be dependent upon the age, sex, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the pharmaceutical effect desired. The ranges of effective doses provided herein are not intended to be limiting and represent preferred dose ranges. The most preferred dosage will be tailored to the individual subject, as is understood and determinable by one skilled in the relevant arts. See, e.g., Berkow et al., eds., The Merck Manual, 16th edition, Merck and Co., Rahway, N.J. (1992); Goodman et al., eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th edition, Pergamon Press, Inc., Elmsford, N.Y. (1990); Avery's Drug Treatment: Principles and Practice of Clinical Pharmacology and Therapeutics, 3rd edition, ADIS Press, LTD., Williams and Wilkins, Baltimore, Md. (1987); Ebadi, Pharmacology, Little, Brown and Co., Boston (1985); Osol et al., eds., Remington's Pharmaceutical Sciences, 17th edition, Mack Publishing Co., Easton, Pa. (1990); Katzung, Basic and Clinical Pharmacology, Appleton and Lange, Norwalk, Conn., (1992), which references are entirely incorporated herein by reference.

The total dose required for each treatment can be administered by multiple doses or in a single dose. The diagnostic/pharmaceutical compound or composition can be administered alone or in conjunction with other diagnostics and/or pharmaceuticals directed to the pathology, or directed to other symptoms of the pathology.

Effective amounts of a diagnostic/pharmaceutical compound or composition of the present invention are from about 0.001 μg/kg to about 10 mg/kg body weight, administered at intervals of 4-72 hours, for a period of 2 hours to 5 years, and/or any range or value therein, such as 0.000001-0.0001, 0.0001-0.01, 0.01-1.0, 1-10, 10-50 and 50-100, 0.000001-0.00001, 0.00001-0.0001, 0.0001-0.001, 0.001-0.01, 0.01-0.1, 0.1-1.0, 1.0-10 and 5-10 mg/kg, at intervals of 1-2, 24, 4-6, 6-8, 8-10, 10-12, 12-14, 14-16, 16-18, 18-20, 20-22, 22-24, 24-26, 26-28, 28-30, 30-32, 32-34, 34-36, 36-40, 40-44, 44-48, 48-52, 52-56, 56-60, 60-64, 64-68, 68-72 hours, for a period of 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 60, 70, 80, 90, 100 days, or 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52 and/or more weeks, and/or 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 36, 40, 50, and/or 60 years, or any range or value therein.

The recipients of administration of compounds and/or compositions of the present invention can be any vertebrate animal, such as mammals, birds, bony fish, frogs and toads. Among mammals, the preferred recipients are mammals of the Orders Primata (including humans, apes and monkeys), Arteriodactyla (including horses, goats, cows, sheep, pigs), Rodenta (including mice, rats, rabbits, and hamsters), and Carnivora (including cats, and dogs). Among birds, the preferred recipients are turkeys, chickens and other members of the same order. The most preferred recipients are humans.

Antibodies Capable of Binding to Specific Jak Proteins Without Interfering With Kinase Activity

The present invention also provides antibodies useful for detecting and extracting specific Jak kinases from eukaryotic cells without disrupting their kinase activity. These antibodies are generated against a peptide fragment representing a portion of the Jak- hinge region between domains 1 and 2 that is different for each Jak kinase. Peptides useful for generating such antibodies are derived from amino acids 758-776 of Jak2 (FIG. 1; the sequence is DSQRKLQFYEDKHQLPAPK (SEQ ID NO:5)), amino acids 786-804 of Jak1 (FIG. 2; the sequence is TLIEKERFYESRCRPVTPS (SEQ ID NO:6)), and amino acids 819-837 of Tyk2 (FIG. 3; the sequence is SPSEKEHFYQRQHRLPEPS (SEQ ID NO:7)). According to the invention antibodies generated against these peptides can specifically bind to and recognize the Jak protein from which the peptide antigen was derived without interfering with kinase activity.

Through the application of standard immunoprecipitation techniques, these antibodies can be used to obtain cell extracts containing a specific Jak protein for use in the in vitro kinase assay. Such a use is demonstrated for antibody generated against the hinge region of Jak₂ kinase in Examples 1-3 and 5.

Jak Genes and Proteins

According to the present invention, the cDNA sequences and corresponding amino acid sequences of Jak kinases are provided, such as Jak3 and murine Jak2 kinase. The nucleotide sequence of a full-length Jak2 cDNA is provided in FIG. 1 (SEQ ID NO:8) and contains an open reading frame (ORF) of 3387 bp encoding the Jak2 protein, which is 1129 amino acids long and has a calculated molecular weight of 130 kDa. The 5' end of the Jak2 cDNA in FIG. 1 has three stop codons before the first ATG. Although the first ATG does not fulfill the Kozak consensus flanking sequences, it is immediately followed by an ATG codon in the typical translation initiation environment (Kozak, M., Nucl. Acids Res. 15:8125-8148 (1987)). The 5' end does not contain an obvious signal peptide. The compiled size of the 3' untranslated region of the Jak2 clones is 0.9 kb which corresponds to a 4.4 kb transcript.

Jak3 cDNA was 3.8 kb and contained a long open reading frame encoding a protein with 1099 amino acids and a size of 122.6 kDa. The sequence (FIG. 6) is highly related to other Jaks and was termed Jak3.

Known method steps for synthesizing oligonucleotides probes useful for cloning and expressing DNA encoding a Jak kinase of the present invention, based on the teaching and guidance presented herein, are disclosed by, e.g., Ausubel, infra; Sambrook, infra; and Wu et al., Prog. Nucl. Acid. Res. Molec. Biol. 21:101-141 (1978), which references are entirely incorporated herein by reference.

A suitable oligonucleotide, or set of oligonucleotides, which is capable of encoding (or which is complementary to a sequence encoding) a Jak fragment is identified as above, synthesized, and hybridized by means well known in the art, against a DNA or, more preferably, a cDNA preparation derived from cells having Jak genes and/or which are capable of expressing a Jak kinase. Single stranded oligonucleotide probes complementary to a Jak activity encoding sequence can be synthesized using method steps (see, e.g., Ausubel, infra; Sambrook, infra).

Such a labeled, detectable probe can be used by known procedures for screening a genomic or cDNA library as described above, or as a basis for synthesizing PCR probes for amplifying a cDNA generated from an isolated RNA encoding a Jak nucleic acid or amino acid sequence. As a further non-limiting example, transformants can be selected for expression by a host cell of a Jak kinase by use of selection media appropriate to the vector used, RNA analysis or by the use of antibodies specific for a target protein as a Jak kinase used in a method according to the present invention.

A target, detectably labeled probe of this sort can be a fragment of an oligonucleotide that is complementary to a polynucleotide encoding a Jak kinase. Alternatively, a synthetic oligonucleotide can be used as a Jak probe which is preferably at least about 10 nucleotides in length (such as 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, or more, or any combination or range therein, in increments of 1 nucleotide), in order to be specific for a target a nucleic acid to be detected, amplified or expressed. The probe can correspond to such lengths of a DNA or RNA encoding a Jak, such as a sequence corresponding to a portion of SEQ ID NO:1 or a Jak1, Jak2, Jak3 or trk1 sequence presented FIG. 6, wherein the probe sequence is selected according to the host cell containing the DNA, e.g., as presented in Table A1.4 of Ausubel, infra. Jak kinase encoding nucleic acids of the present invention can include 15-1500, such as 15-1009, 15-1006, 30-600, and 90-1500 nucleotides, or any range or value therein, substantially complementary to a portion of a sequence presented in FIG. 6, wherein the codons can be substituted by codons encoding the same or conservatively substituted amino acids, as well known in the art.

Culturing of the host and induction of protein expression can be induced by methods known per se. A nucleic acid sequence encoding a Jak kinase of the present invention can be recombined with vector DNA in accordance with conventional techniques, including blunt-ended or staggered-ended termini for ligation, restriction enzyme digestion to provide appropriate termini, filling in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and ligation with appropriate ligases. Known techniques for such manipulations are disclosed, e.g., by Ausubel, infra, and are well known in the art.

A nucleic acid molecule, such as DNA, is said to be "capable of expressing" a polypeptide if it contains nucleotide sequences which contain transcriptional and tanslational regulatory information and such sequences are "operably linked" to nucleotide sequences which encode the polypeptide. An operable linkage is a linkage in which the regulatory DNA sequences and the DNA sequence sought to be expressed are connected in such a way as to permit gene expression of a Jak kinase or peptide having Jak activity in recoverable amounts. The precise nature of the regulatory regions needed for gene expression can vary from organism to organism, as is well known in the analogous art. See, e.g., Sambrook, infra; Ausubel, infra.

The process for genetically engineering Jak2 kinase, according to the invention, is facilitated through the cloning of DNA encoding a Jak kinase and through the expression of such sequences. DNA encoding a Jak kinase may be derived from a variety of sources according to the invention, including genomic DNA, cDNA, synthetic DNA, and combinations thereof.

Genomic DNA may or may not include naturally occurring introns. Moreover, such genomic DNA may be obtained in association with the 5' promoter region of a Jak gene sequence. The 5' promoter region may be retained and employed for expression of a Jak in those host cells which recognize the expression signals present in his promoter region.

Genomic DNA or cDNA, which does not contain introns, may be obtained in several ways. Genomic DNA can be extracted and purified from suitable cells by means well known in the art. Alternatively, messenger RNA (mRNA) may be isolated from a cell which produces a Jak kinase and used to prepare cDNA by means well known in the art. Such suitable DNA preparations are enzymatically cleaved, or randomly sheared, and ligated into recombinant vectors to form either a genomic or cDNA sequence library (see Ausubel, F. M. et al., Current Protocols in Molecular Biology, published by Current Protocols, §§ 5.0.3-5.10.2 (1987, 1992, 1993, 1994)). Such libraries can then be screened for hybridization with nucleic acid probes based upon a Jak gene sequence provided in FIG. 1 (SEQ ID NO:8) or FIG. 6, in order to identify and isolate cloned Jak encoding sequences (see Ausubel, F. M. et al. supra, §§ 6.0.3-6.6.1). The members of the library identified by this screen are then analyzed to determine the extent and nature of the Jak sequences they contain.

In lieu of the above-described recombinant methods, a gene sequence encoding Jak kinase can be prepared synthetically according to methods well known in the art (see Ausubel, F. M. et al., supra, §§ 2.11.1-2.11.18).

The cloned Jak encoding sequences, obtained through the methods described above, may be operably linked to an expression vector and introduced into a bacterial or eukaryotic cell to produce a Jak kinase. Techniques for such manipulations are well known in the art and are disclosed in Ausubel, F. M. et al., supra, at §§ 3.0.3-3.16.11.

A DNA is said to be "capable of expressing" a polypeptide if it contains nucleotide sequences which contain transcriptional and translational regulatory information and such sequences are "operably linked" to nucleotide sequences encoding the polypeptide. An operable linkage is a linkage in which the regulatory DNA sequences and the DNA coding sequence sought to be expressed are connected in such a way as to permit expression of the coding sequence. The precise nature of the regulatory regions needed for gene expression may vary from organism to organism, but shall generally include a promoter region which, in prokaryotes, contains both the promoter (which directs the initiation of RNA transcription) as well as the DNA sequences which, when transcribed into RNA, will signal the initiation of translation of the coding sequence. Such regions will normally include those 5'-non-coding sequences involved with initiation of transcription and translation, such as the TATA box, capping sequence, CAAT sequence, and the like.

If desired, the non-coding region 3' to the gene sequence coding for the Jak2 kinase may be obtained by the above-described methods. This region may be retained for its regulatory sequences, such as transcriptional termination and polyadenylation signals. Thus by retaining the 3'-region naturally contiguous to the DNA sequence coding for a Jak kinase, these regulatory regions may be provided. Where the regulatory signals are not satisfactorily functional in the expression host cell, then a 3' region functional in the host cell may be substituted.

To express a Jak kinase in a prokaryotic cell (such as, for example, E. coli, B. subtilis, Pseudomonas, Streptomyces, etc.), it is necessary to operably link the Jak kinase encoding sequence to a functional prokaryotic promoter. Such promoters may be either constitutive or, more preferably, regulatable (i.e., inducible or derepressible). Examples of constitutive promoters include the int promoter of bacteriophage λ, the bla promoter of the β-lactamase gene sequence of pBR322, and the CAT promoter of the chloramphenicol acetyl transferase gene sequence of pPR325, etc. Examples of inducible prokaryotic promoters include the major right and left promoters of bacteriophage λ (P_(L) and P_(R)), the trp, recA, lacZ, lacI, and gal promoters of E. coli, the α-amylase (Ulmanen, I., et al., J. Bacteriol. 162:176-182 (1985)) and the σ-28-specific promoters of B. subtilis (Gilman, M. Z., et al., Gene sequence 324:11-20 (1984)), the promoters of the bacteriophages of Bacillus (Gryczan, T. J., In: The Molecular Biology of the Bacilli, Academic Press, Inc., NY (1982)), and Streptomyces promoters (Ward, J. M., et al., Mol. Gen. Genet. 203:468-478 (1986)). Prokaryotic promoters are reviewed by Glick, B. R., J. Ind. Microbiol. 1:277-282 (1987); Cenatiempo, Y., Biochimie 68:505-516 (1986); and Gottesman, S., Ann. Rev. Genet. 18:415-442 (1984).

Proper expression in a prokaryotic cell also requires the presence of a ribosome binding site upstream of the gene sequence-encoding sequence. Such ribosome binding sites are disclosed, for example, by Gold, L., et al., Ann. Rev. Microbiol. 35:365-404 (1981).

Preferred eukaryotic hosts include yeast, fungi, insect cells, mammalian cells either in vivo, or in tissue culture. Mammalian cells which may be useful as hosts include, but are not limited to, COS cells and cells or cell lines derived from fibroblasts, myeloid leukemias, or normal hematopoietic tissues.

For a mammalian host, several possible vector systems are available for the expression of the Jak kinase. A wide variety of transcriptional and translational regulatory sequences may be employed, depending upon the nature of the host. The transcriptional and translational regulatory signals may be derived from viral sources, such as adenovirus, bovine papilloma virus, Simian virus, or the like, where the regulatory signals are associated with a particular gene sequence which has a high level of expression. Alternatively, promoters from mammalian expression products, such as actin, collagen, myosin, etc., may be employed. Transcriptional initiation regulatory signals may be selected which allow for repression or activation, so that expression of the gene sequences can be modulated. Of interest are regulatory signals which are temperature-sensitive so that by varying the temperature, expression can be repressed or initiated, or are subject to chemical (such as metabolite) regulation. See, e.g., Ausubel et al., infra, at §§ 1.5, 1.10, 7.1, 7.3, 8.1, 9.6, 9.7, 13.4, 16.2, 16.6, and 16.8-16.11. Factors of importance in selecting a particular plasmid or viral vector include: the ease with which recipient cells that contain the vector can be recognized and selected from those recipient cells which do not contain the vector; the number of copies of the vector which are desired in a particular host; and whether it is desirable to be able to "shuttle" the vector between host cells of different species.

A preferred host for production of catalytically active Jak kinases is insect cells, for example the Drosophila larvae. Using insect cells as hosts, the Drosophila alcohol dehydrogenase promoter can be used (Rubin, G. M., Science 240:1453-1459 (1988)). Alternatively, baculovirus vectors can be engineered to express large amounts of Jak kinase in insects cells (see, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, published by Current Protocols, §§ 16.8.1-16.11.7 (1987, 1993, 1994); Jasny, B. R., Science 238:1653 (1987); Miller, D. W., et al., in Genetic Engineering (1986), Setlow, J. K., et al., eds., Plenum, Vol. 8, pp. 277-297). Expression of Jak kinase in insect cells from baculovirus vectors produces activated Jak kinase which may be used in screening assays for inhibitors of Jak kinase activity as described above.

As discussed above, expression of the Jak kinase in eukaryotic hosts requires the use of eukaryotic regulatory regions. Such regions will, in general, include a promoter region sufficient to direct the initiation of RNA synthesis. Preferred eukaryotic promoters include the promoter of the mouse metallothionein I gene sequence (Hamer, D., et al., J. Mol. Appl. Gen. 1:273-288 (1982)); the TK promoter of Herpes virus (McKnight, S., Cell 31:355-365 (1982)); the SV40 early promoter (Benoist, C., et al., Nature (London) 290:304-310 (1981)); the yeast gal4 gene sequence promoter (Johnston, S. A., et al., Proc. Natl. Acad. Sci. (USA) 79:6971-6975 (1982); Silver, P. A., et al., Proc. Natl. Acad. Sci. (USA) 81:5951-5955 (1984)); and the 9-27 gene promoter (Reid, L. E., et al., Proc. Natl. Acad. Sci. USA 86:840-844 (1989); Ausubel, infra; Lewin, Genes III, John Wiley & Sons, publishers, New York, N.Y. (1990); Sambrook et al., Molecular Cloning: A Laboratory Manual, Second edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1989)).

As is widely known, translation of eukaryotic mRNA is initiated at the codon which encodes the first methionine. For this reason, it is preferable to ensure that the linkage between a eukaryotic promoter and a DNA sequence which encodes the Jak kinase does not contain any intervening codons which are capable of encoding a methionine (i.e., AUG). The presence of such codons results either in a formation of a fusion protein (if the AUG codon is in the same reading frame as the Jak kinase encoding DNA sequence) or a frame-shift mutation (if the AUG codon is not in the same reading frame as the Jak kinase encoding sequence).

The Jak kinase encoding sequence and an operably linked promoter may be introduced into a recipient prokaryotic or eukaryotic cell either as part of a non-replicating DNA (or RNA) molecule, which may either be a linear molecule or, more preferably, a closed covalent circular molecule. Since such molecules are incapable of autonomous replication, the expression of the Jak kinase may occur through the transient expression of the introduced sequence. Alternatively, permanent expression may occur through the integration of the introduced sequence into the host chromosome.

In one embodiment, a vector is employed which is capable of integrating the desired gene sequences into the host cell chromosome. Cells which have stably integrated the introduced DNA into their chromosomes can be selected by also introducing one or more markers which allow for selection of host cells which contain the expression vector. The marker may provide for prototropy to an auxotrophic host, biocide resistance, e.g., antibiotics, or heavy metals, such as copper, or the like. The selectable marker gene sequence can either be directly linked to the DNA gene sequences to be expressed, or introduced into the same cell by co-transfection. Additional elements may also be needed for optimal synthesis of single chain binding protein mRNA. These elements may include splice signals, as well as transcription promoters, enhancers, and termination signals. cDNA expression vectors incorporating such elements include those described by Okayama, H., Molec. Cell. Biol. 3:280 (1983); Ausubel, infra; Sambrook, infra.

In a preferred embodiment, the introduced sequence will be incorporated into a plasmid or viral vector capable of autonomous replication in the recipient host. Any of a wide variety of vectors may be employed for this purpose. Factors of importance in selecting a particular plasmid or viral vector include: the ease with which recipient cells that contain the vector may be recognized and selected from those recipient - cells which do not contain the vector; the number of copies of the vector which are desired in a particular host; and whether it is desirable to be able to "shuttle" the vector between host cells of different species. Preferred prokaryotic vectors include plasmids such as those capable of replication in E. coli (such as, for example, pBR322, Co1E1, pSC101, pACYC 184, πVX. Such plasmids are, for example, disclosed by Sambrook, infra). Bacillus plasmids include pC194, pC221, pT127, etc. Such plasmids are disclosed by Gryczan, T. (In: The Molecular Biology of the Bacilli, Academic Press, NY (1982), pp. 307-329). Suitable Streptomyces plasmids include pIJ101 (Kendall, K. J., et al., J. Bacteriol. 169:4177-4183 (1987)), and streptomyces bacteriophages such as .o slashed.C31 (Chater, K. F., et al., In: Sixth International Symposium on Actinomycetales Biology, Akademiai Kaido, Budapest, Hungary (1986), pp. 45-54). Pseudomonas plasmids are reviewed by John, J. F., et at. (Rev. Infect. Dis. 8:693-704 (1986)), and Izaki, K. (Jpn. J. Bacteriol. 33:729-742 (1978)).

Preferred eukaryotic plasmids include BPV, vaccinia, SV40, 2-micron circle, etc., or their derivatives. Such plasmids are well known in the art (Botstein, D., et al., Miami Wntr. Symp. 19:265-274 (1982); Broach, J. R., In: The Molecular Biology of the Yeast Saccharomyces: Life Cycle and Inheritance, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., p. 445-470 (1981); Broach, J. R., Cell 28:203-204 (1982); Bollon, D. P., et al., J. Clin. Hematol. Oncol. 10:39-48 (1980); Maniatis, T., In: Cell Biology: A Comprehensive Treatise, Vol. 3, Gene sequence Expression, Academic Press, NY, pp. 563-608 (1980)).

Once the vector or DNA sequence containing the construct(s) has been prepared for expression, the DNA construct(s) may be introduced into an appropriate host cell by any of a variety of suitable means: transformation, transfection, conjugation, protoplast fusion, electroporation, calcium phosphate-precipitation, direct microinjection, etc. After the introduction of the vector, recipient cells are grown in a selective medium, which selects for the growth of vector-containing cells. Expression of the cloned gene sequence(s) results in the production of the Jak kinase.

Expressed Jak kinase may be isolated and purified as described herein, using conventional methods such as extraction, precipitation, immunoprecipitation, chromatography, affinity chromatography, electrophoresis, or the like.

Having now generally described the invention, the same will be more readily understood through reference to the following example which is provided by way of illustration, and is not intended to be limiting of the present invention.

EXAMPLES EXAMPLE 1 Structure of the Murine Jak2 Protein Tyrosine Kinase and Its Role in IL-3 Signal Transduction

Summary

Interleukin 3 ,(IL-3) regulates the proliferation and differentiation of a variety of hematopoietic cells including early progenitors and cells committed to various lineages. The receptor for IL-3 consists of α and β subunits that together are required for the expression of a high affinity receptor. The IL-3 receptor chains are members of the cytokine receptor family and contain cytoplasmic domains that lack identifiable kinase catalytic domains. However, IL-3 binding rapidly induces tyrosine phosphorylation of the β chain of the receptor as well as a number of cellular proteins. To investigate the potential role of the Jak family of protein tyrosine kinases in IL-3 signal transduction, we have obtained full-length cDNA clones for murine Jak1 and Jak2 and prepared antiserum against the predicted proteins. Using antisera against Jak2 we demonstrate that IL-3 stimulation results in the rapid and specific tyrosine phosphorylation of Jak2 and activates its in vitro kinase activity. These results support the hypothesis that Jak2 couples IL-3 binding to tyrosine phosphorylation and ultimately to the biological responses mediated by IL-3.

Introduction

Hematopoiesis is regulated through the interaction of a variety of growth factors with their cognate receptors (Metcalf, D., Nature 339:27-30 (1989); Clark and Kamen, Science 236:1229-1237 (1987)). Among the known hematopoietic growth factors, interleukin-3 (IL-3) supports the proliferation and differentiation of early progenitors as well as cells that are committed to several of the myeloid lineages (Ihle, J. N., in Interleukins: Molecular Biology and Immunology, Kishimoto, T., ed., Karger, Basel, pp. 65-106 (1992)). The receptor for IL-3 has been shown to be composed of two subunits, an α subunit of 60-70 kDa and a β subunit of 130-140 kDa which are required for high affinity binding of IL-3 (Miyajima, A., et al., Annu. Rev. Immunol. 10:295-331 (1992)). Both the α and β subunits contain the extracellular conserved motifs found in the cytokine receptor superfamily. Similar to other members of this superfamily, the cytoplasmic domains of the receptor subunits share only a limited similarity with other cytokine receptors and lack any detectable catalytic domains that might suggest a signal transducing mechanism. In spite of the lack of catalytic domains, considerable evidence suggests that signal transduction involves tyrosine phosphorylation (Metcalf, D., Nature 339:27-30 (1989); Miyajima, A., et al., Annu. Rev. Immunol. 10:295-331 (1992)). Specifically, activated tyrosine kinases can abrogate the requirement for IL-3 and IL-3 rapidly induces the tyrosine phosphorylation of several cellular substrates as well as the β subunit of the IL-3 receptor complex. For these reasons there has been considerable interest in identifying a protein tyrosine kinase that may associate with the receptor and be activated by ligand binding.

To identify the spectrum of protein tyrosine kinases that are expressed in IL-3 dependent cells which might be involved in signal transduction, polymerase chain reactions (PCR) have been done with degenerative oligonucleotides to conserved protein tyrosine kinase domains (Wilks, A. F., Methods Enzymol. 200:533-546 (1991)). Using this approach and Northern blot analysis, IL-3 dependent cells have been shown (Mano, H., et al., Oncogene 8:417-424 (1993)) to express the genes for a number of protein tyrosine kinases including lyn, Tec, c-fes, Jak1 and Jak2. The potential involvement of lyn kinase in signal transduction was indicated by a recent study that indicated that IL-3 stimulation increased lyn kinase activity in immune precipitates (Torigoe, T., et al., Blood 80:617-624 (1992)). However, we have not detected an effect of IL-3 on lyn kinase activity or on the status of lyn tyrosine phosphorylation in the murine IL-3 dependent cells we have examined. We have also not detected any tyrosine phosphorylation or activation of kinase activity of Tec or c-fes. Therefore our efforts focused on developing reagents to assess the role of murine Jak1 and Jak2 genes in IL-3 signal transduction.

The Jak (Janus kinase; alternatively referred to as just another kinase) family of kinases was initially detected in PCR amplification of tyrosine kinase domains in hematopoietic cells (Wilks, A. F., Proc. Natl. Acad. Sci. USA 86:1603-1607 (1989)). These studies identified two closely related genes (FD17 and FD22; later termed Jak2 and Jak1) from which the major PCR amplification products were derived. The complete structure of the human Jak1 gene has been reported (Wilks, A. F., et al., Mol. Cell. Biol. 11:2057-2065 (1991)) and, recently, a partial sequence of the murine Jak2 gene was published (Harpur, A. G., et al., Oncogene 7:1347-1353 (1992)). Independently a third member of the family (Tyk2) was isolated by screening a cDNA library with a tyrosine kinase domain probe from the c-fms gene (Firmbach-Kraft, I., et al., Oncogene 5:1329-1336 (1990)). The family is characterized by the presence of two kinase domains, one of which is a carboxyl domain that has all the hallmarks of protein kinases: The second domain is immediately amino terminal and bears all the hallmarks of a protein kinase but differs significantly from both the protein tyrosine and serine/threonine kinases. Amino terminal to the kinase domains, there are no SH2 and SH3 domains that characterize most of the non-receptor tyrosine kinases. However, there is extensive similarity in this region among the Jak family members and a number of homology domains have been defined (Harpur, A. G., et al., Oncogene 7:1347-1353 (1992)).

A link between one member of the Jak family of kinases in signal transduction has been established in recent studies examining the cellular response to interferon alpha (IFNα) (Velazquez, L., et al., Cell 70:313-322 (1992)). Using a genetic approach, the Tyk2 gene was cloned by its ability to functionally reconstitute the cellular response to IFNα in a mutant human cell line that was unresponsive to IFNα. It has been speculated that the kinase activity of Tyk2 is activated following IFNα binding and is responsible for the phosphorylation of the 113 and 91/84 kDa proteins of the interferon-stimulated gene factor 3 α (ISGFα) complex (Fu, X. Y., Cell 70:323-335 (1992); Schindler, C., et al., Science 257:809-813 (1992)). Following phosphorylation this complex associates with the ISGF3γ protein and the complex migrates to the nucleus and activates gene expression by binding to the interferon-stimulated response element.

A role for Jak2 in the-response to erythropoietin (EPO) is described in Example 2. The studies described demonstrated that EPO stimulation induces tyrosine phosphorylation of Jak2 and activates its in vitro autophosphorylation activity. Using a series of mutants of EPOR, the induction of Jak2 tyrosine phosphorylation was found to correlate with the induction of biological responses. Jak2 was also shown to physically associate with the membrane proximal, cytoplasmic region of the EPO receptor that is required for biological activity.

In the studies presented here we disclose the complete structure of the murine Jak2 gene. We demonstrate that Jak2 is rapidly tyrosine phosphorylated in response to IL-3 and there is an associated activation of its in vitro autophosphorylation activity. The results provide evidence that Jak2 is the protein tyrosine kinase that couples IL-3 stimulation to tyrosine phosphorylation and ultimately to the biological responses. Moreover, the involvement of Jak2 in the responses to both IL-3 and EPO shows that Jak2, or family members, are involved in the mitogenic signalling pathway of a variety of hematopoietic growth factor receptors.

Materials and Methods

Isolation of Murine Jak2 Clones. Polymerase chain reactions (PCR) with degenerative oligonucleotides corresponding to the conserved domain were used to amplify cDNAs from murine bone marrow derived monocytes as previously described (Wilks, A. F., Proc. Natl. Acad. Sci. USA 86:1603-1607 (1989)). The Jak2 cDNA clone was ³² P labeled by random priming and used to screen murine monocyte and IL-3 dependent myeloid NFS58 and DA3 cell phage cDNA libraries (Yi and Willman, Oncogene 4:1081-1087 (1989); Morishita, K., et al., Cell 54:831-840 (1988); Bartholomew and Ihle, Mol. Cell. Biol. 11:1820-1828 (1991)). The isolated cDNA fragments were cloned into pBluescript vector and analyzed by restriction mapping and sequencing. Subsequent phage library screenings were done with the most 5' Jak2 cDNA fragments. The longest cDNAs were subcloned into pBluescript vector and the nucleotide sequence was determined by dideoxy chain termination method (Sanger, F., et al., Proc. Natl. Acad. Sci. USA 74:5463-5467 (1977)).

Northern Analysis. Total cellular RNA and poly(A)⁺ RNA were isolated from mouse tissues and cell lines as previously described (Cleveland, J. L., et al., Mol. Cell. Biol. 9:5685-5695 (1989)). Approximately 20 μg of total RNA and 4 μg of poly(A)⁺ RNA were separated on 1.0% agarose/formaldehyde gels and transferred to nitrocellulose filters. The filters were hybridized with ³² P labeled randomly primed 800 bp cDNA fragment derived from the 5' of Jak2. After autoradiography the filters were stripped and probed with β-actin.

Cells and Cell Culture. The properties of the cell lines used in these studies have been described (Ihle and Askew, Int. J. Cell. Cloning 1:1-30 (1989)). The cells were maintained in RPMI supplemented with 10% fetal calf serum (FCS) and murine IL-3 (25 U/ml) for IL3 dependent cells. Mouse bone marrow derived monocytes were grown as previously described (Yi and Willman, Oncogene 4:1081-1087 (1989)).

Computer Analysis. The DNA and protein databases were searched with the Genetics Computer Group sequence analysis software. The SWISSPROT and GENBANK databases were searched with FASTA and TFASTA programs.

Generation of Antibodies. Synthetic peptides corresponding to the N-terminal portion of Jak2 protein (amino acids 19-31) and to the hinge region between domains 1 and 2 (amino acids 758-776 (SEQ ID NO:5)) were coupled to keyhole limpet hemocyanin by MES coupling and used for immunization of rabbits. A synthetic peptide to the analogous hinge region of Jak1 (amino acids 786-804 (SEQ ID NO:6)) was similarly prepared and used for competition studies. Unless otherwise indicated reference to Jak2 antibody or anti-peptide antibody, and manipulations involving Jak2 antibody, refer to antibody generated against the hinge region (amino acids 758-776 (SEQ ID NO:5)).

In vitro Translation and Transcription. Full length Jak1 or Jak2 cDNAs were inserted into pBSK (STRATAGENE) and used to make transcripts with T3 RNA polymerase according to the protocol provided. Approximately 3 μg of RNA was used in translation reactions (Stratagene) in the presence of ³⁵ P translabel (NEN). The products were divided equally and either run on SDS-PAGE without manipulation or immunoprecipitated with Jak1 or Jak2 antisera. Peptide competitions were preformed by incubating peptides (100 μg/ml) with antisera for 1 h at 4° C. prior to use in immunoprecipitations.

In Vitro Kinase Assays. Immunoprecipitated proteins on Protein A-SEPHAROSE (PHARMACIA) were washed with kinase buffer (50 mM NaCl, 5 mM MgCl₂, 5 mM MnCl₂, 0.1 mM Na₃ VO₄, 10 mM HEPES pH 7.4) and subsequently were incubated for 30 min at room temperature with an equal volume of kinase buffer containing 0.25 mCi/ml ³² P-γ-ATP. After extensive washing, proteins were eluted with sample buffer for SDS-PAGE and separated on 7% gels. ³² P-containing proteins were visualized by autoradiography. In vitro phosphorylated Jak2 was isolated from gel slices and the phosphoamino acid content determined by published procedures (Cooper, J. A., et al., Methods Enzymol. 99:387-402 (1983)).

Results

The spectrum of protein tyrosine kinases expressed in hematopoietic growth factor dependent cells was identified by reverse transcriptase/polymerase chain reactions (RT/PCR) using degenerative oligonucleotides corresponding to the conserved regions of the tyrosine kinase domain (Wilks, A. F., Methods Enzymol. 200:533-546 (1991)). One of the most frequently isolated cDNA clones was found to be identical to the clone FD17 (renamed Jak2) (Wilks, A. F., Proc. Natl. Acad. Sci. USA 86:1603-1607 (1989)).

Initial expression analysis indicated that Jak2 was abundantly and widely expressed in hematopoietic cells and prompted us to obtain full length cDNA clones for functional studies. Screening of murine myeloid cDNA libraries resulted in the isolation of several overlapping clones, the longest of which (4 kb) contained the entire coding region of Jak2.

The nucleotide sequence of Jak2 contains an open reading frame (ORF) of 3387 bp and the 5' end has three stop codons before the first ATG (FIGS. 1A-1H). Although the first ATG does not fulfill the Kozak consensus flanking sequences, it is immediately followed by an ATG codon in the typical translation initiation environment (Kozak, M., Nucl. Acids Res. 15:8125-8148 (1987)). The 5' end does not contain an obvious signal peptide. The compiled size of the 3' untranslated region of the Jak2 clones is 0.9 kb which would correspond to a 4.4 kb transcript. One cDNA clone diverged at nucleotide 3271 and had a 1.4 kb 3' untranslated region. Transcripts for this cDNA would be 4.8 kb and may correspond to the larger transcript that is typically seen (see below).

The Jak2 ORF encodes a protein of 1129 amino acids with a calculated molecular weight of 130 kDa. Hydrophilicity analysis, using the Kyte and Doolittle algorithm, failed to identify transmembrane regions. During the course of these studies, a partial sequence of Jak2 was published (Harpur, A. G., et al., Oncogene 7:1347-1353 (1992)) which lacked the first 143 amino acids. A comparison of the sequences indicates 71 nucleotide differences in the coding region, resulting in 9 changes in amino acids (FIGS. 1A-1H). The cDNA clones we have obtained did not contain the insert of 7 amino acids in position 711 that was found in one of four cDNA clones of the studies of Harpur et at. (Oncogene 7:1347-1353 (1992)).

The murine Jak2 gene is very closely related to other Jak family members including the human Tyk2 and Jak1 genes (42% and 43% identities respectively). We have also obtained full length cDNA clones for the murine Jak1 gene which has 45.5% identity to Jak2 at the nucleotide level in the coding region.

Like other members of the family, the murine Jak2 protein has a 600 amino acid long N-terminus that lacks obvious SH2 or SH3 domains. Following this is a kinase related domain (domain 2) and a carboxyl kinase domain (domain 1). The carboxyl kinase domain contains all the structural and functional motifs associated with protein tyrosine kinases including the conserved residues in subdomains VI-VIII that are characteristically associated with protein tyrosine kinases (Hanks, S. K., et at., Science 241:42-52 (1988)). The subdomain VIII, which is hypothesized to contribute to substrate recognition, shows a unique F-W-Y motif that is found in all Jak family members. Domain 2 begins at amino acid 543 and all of the 11 conserved structural subdomains of protein kinases can be identified. However, clear differences in the amino acid composition and spacing in critical kinase subdomains I, II, VI and VIII (Hanks, S. K., et al., Science 241:42-52 (1988)) raise the possibility that this domain may have a regulatory function or alternatively displays a presently unknown substrate specificity.

Although the N-terminus of the Jak family proteins is less homologous than the kinase domains (36-39% verses 49-56%), comparison of the N-terminal sequences of the Jak protein reveals several stretches of homology. Database searches with the N-terminal sequence of Jak2 did not show significant homology with other proteins but the presence of several highly conserved amino acid domains show that Jak proteins are functionally related. Close comparisons of the Jak homology domain 3 reveals some similarity to SH2 domains, but the functional significance of this sequence similarity remains to be determined.

The expression pattern of Jak2 was studied by Northern blot analysis in the following murine tissues: bone marrow, oviduct, ovary, testes, stomach, intestine, skeletal muscle, kidney, liver, thymus, spleen, brain, fetal brain, fetal liver, fetal intestine, and fetal lung. The expression pattern of Jak2 was also studied by Northern blot analysis in the following cell lines: fibroblasts (NIH 3T3); myeloid cells (32D.3, NFS-70, NFS-107, NFS-124, DA-3, DA-22, DA-29, DA31, DA-24, M 1), a mast cell line (AFSTh2), B-cells (DA-8, NFS- 112, plasmacytoma), T-cells (DA-2, EL-4, R-12) and a macrophage cell line (BAC1.2F5). Two transcripts of 4.4 and 4.8 kb were detected in all tissues and cell lines tested, but the level of expression and the relative abundance of the two transcripts varied. The smaller transcript was most abundant in skeletal muscle, spleen and oviduct and barely detectable in liver, kidney and intestine. The Jak2 expression level in adult liver was very low, whereas a more abundant message was detected in fetal liver. The Jak2 expression was detected in all 20 cell lines including 3T3 fibroblasts, B lymphoid, T lymphoid and a variety of myeloid cells representing different stages of differentiation and growth requirements.

In order to biochemically characterize Jak2 protein, anti-peptide antisera were prepared against a region (amino acids 758-776 (SEQ ID NO:5)) that was unique for Jak2 relative to the murine Jak1. To initially assess the reactivity of this antiserum, immunoprecipitations were done with in vitro synthesized Jak2. In vitro translation of Jak2 RNA gave an expected 130 kDa protein. This 130 kDa protein was immunoprecipitated by the Jak2 anti-peptide antiserum, but not by an irrelevant antiserum prepared against a peptide, the sequence of which is not found in Jak2. Immunoprecipitation was competed by the homologous peptide to which the Jak2 antiserum was raised, but not by an irrelevant peptide or by a peptide that is the homologous region of Jak1. The Jak2 anti-peptide antiserum did not immunoprecipitate in vitro synthesized Jak1. Lastly the Jak2 anti-peptide antiserum also immunoprecipitated a comparable 130 kDa protein from in vivo methionine labeled cells which was specifically competed by the homologous peptide. These results demonstrate that the Jak2 cDNA encodes a protein of 130 kDa and that the antipeptide antiserum specifically recognizes the Jak2 protein.

IL-3 stimulation of growth factor dependent cells rapidly induces tyrosine phosphorylation of several cellular substrates including the β subunit of the IL-3 receptor (Ihle, J. N., in Interleukins: Molecular Biology and Immunology, Kishimoto, T., ed., Karger, Basel, pp. 65-106 (1992); Sorensen, P., et al., J. Biol. Chem. 264:19253-19258 (1989)). We therefore examined the possibility that Jak2 might be a substrate of tyrosine phosphorylation.

Western blotting of total cell lysates with a monoclonal antibody against phosphotyrosine (4G10) detected the appearance of several proteins following IL-3 stimulation, including a broad band at 130-140 kDa, a minor band at 70 kDa and major bands at 55 kDa, 50 kDa and 38 kDa. When cell extracts were immunoprecipitated with the Jak2 anti-peptide antiserum, a 130 kDa protein was readily detected in stimulated cells but not in unstimulated cells. Also of note is the presence of induced proteins of 110 kDa, 70 kDa and 60 kDa that coimmunoprecipitated with Jak2. These substrates have been consistently seen in immunoprecipitations of Jak2. Immunoprecipitation with an antiserum against the murine Jak1 consistently detected a weak band at 130 kDa indicating that Jak1 may also be a substrate. Inducible tyrosine phosphorylation of the IL-3 β chain was observed in extracts immunoprecipitated with αIL3Rβ antiserum as a diffuse band with a slightly reduced mobility relative to Jak2 in IL-3 stimulated cells. Thus the broad band seen in total cell lysates consists of both Jak2 and the IL-3 β chain.

To further establish that IL-3 induces Jak2 tyrosine phosphorylation, the kinetics of the response and the ability to detect induction with a second monoclonal antibody against phosphotyrosine were examined. When cells were stimulated with IL-3 and the phosphotyrosine containing fraction was isolated by binding to and elution from sepharose beads containing the IG2 antiphosphotyrosine monoclonal antibody, Jak2 was readily detected in Western blots using the Jake anti-peptide antiserum. A comparable 130 kDa band was not detected in unstimulated cells.

Jak2 tyrosine phosphorylation was readily apparent following 5 min of IL-3 stimulation and subsequently decreased in a manner comparable to the general pattern of tyrosine phosphorylation seen following IL-3 stimulation (Isfort, R., et al., J. Biol. Chem. 263:19203-19209 (1988)). During this period (from 0-120 minutes after IL-3 stimulation) there was no change in the levels of Jak2 as assessed by Western blotting with the Jak2 anti-peptide antiserum.

To determine whether IL-3 binding affected Jak2 kinase activity, cells were stimulated with IL-3 for 10 min, Jak2 was immunoprecipitated and in vitro kinase assays were performed. The results are shown in FIG. 4. When extracts were immunoprecipitated with normal rabbit serum, no in vitro kinase activity was detected with extracts from unstimulated or stimulated cells. However, when extracts were immunoprecipitated with Jak2 anti-peptide antiserum, a 130 kDa was readily detected with extracts from IL-3 stimulated cells that co-migrated with the immunoprecipitated Jak2. By contrast, the 130 kDa band was not detected when extracts of unstimulated cells were used. Phosphoamino acid analysis of the 130 kDa band demonstrated the presence of predominantly phosphotyrosine.

Interestingly, there were no other major protein bands phosphorylated in these in vitro reactions, including the heavy chain of IgG (FIG. 3). As discussed below this may reflect the substrate specificity of Jak2 kinase. The specificity for Jak2 is indicated by the ability of the corresponding peptide to block precipitation of kinase activity while a peptide to the corresponding region of Jak1 had no effect. Together the data demonstrate that IL-3 stimulation results in the tyrosine phosphorylation of Jak2 and activation of its autophosphorylation activity.

Discussion

Our studies provide the first complete sequence of the murine Jak2 gene. Three lines of evidence indicate that the cDNA clones we have obtained contain the entire coding region. First, comparison of the murine Jak2 5' sequence with the published sequences of human Tyk2 and Jak1 show that all proteins start at the same site. Second, the fat ATG is preceded by stop codons in all reading frames. Lastly, the sizes of the compiled cDNA sizes are consistent with the 4.4 and 4.8 kb sized transcripts.

The sequence of our murine Jak2 cDNAs varies from the published partial sequence of the gene (Harpur, A. G., et al., Oncogene 7:1347-1353 (1992)) and includes nine amino acid changes, seven of which are conservative substitutions. Our cDNA clones lacked an insert of 7 amino acids found in one of four Jak2 cDNA clones in the published sequence. A similar putative additional exon was also observed in the human Tyk2 cDNA (Velazquez, L., et al., Cell 70:313-322 (1992)).

IL-3 stimulation of hematopoietic growth factor dependent cells has been shown to rapidly induce tyrosine phosphorylation of a number of cellular substrates (Ihle, J. N., in Interleukins: Molecular Biology and Immunology, Kishimoto, T., ed., Karger, Basel, pp. 65-106 (1992); Ihle, J. N., in Peptide Growth Factors and Their Receptors, Sporn and Roberts, eds., Springer Verlag, New York (1990)). Our results demonstrate that one of these substrates is Jak2 (Ihle, J. N., in Interleukins: Molecular Biology and Immunology, Kishimoto, T., ed., Karger, Basel, pp. 65-106 (1992)). Among the protein tyrosine kinases that are expressed in IL-3 dependent cells and which we could examine, there was a remarkable specificity for Jak2.

In particular, we have not detected any changes in the tyrosine phosphorylation of lyn, tec or c-fes. However we have consistently seen a low level of tyrosine phosphorylation of Jak1 following IL-3 stimulation This is not due to cross-reactivity of the antisera used and, since both Jak1 and Jak2 are expressed at comparable levels in the cells, is not due to differences in protein levels. Therefore, it is likely that Jak1 shares sufficient similarity to Jak2 to weakly associate with the IL-3 receptor complex. Alternatively, since there is considerable sequence homology between Jak1 and Jak2 at the potential autophosphorylation site, Jak1 may be a substrate for Jak2. To date, we have not detected an effect of IL-3 stimulation on Jak1 in vitro kinase activity.

IL-3 stimulation results in both the induction of tyrosine phosphorylation of Jak2 and activation of Jak2 in vitro kinase activity. The carboxyl protein tyrosine kinase domain of Jak2 contains the characteristic autophosphorylation site that is associated with the activation kinase activity of a number of kinases (Hanks, S. K., et al., Science 241:42-52 (1988)). The in vivo tyrosine phosphorylation is expected to occur at this site based on the concomitant appearance of tyrosine phosphorylation and detectable in vitro kinase activity.

The requirement for IL-3 binding for detection of kinase activity indicates that Jak2 kinase activity is highly regulated in cells, consistent with a major role in growth regulation. The primary substrate of the in vitro kinase reactions was Jak2. In particular, there was no detectable phosphorylation of immunoglobulins nor is enolase a substrate for Jak2, indicating that Jak2 may have a strict substrate specificity. The requirement for receptor activation and the substrate specificity may account for the inability to demonstrate Jak1 protein tyrosine kinase activity under a variety of conditions in previous studies (Wilks, A. F., et al., Mol. Cell. Biol. 11:2057-2065 (1991)).

Jak2 is also tyrosine phosphorylated and activated following EPO stimulation (see Example 2). Moreover, these studies demonstrated that Jak2 physically associates with a membrane proximal region of the cytoplasmic domain of the EPO receptor (EPOR) that is essential for function. Whether Jak2 physically associates with one or both subunits of the IL-3 receptor is currently-being examined. However, like EPOR, the β subunit of the IL-3 receptor is rapidly tyrosine phosphorylated and it can be hypothesized that this phosphorylation is mediated by Jak2.

In the case of EPOR, tyrosine phosphorylation occurs at sites in the cytoplasmic, carboxyl end and this region is not required for mitogenesis. Whether the tyrosine phosphorylation of the IL-3 β subunit contributes to the biological response is not known.

The ability of both IL-3 and EPO to induce the tyrosine phosphorylation and activation of Jak2 shows the possibility that Jak2 may be a component in the signal transducing pathways of several cytokine receptors. We have also found that GM-CSF and G-CSF induce the tyrosine phosphorylation of Jak2. This is consistent with several studies that have shown that these hematopoietic growth factors induce comparable patterns of tyrosine phosphorylation (Ihle, J. N., in Interleukins: Molecular Biology and Immunology, Kishimoto, T., ed., Karger, Basel, pp. 65-106 (1992)). We have also observed tyrosine phosphorylation of Jak2 in response to IFNγ in a macrophage cell line.

The hematopoietic growth factor receptors are members of a receptor superfamily that also includes the receptors for growth hormone, the prolactin receptor, ciliary neurotropic factor and others (Bazan, J. F., Science 257:410-413 (1992)). Moreover, the receptors for interferon, although more distantly related, have been speculated to have evolved from a common progenitor. Recent studies (Velazquez, L., et al., Cell 70:313-322 (1992)) have shown that Tyk2 is involved in IFNα signalling. Our studies have shown that Jak2 are involved in the signalling pathways of IL-3 and EPO (see Example 2) as well as G-CSF, GM-CSF and IFNγ. In addition, recent studies have implicated Jak2 in the response to growth hormone. Therefore Jak family kinases are involved in the signal transducing pathways utilized by several members of the cytokine/interferon superfamily of receptors. Moreover, the Jak family of kinases may also regulate gene expression through comparable pathways involving family members related to the ISGF3α proteins (Schindler, C., et al., Proc. Natl. Acad. Sci. USA 89:7836-7839 (1992); Fu, X-Y., et al., Proc. Natl. Acad. Sci. USA 89:7840-7843 (1992)) and the ISGF3γ related DNA binding proteins including ICSBP, IRF1, IRF2 and possibly myb Veals, S. A., et al., Mol. Cell. Biol. 12:3315-3324 (1992)).

EXAMPLE 2 Jak2 Associates with the Erythropoietin Receptor and is Tyrosine Phosphorylated and Activated Following Stimulation With Erythropoietin

Summary

Erythropoietin (EPO) regulates the proliferation and terminal differentiation of erythroid lineage cells through its interaction with its receptor (EPOR). EPOR is a member of the cytokine receptor family and contains a cytoplasmic domain that lacks an identifiable kinase catalytic domain. Binding of EPO, however, rapidly induces tyrosine phosphorylation of EPOR as well as a number of cellular proteins. The ability to induce tyrosine phosphorylation is tightly correlated with the ability of the receptor to induce transcription of immediate early genes and to be mitogenic. These biological responses have been shown to require a membrane proximal region of the receptor cytoplasmic domain. Here we demonstrate that one of the substrates of protein tyrosine phosphorylation is the 130 kDa Jak2, a protein tyrosine kinase. Moreover, EPO stimulation activates Jak2 in vitro autophosphorylation activity. Using a series of mutants of EPOR, the induction of Jak2 tyrosine phosphorylation and autophosphorylation activity were found to correlate with the induction of biological responses. Furthermore, we show that Jak2 physically associates with the membrane proximal region of the EPOR cytoplasmic domain that is required for biological activity. Together the results indicate that Jak2 is the kinase that couples EPO binding to tyrosine phosphorylation and ultimately the biological responses that are required for erythropoiesis.

Introduction

Hematopoiesis is regulated through the interaction of a variety of hematopoietic growth factors with their cognate receptors (Clark and Kamen, Science 236:1229-1237 (1987); Metcalf, D., Nature 339:27-30 (1989)). The majority of hematopoietic growth factor receptors belong to a common cytokine receptor family that is characterized by the presence of four positionally conserved cysteines and a WSXWS (SEQ ID NO: 1) motif in the extracellular domain. The family is also characterized by variably sized cytoplasmic domains that show very limited sequence similarity and which do not contain identifiable motifs that might indicate the signal transducing mechanisms. Erythropoietin (EPO) is the hematopoietic growth factor which uniquely supports the proliferation and terminal differentiation of cells committed to the erythroid lineage (Krantz, S. B., Blood 77:419-434 (1991)). The EPO receptor (EPOR) was cloned by expression cloning (D'Andrea et al., Cell 57:277-285 (1989)) and the sequence of the cDNA predicts a protein of 507 amino acids with a single membrane-spanning domain and the motifs associated with the cytokine receptor superfamily. Unlike several of the hematopoietic growth factor receptors, a single gene product has been shown to be sufficient for EPO binding and function (D'Andrea et al., Cell 57:277-285 (1989)).

Introduction of the EPOR into IL-3 dependent cell lines confers on the cells the ability to proliferate in response to EPO and this has provided an important model to study receptor signal transduction (D'Andrea et al., Cell 57:277-285 (1989); Miura et al., Mol. Cell Biol. 11:4895-4902 (1991)). In transfected cells, EPO induces the expression of a series of immediate early genes including c-myc, c-fos, c-pim-1 and egr-1 (Miura et al., Mol. Cell. Biol. 13:1788-1795 (1993)). In addition, EPO induces the rapid tyrosine phosphorylation of a series of cellular substrates (Linnekin et al., Proc. Natl. Acad. Sci. USA 89:6237-6241 (1992); Dusanter-Fourt et al., J. Biol. Chem 267:10670-10675 (1992); Quelle and Wojchowski, J. Biol. Chem. 266:609-614 (1991); Miura et al., Mol. Cell Biol. 11:4895-4902 (1991); Yoshimura and Lodish, Mol. Cell. Biol. 12:706-715 (1992); Damen et al., Blood 80:1923-1932 (1992)), suggesting that EPOR may function by coupling ligand binding to the activation of a protein tyrosine kinase. One of the substrates of EPO induced tyrosine phosphorylation is the receptor (Dusanter-Fourt et al., J. Biol. Chem. 267:10670-10675 (1992); Yoshimura and Lodish, Mol. Cell. Biol. 12:706-715 (1992); Miura et al., Mol. Cell Biol. 11:4895-4902 (1991)).

The cytoplasmic domain of EPOR consists of 236 amino acids and contains some amino acid sequence similarity to the cytoplasmic domain of the IL-2 receptor β chain (D'Andrea et al., Cell 58:1023-1024 (1989)). EPOR also contains a region that has similarity to the cytokine receptor conserved domains, termed box 1 and 2, which were initially defined in the IL-6 signal transducing gp130 protein (Murakami et al., Proc. Nat. Acad. Sci. USA 88:11349-11353 (1991)). The membrane proximal region of the cytoplasmic domain has been shown to be essential for the biological activities of the receptor. Carboxyl truncation of 108 amino acids has no effect on the ability of the receptor to induce immediate early genes, induce tyrosine phosphorylation or cause mitogenesis (Miura et al., Mol. Cell. Biol. 13:1788-1795 (1993); Miura et al., Mol. Cell Biol. 11:4895-4902 (1991a)). In some cells lines, carboxyl truncations have increased the mitogenic response (D'Andrea et al., Mol. Cell Biol. 11:1980-1987 (1991a)), suggesting that the membrane distal region negatively affects the response to EPO.

Within the membrane proximal region, carboxyl truncations or deletions of the box 1 and box 2 domains can inactivate the receptor for all biological activities (Miura et al., Mol. Cell. Biol. 13:1788-1795 (1993); Miura et al., Mol. Cell Biol. 11:4895-4902 (1991)). The importance of this region was further demonstrated by the inactivation of receptor functions by mutation of a conserved Trp residue between box 1 and box 2. Together the results demonstrate that the membrane proximal region of EPOR is essential for all the biological responses that have been examined, including the induction of tyrosine phosphorylation.

Although the importance of EPOR to couple to protein tyrosine phosphorylation for biological activities has been clearly demonstrated, very little has been known concerning the kinases that might be involved. The rapid induction of tyrosine phosphorylation of the carboxyl region of EPOR (Miura et al., Mol. Cell Biol. 11:4895-4902 (1991); Yoshimura and Lodish, Mol. Cell. Biol. 12:706-715 (1992); Dusanter-Fourt et al., J. Biol. Chem. 267:10670-10675 (1992)) suggests that the receptor is closely associated with a kinase either constitutively or following ligand binding. One study (Yoshimura and Lodish, Mol. Cell. Biol. 12:706-715 (1992)) identified a non-glycosylated protein of 130 kDa that could be cross-linked with the receptor and which was tyrosine phosphorylated either in vivo or in in vitro kinase assays as assessed by its ability to be detected by an antiphosphotyrosine antibody. Whether the 130 kDa was a kinase could not be determined. Recent studies (Linnekin et al., Proc. Nat. Acad. Sci. USA 89:6237-6241 (1992)) also identified a 97 kDa substrate of tyrosine phosphorylation which could be radiolabeled with an azido derivative of ATP, suggesting that it was a kinase. Whether the 130 kDa or 97 kDa potential kinases are previously characterized kinases was not determined.

To detect potentially novel protein tyrosine kinases at might be involved in EPO signal transduction, we have utilized PCR amplification approaches comparable to those described by Wilks, A. F., Proc. Natl. Acad. Sci. USA 86:1603-1607 (1989). Similar to the studies of Wilks et al. (Wilks, A. F., Proc. Natl. Acad. Sci. USA 86:1603-1607 (1989); Wilks et al., Mol. Cell. Biol. 11:2057-2065 (1991)) as well as others (Partanen et al., Proc. Nat. Acad. Sci. USA 87:8913-8917 (1990)), two of the products encode two closely related genes (Jak1 and Jak2) which constitute a relatively new kinase subfamily termed the Janus kinases (alternatively referred to as just another kinase family) that also includes the Tyk2 gene (Firmbach-Kraft et al., Oncogene 5:1329-1336 (1990)). The Tyk2 gene product has recently been implicated in signal transduction through the interferon a (INFα) receptor (Velazquez et al., Cell 70:313-322 (1992)). To explore the potential role of Jak1 and Jak2 genes in hematopoietic signal transduction we have isolated full-length cDNA clones for the murine genes and prepared antisera against the proteins (see Example 1). We report here that EPO stimulation rapidly induces the specific tyrosine phosphorylation of Jak2 and activates its in vitro kinase activity. The induction of tyrosine phosphorylation and activation of kinase activity is dependent upon a membrane proximal region of the EPOR cytoplasmic domain that is essential for mitogenesis. Finally, we demonstrate that Jak2 physically associates with the EPOR and this association requires the membrane proximal region. Together the data demonstrate that Jak2 is involved in EPOR signal transduction.

Results

Jak2 is Specifically and Rapidly Tyrosine Phosphorylated Following EPO Stimulation

EPO rapidly induces the tyrosine phosphorylation of a number of cellular substrates, including the receptor for EPO, suggesting that the receptor associates with a cytoplasmic tyrosine kinase(s) (Yoshimura et al., Nature 348:647-649 (1990); Damen et al., Blood 80:1923-1932 (1992); Quelle and Wojchowski, J. Biol. Chem. 266:609-614 (1991); Quelle et al., J. Biol. Chem. 267:17055-17060 (1992); Miura et al., Mol. Cell Biol. 11:4895-4902 (1991); Linnekin et al., Proc. Natl. Acad. Sci. USA 89:6237-6241 (1992); Dusanter-Fourt et al., J. Biol. Chem. 267:10670-10675 (1992)). To identify the kinases that might be involved, we and others (Wilks, A. F., Proc. Natl. Acad. Sci. USA 86:1603-1607 (1989); Wilks et al., Mol. Cell. Biol. 11:2057-2065 (1991); Partanen et al., Proc. Natl. Acad. Sci. USA 87:8913-8917 (1990); see Example 1) have used PCR approaches to detect known and potentially novel kinases that are present in hematopoietic growth factor dependent cell lines. These studies, coupled with Northern blot analysis, identified transcripts for lyn, c-fes, tec, Jak1 and Jak2 in DA3 myeloid cells (Mano et al., Oncogene 8:417-424 (1993)).

To initially determine whether any of these kinases might be involved in EPO signal transduction we examined their ability to be induce tyrosine phosphorylated as follows. DA3(EPOR) cells were removed from growth factors for approximately 14 hr. The cells were either not stimulated (-) or stimulated (+) with 30 U/ml of human EPO for 10 minutes. The cells were subsequently collected by centrifugation and cell extracts prepared as described in Experimental Procedures below. Aliquots of extracts (2×10⁷ cells) from unstimulated and stimulated cells were immunoprecipitated with antisera against Jak2, Jak1, c-fes, lyn or tec. The immunoprecipitates were resolved by SDS-PAGE, transformed to nitrocellulose filters and the filters were probed with the 4G10 anti-phosphotyrosine monoclonal antibody as described in Experimental Procedures. To assess the levels of each of the immunoprecipitated tyrosine kinases, comparable blots were probed with antisera against the individual kinases as described in Experimental Procedures below.

In experiment described above, EPO stimulation resulted in the appearance of a p130 kDa band that was immunoprecipitated by an antiserum against Jak2. This band was not observed when the immunoprecipitation was done in the presence of the peptide to which the antiserum was raised. Comparable results were also obtained when the blots were probed with a different monoclonal antibody against phosphotyrosine (PY20). In contrast, there was no apparent induction of tyrosine phosphorylation of lyn, fes or tec under comparable conditions.

A weak 130 kDa band was seen with antiserum against Jak1 in several experiments conducted as described above. This was not due to the cross-reactivity of the antisera. Both antisera were prepared against peptides with minimal sequence identity between Jak1 and Jak2 and only immunoprecipitate the appropriate kinase from in vitro translation reactions (see Example 1). Together the results show that the Jak kinases are inducibly tyrosine phosphorylated in response to EPO but that Jak2 is preferentially phosphorylated.

To further establish that EPO stimulation induces tyrosine phosphorylation of Jak2, we examined the ability of the monoclonal antibody 1G2 to detect changes in phosphorylation. Cells were treated as above, lysed and the phosphotyrosine containing fraction of proteins was isolated by binding to and elution from 1G2 monoclonal antibody sepharose beads as previously described (Frackelton et al., Mol. Cell Biol. 3:1343-1352 (1983); Isfort et al., J. Biol. Chem. 263:19203-19209 (1988)). The eluted proteins were resolved by SDS-PAGE, blotted to filters and the filters were probed with an antiserum against Jak2. The results were as follows. EPO induced the appearance of a p130 kDa band that was readily detectable with the antiserum against Jak2 in the 1G2 eluates. Western blotting of total cell lysates indicated comparable levels of the p130 kDa Jak2 in both stimulated and unstimulated cells. Probing of blots with antisera against lyn, tec or c-fes failed to detect these kinases.

To determine the kinetics of appearance of tyrosine phosphorylated Jak2, extracts from DA3(EPOR) cells were prepared at 0, 5, 10, 30 and 60 minutes following EPO treatment, immunoprecipitated with antisera against Jak2 and the immunoprecipitates were resolved by SDS-PAGE. The proteins were transferred to nitrocellulose and Western blotted with the 4G10 monoclonal antibody. Under these conditions the induction of a 130 kDa band was readily evident. Stimulation was maximal at 5 min and subsequently declined and was not evident at 1 hour.

Together the above results indicated that EPO stimulation results in the rapid and specific tyrosine phosphorylation of Jak2, relative to other protein tyrosine kinases, in growth factor dependent cells.

EPO Stimulation Activates Jak2 In Vitro Kinase Activity

Tyrosine phosphorylation of protein tyrosine kinases is commonly associated with the activation of kinase activity (Hanks et al., Science 241:42-52 (1988)). We therefore examined the in vitro Jak2 kinase activity in immunoprecipitates. In these experiments cells were stimulated with EPO for 10 minutes, then cell extracts were prepared and immunoprecipitated with either normal rabbit serum (NRS) or antiserum specific for Jak2, in vitro kinase assays were performed and the phosphorylated proteins resolved by SDS-PAGE. Immunoprecipitates of extracts with normal rabbit serum, from unstimulated or EPO stimulated cells, had no detectable in vitro kinase activity. In contrast, immunoprecipitates of extracts with Jak2 antiserum from EPO stimulated cells had readily detectable kinase activity. The major product of phosphorylation was a 130 kDa protein that co-migrated with Jak2. A comparable activity was not detected in extracts from unstimulated cells. The specificity for Jak2 was indicated by the ability of the peptide to which the Jak2 antiserum was raised to block immunoprecipitation of kinase activity while a peptide to the comparable region of Jak1 had no effect. The primary phosphoamino acid in the in vitro kinase assays detected by 2 dimensional thin layer electrophoresis was determined to be tyrosine.

Tyrosine Phosphorylation of Jak2 and Activation of In Vitro Kinase Activity Correlates with Mitogenesis

Our previous studies (Miura et al., Mol. Cell Biol. 11:4895-4902 (1991); Miura et al., Mol. Cell. Biol. 13:1788-1795 (1993)) defined a membrane proximal region of the cytoplasmic domain of EPOR that is essential for induction of tyrosine phosphorylation, induction of the expression of several immediate early genes and for mitogenesis. It was therefore important to determine whether the induction of Jak2 phosphorylation required a comparable domain and whether Jak2 phosphorylation could be correlated with these biological responses. We therefore examined EPO-induced tyrosine phosphorylation mediated by a series of mutated receptors. The H mutant of EPOR lacks the carboxyl terminal 108 amino acids but retains complete biological activity (Miura et al., Mol. Cell. Biol. 13:1788-1795 (1993)).

EPO stimulation of cells expressing the H mutant resulted in the tyrosine phosphorylation of a 130 kDa band. It should also be noted that the observed Jak2 tyrosine phosphorylation with cells expressing the H mutant was stronger than with cells expressing the wild-type receptor. This could be due to somewhat higher levels of Jak2, as indicated in the lower panel, or could be due to the removal of a negatively acting domain in the carboxyl region of the receptor (D'Andrea et al., Mol. Cell Biol. 11:1980-1987 (1991)). Also of note in these experiments is the presence of an inducible 72 kDa phosphoprotein that is detected in the Jak2 immunoprecipitates from extracts of cells expressing the wild-type receptor. This is the size expected for EPOR and the possibility that it is EPOR is further supported by the absence of a comparable band in the experiments with the H mutant in which the carboxyl truncation removes the sites of tyrosine phosphorylation (Miura et al., Mol. Cell Biol. 11:4895-4902 (1991)). This observation showed that EPOR may physically associate with Jak2.

Carboxyl deletions that extend further than the H mutant, such as is present in the S mutant which lacks the carboxyl 146 amino acids of the receptor, inactivate the receptor for induction of tyrosine phosphorylation, induction of the immediate early genes and mitogenesis in DA-3 cells (Miura et al., Mol. Cell Biol. 11:4895-4902 (1991)). No induction of Jak2 tyrosine phosphorylation was evident following EPO stimulation of cells expressing this mutant.

We also previously demonstrated that the deletion of 20 amino acids (PB mutant) in the membrane proximal region of the cytoplasmic domain inactivates the receptor for all biological activities. No tyrosine phosphorylation of Jak2 was detected in EPO treated cells expressing this mutant.

Lastly we examined a point mutant, PM4, which contains the inactivating mutation W²⁸² to R of the conserved W residue between the box 1 and box 2 regions (Miura et al., Mol. Cell. Biol. 13:1788-1795 (1993)). No tyrosine phosphorylation of Jak2 was seen in cells expressing this mutant.

We next examined the correlation between induction of Jak2 tyrosine phosphorylation and mitogenesis with the ability to activate in vitro Jak2 kinase activity. Clones of cells expressing the various mutant receptors were either not stimulated or stimulated with EPO for 10 min. The cells were lysed and Jak2 was immunoprecipitated and the precipitates used in in vitro kinase assays as above. Phosphorylations were assessed by resolving the immunoprecipitates by SDS-PAGE and autoradiography.

As in the previously described results, the major product of phosphorylation detected in the reactions was a 130 kDa phosphoprotein that migrates at the position of Jak2. Phosphorylation of Jak2 was evident in cells stimulated with EPO that expressed the mitogenically active H mutant. No kinase activity was detected in immunoprecipitates of EPO stimulated cells-expressing the mitogenically inactive S truncation mutation, the PB deletion mutant or the PM4 point mutant. These results demonstrate that the membrane proximal region, which is essential for biological activity, is also required for induction of Jak2 tyrosine phosphorylation and for activation of its kinase activity.

Induction of Jak Tyrosine Phosphorylation in 3T3 Cells Expressing EPOR

Jak2 is expressed in a wide variety of cell lineages (see Example 1); Harpur et al., Oncogene 7:1347-1353 (1992)). We therefore determined whether Jak2 might couple with EPOR and be inducibly tyrosine phosphorylated in a non-hematopoietic lineage. For this, we examined the response of 3T3 fibroblasts that had been transfected with EPOR expression constructs and express high affinity receptors for EPO.

To initially determine whether EPO stimulation is coupled to tyrosine phosphorylation in fibroblasts expressing the receptor, the ability of EPO to induce tyrosine phosphorylation of cellular proteins as well as the receptor was examined. When blots of extracts from 3T3(EPOR) cells were probed with a antiphosphotyrosine monoclonal antibody, a variety of bands were detected and no detectable differences were seen in cells treated with EPO. However, when the extracts were first immunoprecipitated with an antiserum against EPOR and the blots were probed for phosphotyrosine containing proteins, a 72 kDa protein was detected in EPO stimulated cells, consistent with the induction of tyrosine phosphorylation of EPOR.

When cell extracts were first immunoprecipitated with antiserum against Jak2 and then Western blotted for phosphotyrosine containing proteins or Jak2, the results obtained were as follows. Immunoprecipitates from unstimulated and EPO stimulated fibroblasts contained comparable levels of Jak2 as assessed by probing the blots with an antiserum against Jak2. Following stimulation of the cells with EPO, a 130 kDa band, co-migrating with Jak2, was readily detected by a monoclonal antibody against phosphotyrosine (4G10). A comparable band was not detected in control fibroblasts that did not contain EPOR. These data demonstrate that EPOR can functionally couple with Jak2 in fibroblasts and mediate EPO induced tyrosine phosphorylation of Jak2.

Jak2 Associates with Mitogenically Active Receptors for Erythropoietin

The rapid induction of tyrosine phosphorylation of EPOR and Jak2 showed the possibility that Jak2 physically associates with EPOR. This possibility was particularly intriguing since previous studies (Yoshimura and Lodish, Mol. Cell. Biol. 12:706-715 (1992)) identified a 130 kDa protein which could be cross-linked to EPOR and which could be phosphorylated in vitro. The possibility of an association of Jak2 and EPOR was also indicated in several experiments in which a phosphotyrosine containing 72 kDa protein co-immunoprecipitated with Jak2.

To directly examine the ability of Jak2 to physically associate with EPO, a series of GST (glutathione-S-transferase)-fusion proteins containing the cytoplasmic domains of wild type and mutant EPORs were constructed and expressed in bacteria. The fusion proteins were purified by affinity binding to glutathione-sepharose beads and the proteins, on affinity beads, were incubated with extracts of unstimulated or EPO stimulated DA3(EPOR) cells. The bound proteins were recovered from the beads, resolved on SDS-PAGE and the gels blotted to nitrocellulose. The blots were subsequently probed with antisera against various tyrosine kinases.

A 130 kDa protein was readily detectable when extracts from either unstimulated or stimulated cells were used and the blots were probed with an antiserum against Jak2. The 130 kDa protein was not detected when the antiserum was incubated with an excess of the peptide to which it was raised. A 130 kDa protein was also detected with an antiserum against Jak1, although at much lower levels than that seen with antiserum against Jak2. Bands were not detected that would be consistent with the presence of lyn, c-fes or tec when the blots were probed with the respective antisera. These results demonstrated that among the tyrosine kinases examined, Jak2 associated with the GST fusion protein containing the cytoplasmic domain of EPOR.

If the physical association of Jak2 and EPOR detected above was biologically relevant it might be predicted that mutations which affect the receptor's mitogenic activity would alter binding and, conversely, truncations of the receptor that do not affect biological activity would not affect binding. To explore this possibility, fusion proteins were constructed that contained the cytoplasmic portion of the truncated, but mitogenically active, H mutant as well as the mitogenically inactive PB and PM4 mutants. When cell extracts were incubated with GST alone bound to glutathione-sepharose and the blots were probed with an antiserum against Jak2, a 130 kDa protein was not detected. In contrast, when fusion proteins containing either the complete cytoplasmic domain or the carboxyl-truncated cytoplasmic domain of the H mutant were used, a 130 kDa protein was readily detectable. The 130 kDa protein was not detected when extracts were incubated with a fusion protein containing the PB mutant deletion. However, the 130 kDa protein was detected when a fusion protein containing the mitogenically inactive PM4 mutation was used. This may be due to the differences in the assays to detect functional verses physical interactions as discussed below. These results show that the membrane proximal domain that is required for mitogenesis also mediates the association of EPOR and Jak2.

Discussion

These studies are the first to identify a protein tyrosine kinase that associates with EPOR and which is tyrosine phosphorylated and activated in response to ligand binding. Previous studies have demonstrated that EPO binding rapidly induces tyrosine phosphorylation of cellular substrates, as well as EPOR, and that this ability is tightly coupled to the induction of mitogenesis (Miura et al., Mol. Cell Biol. 11:4895-4902 (1991); Miura et al., Mol. Cell. Biol. 13:1788-1795 (1993)). Therefore there has been considerable interest in identifying the kinase (or kinases) that couples EPO binding to the biological responses. Using PCR approaches (Wilks, A. F., Proc. Natl. Acad. Sci. USA 86:1603-1607 (1989); Wilks, A. F., Meth. Enzymol. 200:533-546 (1991); Partanen et al., Proc. Natl. Acad. Sci. USA 87:8913-8917 (1990); Mano et al., Oncogene 8:417-424 (1993)), attempts have been made to define the spectrum of protein tyrosine kinases that are present in myeloid cells and which might contribute to signal transduction.

Among the kinases expressed in IL-3/EPO dependent cells, there has been an interest in lyn, a member of the src gene family kinase, in signal transduction. This was based on the demonstration that IL-2 stimulation of T cells causes an increase in the kinase activity of the highly related lck kinase (Horak et al., Proc. Natl. Acad. Sci. USA 88:1996-2000 (1991)) and the demonstration of a physical association of Ick with the cytoplasmic domain of the IL-2 receptor β chain (Hatakeyama et al., Science 252:1523-1528 (1991)). It should be noted however, that lck associates with a region of the IL-2 receptor β chain which is not required for mitogenesis (Hatakeyama et al., Cell 59:837-845 (1989); Hatakeyama et al., Science 252:1523-1528 (1991)). A role for lyn in IL-3 signal transduction was indicated by a report showing that IL-3 stimulation induces an increase in lyn kinase activity (Torigoe et al., Blood 80:617-624 (1992)). However, we have been unable to see a consistent effect of either IL-3 or EPO on lyn kinase activity in the hematopoietic growth factor dependent cells we have examined. As illustrated here, we have also been unable to detect any effect of EPO binding on the state of tyrosine phosphorylation of lyn nor have we been able to demonstrate association of lyn with EPOR.

We have also been unable to detect any changes in tec tyrosine phosphorylation, activation of kinase activity or association with EPOR Tec is expressed in myeloid cells (Mano et al., Oncogene 8:417-424 (1993)) and its potential importance has been suggested by the identification of highly related kinases in T-cells, itk (IL-2 inducible T cell kinase) and in B-cells BPK/atk (B-cell progenitor kinase, agammaglobulinemia tyrosine kinase) (Silicano et al., Proc. Natl. Acad. Sci. USA 89:11194-11198 (1992); Tsukada et al., Cell (in press, 1993); Vetrie et al., Nature 361:226-233 (1993)). The BPK/atk gene is tightly linked to X-linked agammaglobulinemia (XLA) and kinase activity is reduced or absent in XLA pre-B and B-cell lines (Tsukada et al., Cell (in press, 1993)). Moreover, genetically acquired mutations that would be predicted to inactivate the kinase have been detected in BPK/atk, in patients with XLA (Vetrie et al., Nature 361:226-233 (1993)). Therefore BPK/atk is likely to play a critical role in B-cell signalling. The possibility that tec is involved in a more specialized responses of myeloid cells is currently being examined.

We have also not observed evidence for a role for the c-fes gene in EPO signal transducing pathways that regulate cell proliferation. Recent studies have suggested that c-fes may be involved in the terminal differentiation of myeloid cells (Borellini et al., J. Biol. Chem. 266:15850-15854 (1991)) since the levels of c-fes expression increase with differentiation, introduction of an activated form of c-fes into myeloid cells promotes their differentiation (Borellini et al., J. Biol. Chem. 266:15850-15854 (1991)) and c-fes antisense constructs interfere with differentiation (Ferrari et al., Cell Growth Differ. 1:543-548 (1990)).

In contrast to the results obtained with lyn, tec or fes, the experiments with Jak2 readily demonstrated an effect on tyrosine phosphorylation, activation of kinase activity and the ability to associate with EPOR. Moreover, the results were quite striking in the specificity for Jak2 relative to Jak1. Jak1 and Jak2 are highly related and have considerable amino acid sequence identity in both the catalytic domains as well as the amino terminal region (Harpur et al., Oncogene 7:1347-1353 (1992); see also Example 1 herein). The amino acid sequence of Jak2 encodes a protein of 1129 amino acids with a calculated size of 130 kDa which has 45.5% identity with the murine Jak1 kinase.

Although there was a clear specificity for Jak2 in our studies, Jak1 was consistently detected in all assays at low levels. This was not due to cross-reactivity of the antisera since all the antisera used were against peptides from regions that do not contain extensive amino acid identity. In addition the lack of cross-reactivity of the antisera has been established by examining the reactivity with in vitro translated proteins (see Example 1). The difference in reactivity is also not due to differences in the levels of the expression of the two kinases, since both are expressed at comparable levels. Therefore, there appears to be sufficient similarity between Jak1 and Jak2 to allow Jak1 to associate with EPOR but with a much lower affinity.

EPO induction of Jak2 tyrosine phosphorylation was assessed by changes in reactivity with monoclonal antibodies against phosphotyrosine. Importantly, tyrosine phosphorylation was readily demonstrable with both the 4G10 and PY20 monoclonal antibodies by Western blotting techniques. In addition, Jak2 could be isolated from EPO stimulated cells, but not from unstimulated cells, by affinity purification with the IG2 anti-phosphotyrosine monoclonal antibody coupled to sepharose. These approaches are commonly used to detect changes in protein tyrosine phosphorylation.

Our results demonstrate that EPO stimulation activates the in vitro kinase activity of Jak2 and that the primary substrate is Jak2. Previous studies have found it difficult to demonstrate the kinase activity of Jak1. In particular Wilks et al., Mol. Cell. Biol. 11:2057-2065 (1991) were unable to demonstrate protein tyrosine kinase activity in immunoprecipitates of Jak1 under a variety of conditions. However, they were able to demonstrate protein tyrosine phosphorylation in bacteria with an expression construct containing a fusion protein with the carboxyl kinase domain of Jak1. A comparable fusion protein containing the amino terminal kinase-like domain had no activity. Interestingly, relatively few bacterial proteins were phosphorylated, suggesting that Jak1 may have a restricted substrate specificity. Our results would show that the inability to detect in vitro Jak1 kinase activity is due to lack of appropriate activation in vivo since the ability to detect Jak2 kinase activity was absolutely dependent upon stimulation of the cells with EPO. In this regard, we have been unable to demonstrate Jak1 in vitro kinase activity although Jak1 appears to weakly associate with EPOR and is weakly tyrosine phosphorylated following EPO stimulation.

The primary substrate of tyrosine phosphorylation in the in vitro reactions was Jak2 and specifically no phosphorylation of the immunoglobulin heavy chain was detected. This shows that Jak2 may have very specific substrate specificities. Regarding the mechanism of Jak2 activation, it is possible that ligand binding promotes Jak2 association such that intermolecular phosphorylations occur and result in the activation of kinase activity. Activated Jak2 then has the ability to continue such intermolecular phosphorylations in vitro in immunoprecipitates in a manner that is completely analogous to the receptor protein tyrosine kinases (Ohtsuka et al., Mol. Cell Biol. 10:1664-1671 (1990); Yarden and Schlessinger, Biochemistry 26:1434-1442 (1987)).

EPO stimulation results in the rapid tyrosine phosphorylation of the EPOR receptor with kinetics that are comparable to that of the tyrosine phosphorylation of Jak2. This indicates that Jak2 is the kinase that is responsible for the EPOR phosphorylation. Phosphorylation of EPOR occurs in the membrane distal carboxyl domain, a region that is not required for mitogenesis. This phosphorylation does not occur in mutants containing a 20 amino acid deletion in the membrane proximal region or with the W²⁸² to R mutation in this region. Since both of these mutations also affect Jak2 phosphorylation and kinase activation and the amino acid deletion eliminates the ability of Jak2 to associate with EPOR in vitro, it is likely that Jak2 is the kinase responsible for EPOR phosphorylation. Alternatively, another kinase may associate with Jak2 and thereby be brought into the region of the receptor. If so this additional kinase may also be required for the phosphorylation of Jak2.

With the exception of Jak2 and EPOR, relatively little is known concerning the substrates of EPO induced tyrosine phosphorylation. Substrates of 92 kDa, 70 kDa and 55 kDa have been consistently detected in our studies (Miura et al., Mol. Cell Biol. 11:4895-4902 (1991)) and others have identified similar as well as additional substrates (Damen et al., Blood 8:1923-1932 (1992); Quelle and Wojchowski, J. Biol. Chem. 266:609-614 (1991); Quelle et al., J. Biol. Chem. 267:17055-17060 (1992); Linnekin et al., Proc. Natl. Acad. Sci. USA 89:6237-6241 (1992); Dusanter-Fourt et al., J. Biol. Chem. 267:10670-10675 (1992)). It is also important to note that there are readily detectable substrates of inducible tyrosine phosphorylation of 55 and 70 kDa that co-immunoprecipitate with Jak2. We have excluded a number of potentially interesting substrates including vav, rat, GAP and SHC. However, we have not examined the ISGF3α proteins of 113 and 91/84 kDa which may be substrates of the Jak family kinase Tyk2 and which are involved in the INFα response (Schindler et al., Science 257:809-813 (1992); Fu, X. Y., Cell 70:323-335 (1992)). Alternatively, related proteins may exist that interact with Jak2 which specifically mediate the transcriptional activation of the genes associated with the response to EPO.

Previous studies identified a 130 kDa phosphoprotein that associates with the EPOR (Yoshimura and Lodish, Mol. Cell. Biol. 12:706-715 (1992)). By cross-linking, it was shown to be associated with EPOR suggesting the possibility that it was a subunit of a receptor complex comparable to the β chain of the IL-3 or GM-CSF receptor or the pp130 chain of the IL-6 receptor. However, unlike these proteins, the p130 was not N-glycosylated suggesting the it might be a cytosolic protein The tyrosine phosphorylation of p130 was demonstrated by immunoprecipitation with an anti-phosphotyrosine antibody. However it was not possible to determine whether tyrosine phosphorylation was induced by EPO because of the procedures used to isolate the EPOR/p130 complex. Irrespective, the properties of the p130 are consistent with the hypothesis that it is Jak2.

Our results demonstrate that Jak2 tyrosine phosphorylation and receptor association requires a membrane proximal region that is essential for mitogenesis. This was most strikingly illustrated by the deletion mutant (PB) and by the W²⁸² to R point mutant, both of which are mitogenically inactive and concomitantly fail to couple to Jak2 tyrosine phosphorylation or activation of kinase activity. However, only the mutant with the 20 amino acid deletion (PB) lost the ability to physically associate with Jak2. It is likely that the point mutation is sufficient to disrupt a functional interaction of EPOR and Jak2 in vivo, but does not sufficiently lower the affinity of the interaction to eliminate physical interaction in vitro at high protein concentrations.

Our results show that Jak2 association with EPOR is independent of ligand binding. Therefore it can be hypothesized that Jak2 phosphorylation occurs as a consequence of changes affecting the receptor/Jak2 complex. Considerable evidence supports the hypothesis that EPO binding induces dimer- and oligomerization of the receptor and that this is critical for receptor function (Watowich et al., Proc. Natl. Acad. Sci. USA 89:2140-2144 (1992)). This is supported by the existence of a mutant EPOR (R¹⁹⁹ to C) which results in constitutive activation of the receptor (Yoshimura et al., Nature 348:647-649 (1990)). This mutation requires the cysteine conversion and results in the ability to form disulfide-linked oligomers in the absence of ligand (Watowich et al., Proc. Natl. Acad. Sci. USA 89:2140-2144 (1992)). In cells expressing this mutation, in the absence of EPO, Jak2 kinase is constitutively tyrosine phosphorylated and has in vitro kinase activity. Based on these data, we would further hypothesize that EPO binding causes oligomerization of the EPOR/Jak2 complexes, bringing the kinase molecules in sufficient proximity to result in intermolecular tyrosine phosphorylations. This model is identical to that proposed for several receptor protein tyrosine kinases (Ullrich and Schlessinger, Cell 61:203-212 (1990)).

Studies with the IFNα receptor have suggested that high affinity binding may require the association of Tyk2 (Firmbach-Kraft et al., Oncogene 5:1329-1336 (1990)). This possibility also exists for EPOR. In particular, since Jak2 is ubiquitously expressed, the binding affinities of the receptor have not been measured in the absence of Jak2. Moreover, as demonstrated here, EPOR can functionally associate with Jak2 in fibroblasts. Therefore it will be necessary to express the receptor in phylogenetically distant cells which do not contain a Jak kinase with sufficient homology to associate with the receptor. Under such conditions, it should be possible to address the role of Jak2 binding on the affinity of the receptor.

Jak family kinases are ubiquitously expressed (Wilks et al., Mol. Cell. Biol. 11:2057-2065 (1991); see also Example 1). Therefore it was important to determine whether, in fibroblasts, expression of the EPOR was sufficient to couple to activation of tyrosine phosphorylation. As demonstrated, tyrosine phosphorylation of both EPOR and Jak2 was detected following EPO stimulation. Due to the high background of protein tyrosine phosphorylation in the cells used, we were not able to determine whether EPO stimulation resulted in the tyrosine phosphorylation of other cellular substrates. However, EPO stimulation of serum starved cells, does not induce a mitogenic response suggesting that some components required for coupling ligand binding to cell proliferation are missing. Alternatively, insufficient receptors may be expressed. In contrast, a recent report (Watanabe et al., Mol. Cell. Biol. 13:1440-1448 (1993)) demonstrated that a reconstituted GM-CSF receptor complex in fibroblasts can transduce a growth-promoting signal.

The membrane proximal region of the EPO receptor with which Jak2 associates contains limited sequence similarity with other hematopoietic growth factor receptors (Murakami et al., Proc. Natl. Acad. Sci. USA 88:11349-11353 (1991)). In all cases examined, this region has been shown to be essential for mitogenesis. Thus it will be important to determine whether other members of the hematopoietic cytokine receptor superfamily associate with Jak2, or possibly another member of the Jak family of kinases. In this regard, we have found that IL-3, GM-CSF and G-CSF also induce the specific tyrosine phosphorylation of Jak2. It will be important to further explore the role of Jak family kinases in the responses to other cytokines including IL-2, IL-4 and IL-6.

The ubiquitous expression of the Jak kinases further indicates that they may couple ligand binding to mitogenesis with other non-hematopoietic members of the cytokine receptor superfamily. It has been recognized that there exists structural relationships in the extracellular domains of endocrine growth hormones, the hematopoietic cytokine receptors and a more distant possible relationship with the receptors for tissue factor and interferons (Bazan, J. F., Immunol. Today 10:350-354 (1991); Bazan, J. F., Proc. Natl. Acad. Sci. USA 87:6934-6938 (1990); De Vos et al., Science 255:306-312 (1992)). If these relationships reflect a divergent evolution of a class of signaling receptors, it is possible that they couple signal transduction in a similar manner through interactions with members of the Jak kinase family. Thus the INFα receptor couples through Tyk2 while the receptors for IL-3, GM-CSF, G-CSF and EPO couple through Jak2. Consistent with this we have found that IFNγ induces the tyrosine phosphorylation of Jak2 in a macrophage cell line. In addition recent studies have found that the growth hormone receptor binds to and activates Jak2. It will be of considerable interest to identify which of the Jak kinases other members of the cytokine receptor superfamily associate with and activate.

It will also be of interest to determine whether the Jak family of kinases utilize similar mechanisms to affect gene regulation. Considerable evidence suggests that Tyk2 couples INFα/β binding to tyrosine phosphorylation of the 113 kDa and 91/84 kDa proteins of the ISGF3α (interferon-stimulated gene factor 3) complex (Fu, X. Y., Cell 70: 323-335 (1992)). Following phosphorylation this complex associates with the 48 kDa ISGF3γ protein and the complex migrates to the nucleus where it binds the interferon-stimulated response element and activates gene expression. Recent studies (Shuai et al., Science 259:1808-1812 (1992)) have demonstrated that IFNγ also induces tyrosine phosphorylation of the 91 kDa protein, but not of the 113 kDa protein, and that it migrates to the nucleus and binds a γ-activated site. As noted above, Jak2 is inducibly tyrosine phosphorylated following IFNγ binding and thus may be the kinase involved. If correct, stimulation of cells with EPO, IL-3, GM-CSF or G-CSF may result in the tyrosine phosphorylation of the 91 kDa ISGF3γ protein or a member of this gene family. I this regard it is important to note that one of the major substrates of tyrosine phosphorylation seen in response to EPO or IL-3 is a protein of approximately 92 kDa (Miura et al., Mol. Cell Biol. 11:4895-4902 (1991); Miura et al., Mol. Cell. Biol. 13:1788-1795 (1993)). From the above, it can by hypothesized that members of the cytokine receptor superfamily couple ligand binding to inducing gene expression, in part, by the activation of Jak family kinases by autophosphorylation following ligand binding which results in the phosphorylation of members of the ISGF3γ family which, in turn, associate with members of the ISGF3α family of DNA binding proteins, including ICSBP, IR-1, IFR-2 and c-myb (Veals et al., Mol. Cell. Biol. 12:3315-3324 (1992)).

Experimental Procedures

Cell Lines and Culture Coins

DA3(EPOR) cells expressing the wild type receptor and DA3 cells expressing various mutations were maintained on RPMI-1640 supplemented with 5 mM glutamine, 10% FCS 1 U/mi EPO and G418 as previously described (Miura et al., Mol. Cell Biol. 11:4895-4902 (1991)). Starvation of cells was done by washing cells with PBS three times and incubating in RPMI-1640 supplemented with 5 mM glutamine and 10% FCS in the absence of growth factor for 12 to 16 hr. Cells were stimulated with 10-30 U/ml EPO.

Reagents

The preparation and properties of rabbit polyclonal antisera against peptides from Jak1 and Jak2 is described in Example 1. The antiserum against c-fes was kindly provided by J. Downing (St. Jude Children's Research Hospital, Memphis) and its properties have been described (Haynes and Downing, Mol. Cell. Biol. 8:2419-2427 (1988)). The antiserum against lyn has also been described (Yi et al., Mol. Cell. Biol. 11:2391-2398 (1991)). The antiserum against murine Tec was prepared against GST-fusion proteins and specifically immunoprecipitates a 70 kDa protein from cells expressing Tec but not from control cells. Antiphosphotyrosine monoclonal antibodies included 4G10 (UBI), 1G2 (Oncogene Sciences) and PY20 (ICN) which were purchased from commercial sources. Human EPO was provided by Amgen.

Transfection of 3T3 cells with the pXM EPOR

The plasmid pXM-EPOR (D'Andrea et al., Cell 57:277-285 (1989b)) was transfected into 3T3 fibroblast by electroporation as previously described (Miura et al., Mol. Cell Biol. 11:4895-4902 (1991)). The cells were maintained in Dulbecco's modified Eagles Media (DMEM) with 10% FCS. In the experiments the cells were starved of growth factors by culturing overnight in media containing 0.5% FCS. The cells were subsequently stimulated with EPO (3 U/ml) in the same medium.

Construction of Fusion Proteins

Bacterially expressed fusion proteins were prepared which contain an amino-terminal glutathione-S-transferase (GST) domain and a carboxyl portion of the murine EPOR cytoplasmic domain. Constructs containing the full length EPOR cytoplasmic domain (amino acids 257-483) were prepared by inserting a blunt-ended BgIII-Kpnl fragment of the EPOR cDNA into the SmaI site of pGEX-2T. Constructs containing the membrane proximal cytoplasmic domain of EPOR (amino acids 257-375) were obtained by inserting a blunt-ended BgIII-HindIII fragment of the EPOR cDNA into the SmaI site of pGEX-2T. Identical constructs were prepared using EPOR cDNAs containing the PB and PM-4 mutations previously described (Miura et al., Mol. Cell Biol. 11:4895-4902 (1991)). Fusion proteins then were obtained from E. coli strain DH5-alpha transformed with the plasmid constructs and were affinity-purified on glutathione-sepharose (PHARMACIA) as previously described (Smith and Johnson, Gene 67:31-40 (1988)).

Fusion Protein Binding Assays

Following growth factor stimulation, cells were lysed at 5×10⁷ cells/ml in lysis buffer [1% Triton X-100, 50 mM NaCl, 30 mM Na₄ P₂ O₇, 50 mM NaF, 0.1 mM Na₃ VO₄, 5 mM EDTA, 0.1% bovine serum albumin (BSA), 0.05 mg/ml phenylmethylsulphonyl fluoride (PMSF), 10 mM Tris pH 7.6]. Lysates were cleared of debris at 12,000×g for 10 min and were subsequently incubated with GST-EPOR fusion proteins immobilized on glutathione sepharose. Resins were extensively washed in lysis buffer without BSA and associated proteins then were eluted with sample buffer for SDS-PAGE. Eluted proteins were separated on 8% SDS-PAGE gels and immunoblotted with various antisera.

In Vitro Kinase Assays

Immunoprecipitated proteins on Protein A-SEPHAROSE (PHARMACIA) were washed with kinase buffer (50 mM NaCl, 5 mM MgCl₂, 5 mM MnCl₂, 0.1 mM Na₃ VO₄, 10 mM HEPES pH 7.4) and subsequently were incubated for 30 min at room temperature with an equal volume of kinase buffer containing 0.25 mCi/ml ³² P-γ-ATP. After extensive washing, proteins were eluted with sample buffer for SDS-PAGE and separated on 7% gels. ³² P-containing proteins were visualized by autoradiography. In vitro phosphorylated Jak2 was isolated from gel slices and the phosphoamino acid content determined by published procedures (Cooper et al., Methods Enzymol. 99:387-402 (1983)).

Immunoprecipitation, SDS-PAGE and Western Blotting

Cells were harvested and lysed for 20 min in 1 ml of ice cold lysis buffer (5 mM) Tris-HCl (pH 7.5), 150 mM NaCl, 1% (vol/vol) Triton-X 100, 100 μM sodium vanadate, 1 mM phenylmethylsulfonylfluoride, and 1 mM EDTA. Lysates were pre-cleared by centrifugation for 30 min at 4° C. Supernatant was removed and incubated with preimmune serum and protein A-SEPHAROSE (40 μl of 50% slurry) for 1 hr. The designated serum or monoclonal antibody were then added and incubated at 4° C. for 1-2 hr. Protein A-SEPHAROSE (40 μl of 50% slurry) was added when required, the immunoprecipitates were washed three times in 1 ml of cold lysis buffer, resuspended in Lamelli's samples buffer 10% (vol/vol) glycerol, 1 mM DTT, 1% (wt/vol) SDS, 50 mM M Tris-HCl (pH 6.8) and 0.002% (wt/vol) bromophenol blue and subjected to 7.5% SDS-PAGE. Gels were then transferred electrophoretically to nitrocellulose. The filters were incubated for 2 hr in blotto (5% dehydrated milk in TBSS, 10 mM Tris-HCl pH 7.6 and 137 mM NaCl), then incubated in relevant primary antibody for 1 hr, rinsed in TBSS and incubated for 1 hr in horseradish peroxidase (Amersham) or alkaline phosphatase (Promega) conjugated anti-mouse or anti-rabbit. The filters were then washed and exposed to ECL™ (Amersham Life Science) or 5-bromo-4chloro-3-indoyl phosphate/nitroblue tetrasodium detection. The ECL detection was subsequently recorded on Kodak XAR-5 film. Competition studies using synthetic peptides were done by incubating the antiserum with 100 μg/ml of peptide for 1 hr at 4° C. prior to adding the mixture to cell lysates or dilution in solutions for Western blotting.

EXAMPLE 3 Identification of Jak2 as a Growth Hormone Receptor-Associated Tyrosine Kinase

Summary

Growth hormone receptor (GHR) forms a complex with a tyrosine kinase, suggesting involvement of a ligand-activated tyrosine kinase in intracellular signaling by growth hormone (GH). Here we identify Jak2, a nonreceptor tyrosine kinase, as a GHR-associated tyrosine kinase. Immunological approaches were used to establish GH-dependent complex formation between Jak2 and GHR, activation of Jak2 tyrosine kinase activity, and tyrosyl phosphorylation of both Jak2 and GHR. The Jak2-GHR and Jak2-erythropoietin receptor interactions described here and in the accompanying Example 2 provide a molecular basis for the role of tyrosyl phosphorylation in physiological responses to these ligands, thus evidencing shared signaling mechanism among members of the cytokine/hematopoietin receptor family.

Introduction

Although the ability of growth hormone (GH) to promote growth and regulate metabolism has been known for many years (Cheek, D. B. and Hill, D. E., "Effect of growth hormone on cell and somatic growth," in E. Knobli and W. H. Sawyer, eds., Handbook of Physiology, Vol. 4:159-185, Washington, D.C. (1974); Davidson, M. B., Rev. 8:115-131 (1987)), the molecular mechanism by which GH binding to its receptor elicits its diverse responses has remained an enigma. New insight into GH signaling mechanisms was recently provided by the demonstration that a tyrosine kinase activity is present in a complex with GH receptor (GHR) prepared from GH-treated fibroblasts (Carter-Su., C. et al., J. Biol. Chem. 264:18654-18661 (1989); Stred, S. E. et al., Endocrinol. 130:1626-1636 (1992); Wang, X. et al., J. Biol. Chem. 267:17390-17396 (1992)). Additional studies in 3T3-F442A cells showing rapid GH-dependent tyrosyl phosphorylation of multiple proteins, tyrosyl phosphorylation of microtubule-associated protein kinases, and stimulation of microtubule-associated protein kinase activity, as well as the inhibition of these actions by inhibitors of the GHR-associated tyrosine kinase (Campbell, G. S. et al., J. Biol. Chem. 268:7427-7434 (1993)), suggest a central role for a GHR-associated tyrosine kinase in signaling by GH. Recently, a nonreceptor tyrosyl phosphorylated 122 kd protein was identified in a kinase-active GH-GHR preparation (Wang, X. et al., J. Biol. Chem. 268:3573-3579 (1993)). Since autophosphorylation is often a manifestation of an activated kinase, it was hypothesized that this 121 kd phosphoprotein is the GHR-associated kinase.

In this study, we identify Jak2, a 130 kd tyrosine kinase (Harpur, A. G. et al., Oncogene 7:1347-1553 (1992)) as a GHR-associated kinase. Jak2 is a member of the recently described Janus family of tyrosine kinases including Jak1, Jak2, and Tyk2. In addition to having a kinase domain, these proteins are characterized by the presence of a second kinase-like domain and the absence of Src homology 2 (SH2), SH3, and membrane-spanning domains (Wilks, A. F. et al., Mol. Cell. Biol. 11:2057-2065 (1991); Firmbach-Kraft I. et al., Oncogene 5:1329-1336 (1990); Harpur, A. G. et al., Oncogene 7:1347-1553 (1992)).

Here we show that GH binding promotes association of Jak2 with GHR, activation of Jak2, and tyrosyl phosphorylation of both Jak2 and GHR The identification of Jak2 as a signaling molecule early in the GHR signal transduction pathway provides important insight into signaling by GHR and into the function of Jak2. Work presented in the accompanying Example 2 indicates that Jak2 also associates with the receptor for erythropoietin (EPO), and other data indicate that at least four other members of the cytokine/hematopoietin receptor family (receptors for interleukin [IL]-3), granulocyte-macrophage colony-stimulating factor [GM-CSF], granulocyte colony-stimulating factor [G-CSF], and prolactin) and the more distantly related IFN-γ receptor activate Jak2 (see accompanying Examples). It therefore seems likely that the Jak2-GHR and Jak2-EPO receptor interactions shown herein serve as prototypes for signaling through many members of this large receptor superfamily.

Results

GH Stimulates Tyrosyl Phosphorylation of Jak2

On the basis of previous studies establishing the existence of a GHR-associated tyrosine kinase (Carter-Su., C. et al., J. Biol. Chem. 264:18654-18661 (1989); Stred, S. E. et al., Endocrinol. 130:1626-1636 (1992); Wang, X. et al., J. Biol. Chem. 268:3573-3579 (1993); Campbell, G. S. et al., J. Biol. Chem. 268:7427-7434 (1993)), the GHR-associated tyrosine kinase would be expected; first, to be a protein of ˜120 kd; second, to be tyrosyl phosphorylated in response to GH; third, to be present in a complex with GHR; and fourth, to exhibit increased activity in response to GH.

Jak2 is a tyrosine kinase of the correct size (M_(r) of ˜130,000; see example 1) to be the GHR-associated kinase and was therefore tested for its ability to be phosphorylated in response to GH. Solubilized proteins from GH-treated 3T3-F442A fibroblasts were immunoprecipitated using antiserum to Jak2 (αJak2) and analyzed by anti-phosphotyrosine antibody (αPY) immunoblot. Cells were incubated with varying physiological concentrations of GH in ranging in 10-fold increments from 0.5 ng/ml to 500 ng/ml (the standard concentration used) for 0, 0.5, 5, 50, and 60 minutes.

GH-dependent tyrosyl phosphorylation of a protein with an M_(r) (˜130,000) appropriate for Jak2 was clearly evident at times as early as 30 seconds and at physiological concentrations of GH as low as 5.0 ng/ml (230 pM). Phosphorylation was transient, being greatly diminished by 60 min after addition of GH. The 130 kd phosphoprotein was detected in αPY immunoblasts of αJak2 immunoprecipitates. The appearance of this 130 kd protein corresponded in time course and GH dose response with the appearance in whole-cell lysates of a tyrosyl-phosphorylated protein designated pp121 in previous work (Campbell, G. S. et al., J. Biol. Chem. 268:7427-7434 (1993); Wang, X. et al., J. Biol. Chem. 268:3573-3579 (1993)). The identity of these two proteins is suggested by their co-migration in cell lysates of tyrosyl phosphorylated pp121 and Jak2 and depletion of tyrosyl-phosphorylated pp121 from cell lysates following immunoprecipitation with αJak2.

The 130 kd phosphoprotein was precipitated specifically by αJak2. Non-immune serum, an unrelated immune serum (αG-LUT-1), and αJak2 preadsorbed with the peptide used to make the antibody failed to immunoprecipitate pp130. Preadsorption of αJak2 with the analogous peptide from murine Jak1 (see Example 1) did not interfere with precipitation of the 130 kd phosphoprotein by αJak2. In contrast with these results using αJak2, immunoprecipitation of 3T3-F442A and IM-9 cell lysates, respectively, with antibodies specific for Jak1 (αJak1) and Tyk2 (αTyk2) revealed little (αJak1) or no (αTyk2) GH-dependent tyrosyl phosphorylation of a ˜130 kd protein, despite the presence of these kinases in the respective cell types.

Tyrosyl phosphorylation of the 130 kd protein precipitated from 3T3-F442A cells by αJak2 was increased specifically by GH. Phosphorylation was not increased by platelet-derived growth factor, epidermal growth factor, or insulin-like growth factor 1. These growth factors stimulate tyrosine kinase activity intrinsic to their receptors (Ulrich, A. and Schlessinger, J., Cell 61:203-212 (1990)) and promote tyrosyl phosphorylation of multiple proteins in 3T3-F442A fibroblasts (Campbell, G. S. et al., J. Biol. Chem 268:7427-7434 (1993)). The inability to stimulate Jak2 tyrosyl phosphorylation is consistent with the previously reported inability of these growth factors to stimulate tyrosyl phosphorylation of pp121 in whole-cell lysates (Campbell, G. S. et al., J. Biol. Chem. 268:7427-7434 (1993)).

Jak2 Associates with the GH Receptor

To determine whether Jak2 forms a complex with GHR, GH-GHR complexes and associated proteins were immunoprecipitated from solubilized, GH-treated 3T3-F442A fibroblasts using antibody to GH (αGH). The presence of Jak2 in αGH immunoprecipitates was assessed either by immunoblotting with αJak2 or by immunoprecipitating with αJak2 and immunoblotting with αPY. When material precipitated using αGH was analyzed, αJak2 was found to immunoblot a 130 kd protein and to immunoprecipitate a tyrosyl-phosphorylated 130 kd protein that co-migrates with a protein recognized by αJak2, indicating that Jak2 associates with GH-GHR complexes. When instead of αGH, the initial immunoprecipitation was performed with antibody to either the cytoplasmic or extracellular domains of GHR (αGHR), αJak2 recognized a 130 kd protein only when cells had been incubated with GH. Consistent with the presence of Jak2 in the αGHR precipitate because of its association with GH-bound GHR, no signal was detected in αJak2 immmunoblots of αGH immunoprecipitates when cells had not been incubated with GH nor when immunoprecipitation was performed using an unrelated immune serum (αGLUT-1). These results provide evidence that GH binding to its receptor is necessary to the formation of a complex between GHR and Jak2.

In addition to the 130 kd phosphoprotein believed to be Jak2, a diffusely migrating phosphoprotein of ˜120 kd identified by αPY immunoblot was precipitated by αGH, αGHR, and to a lesser extent by αJak2. Consistent with this diffuse band being GHR, its size corresponds to that previously reported for GHR in these cells (Schwartz, J. and Carter-Su, C., Endocrinology 122:2247-2256 (1988); Stred, S. E. et al., Endocrinol. 130:1626-1636 (1992)), and it co-migrates with a similarly diffuse ˜120 kd band identified by αGHR in Western blots of αGH immunoprecipitates. The finding that tyrosyl residues are phosphorylated in the diffuse 120 kd protein present in αGHR immunoprecipitates only when the cells have been incubated with GH offers evidence that tyrosyl phosphorylation of GHR, like tyrosyl phosphorylation of Jak2, is GH dependent. Additional evidence that both Jak2 and GHR are tyrosyl phosphorylated in response to GH is provided by the finding that in a transfected Chinese hamster ovary cell line (CHO4) that expresses a smaller (84 kd) GHR (Eminer, M. et al., Mol. Endocrinol. 4:2014-2020 (1990); Wang, X. et al., J. Biol. Chem. 268:3573-3579 (1993)), tyrosyl phosphorylation of a 130 kd protein in αGH, αGHR, and αJak2 immunoprecipitates and a diffusely migrating 84 kd protein in αGH and αGHR immunoprecipitates is GH dependent.

Stimulation by GH of Jak Kinase Activity

Previous studies have established that when αGH precipitates are prepared from GH-treated CHO4 cells, the addition of ATP results in the tyrosyl phosphorylation of both a 130 kd and a 84 kd protein (Wang, X. et al., J. Biol. Chem. 268:3573-3579 (1993)). To determine whether the 130 kd and 84 kd proteins phosphorylated in this in vitro kinase assay are Jak2 and GHR, respectively, GH-GHR complexes and associated proteins were precipitated from GH-treated and control CHO4 cells using αGH, incubated with [γ-³² P]ATP, dissociated by boiling in buffer containing SDS, β-mercaptoethanol, and dithiothreitol (DTT), and re-precipitated using either αJak2 or αGHR. In this experiment αJak2 was able to precipitate a 130 kd ³² P-labeled protein appropriate for Jak2, and αGHR was able to precipitate an 84 kd ³² P-labeled protein appropriate for GHR, indicating that both Jak2 and GHR incorporate ³² P in the in vitro kinase assay.

To verify that Jak2 functions as a GH-dependent tyrosine kinase, Jak2 was purified from GH-treated and control 3T3-F442A cells either by direct immunoprecipitation with αJak2 or, to permit a higher degree of purification, by sequential immunoprecipitation using αPY followed by αJak2. When the αJak2 immune complexes were incubated with [γ-³² P]ATP. ³² P-labeled proteins migrating with a M_(r) (130,000) appropriate for Jak2 were detected only when the cells had been incubated with GH, indicating an exquisite sensitivity of Jak2 to activation by GH. To verify that Jak2 incorporates phosphate into tyrosyl residues, phosphoamino acid analysis was performed on the ³² P-labeled 130 kd protein isolated from GH-treated 3T3-F442A cells. ³² P was found incorporated almost exclusively into tyrosyl residues, consistent with Jak2 being a GH-sensitive tyrosine kinase. However, the incorporation of a small amount of ³² P (under 1%) into threonine residues in the αJak2 immunoprecipitate leaves open the possibility that Jak2 is a mixed function threonine/serine/tyrosine kinase.

Discussion

Identification of Jak2 As a Signaling Molecule for GHR

The identification of Jak2 as a GH-dependent, GHR-associated tyrosine kinase has important implications for signal transduction by both GHR and Jak2. With regard to GHR, Jak2 is identified as a signaling molecule that interacts with GHR and is activated in response to GH binding. Its sensitivity to GH and rapid onset following GH addition make tyrosyl phosphorylation of Jak2 among the most sensitive and rapid responses known for GH; activation of Jak2 is an initiating step for GH signal transduction.

Tyrosine kinases have been shown to elicit responses similar to those attributable to GH, including metabolic responses (e.g., insulin receptor) and differentiation (e.g., nerve growth factor receptor) (reviewed by Davidson, M. B., Rev. 8:115-131 (1987); Isaksson, O. G. P. et al., Endocrinol. Rev. 8:426-438 (1987); Levi-Montaicini, R., Science 237:1154-1162 (1987); Kaplan, D. R. et al., Science 252:554-558 (1991)). Therefore, Jak2 plays a vital role in eliciting the known responses to GH. Consistent with this, no biological functions, other than binding of GH, have been reported for GHR expressed in cells that have low levels of GHR-associated tyrosine kinase activity (e.g., COS-7 and mouse L cells; Leung, D. W. et al., Nature 330:537-543 (1987); Wang, X. et al., J. Biol. Chem. 267:17390-17396 (1992)). In contrast, a variety of biological functions (e.g., insulin synthesis in RIN5-AH cells and protein synthesis, microtubule-associated protein kinase activity, c-fos gene expression, and lipid synthesis in Chinese hamster ovary cells) can be activated by GH binding when the cloned liver GHR is expressed in cells that have reasonably high levels of GHR-associated kinase activity (Bitlestrup, N. et al., Proc. Natl. Acad. Sci. USA 87:7210-7214 (1990); Eminer, M. et al., Mol. Endocrinol. 4:2014-2020 (1990); Moller, C.; in Aspects of the Mechanism of Growth Hormone Action, Ph.D. Thesis, Karolinska Institute, NO-VUM, Huddinge, Sweden (1992), pp. 1-9; Wang, X. et al., J. Biol. Chem. 267:17390-17396 (1992); Moller, C. et al., J. Biol. Chem. 267:23403-23408 (1992)).

Furthermore, in 3Tn-F442A cells, multiple proteins exhibit GH-dependent increases in tyrosyl phosphorylation. Consistent with activation of Jak2 being required for these phosphorylations, tyrosyl phosphorylation of Jak2/pp121 is simultaneous with or precedes tyrosyl phosphorylation of all the proteins exhibiting GH-dependent tyrosyl phosphorylation, at all GH concentrations tested (this work and Campbell, G. S. et al., J. Biol. Chem. 268:7427-7434 (1993)).

Jak2 serves as a signaling molecule for GHR by phosphorylating other proteins. Two proteins have been identified as substrates of Jak2: Jak2 itself and GHR.

Studies using truncated GHR indicate that in the cytoplasmic domain of the GHR, at least 1 of the 4 tyrosyl residues most proximal to the membrane is phosphorylated in response to GH. Studies are underway to identify which of the 4 tyrosines are phosphorylated by Jak2, as well as to identify tyrosines in the C-terminal portion of GHR that might also be phosphorylated. It is important to determine the identity and number of tyrosines phosphorylated in Jak2 and GHR, because these sites are likely to be binding sites for SH2-containing proteins (e.g., phospholipase C-γ, p85 phosphatidylinositol-3 kinase, and GTPase-activating protein; Koch, A. A. et al., Science 252:668-674 (1991)) in intercellular signaling pathways. Signaling pathways involving SH2-containing proteins that bind to phosphorylated Jak2 would be expected to be shared by all ligands that activate Jak2, whereas SH2-containing proteins that bind to phosphorylated tyrosyl residues in GHR could provide specificity to a signaling mechanism that utilizes a kinase (i.e., Jak2) with the apparent capacity to service more than one receptor (see below).

Jak2 has also been shown to be activated following the binding of EPO to its receptor (example 2). Other data indicate that IL-3, GM-CSF, G-CSF, IFN-γ, and prolactin also activate Jak2 (see Example 1). Thus, Jak2 serves as a kinase for multiple members of the cytokine/hematopoietin receptor family. Since each ligand elicits a separate constellation of responses, kinase activation alone cannot account for specificity. As mentioned above, a set of responses dependent upon phosphorylation of the receptor could provide the specificity. Additionally, specificity could be obtained by interaction between multiple signaling pathways or by the expression of only one receptor type in a particular cell type. This latter mechanism is suggested by the ability of GH, G-CSF, and EPO to stimulate proliferation of IL-3-dependent cells transfected with the cDNA from the appropriate receptor (Fukunaga, R. et al., EMBO J. 10:2855-2865 (1991); Ishizaka-Ikeda, E. et al., Proc. Natl. Acad. Sci. USA 90:123-127 (1993); Yoshimura, A. et al., Proc. Nat. Acad. Sci. USA 87:4139-4143 (1990)).

The commonality of Jak2 activation suggests that there will be shared pathways activated by the ligands that bind Jak2-coupled receptors. Of particular interest for gaining insight into regulation of gene transcription by GH is a pathway initiated by IFN-γ. In response to IFN-γ, the 91 kd protein of the ISGF-3 (IFN-stimulated gene factor 3) complex undergoes tyrosyl phosphorylation and then translocates to the nucleus, where it binds to DNA at the γ-activated site (Shuai, K. et al., Science 258:1808-1812 (1992)). Identification of the 90 kd. protein phosphorylated in response to GH (Campbell, G. S. et al., J. Biol. Chem. 268:7427-7434 (1993)) as the 91 kd protein of the ISGF-3 complex or a family member would implicate one pathway by which GH might elicit some of the effects on gene transcription.

Activation of Jak2 by GH

The exact mechanism by which GH activates Jak2 is not yet known. Earlier studies using an exogenous substrate (poly Glu, Tyr) established that more tyrosine kinase activity is present in a complex with GHR when GHR is prepared from GH-treated cells than from control cells (Stred, S. E. et al., Endocrinol. 130:1626-1636 (1992)). The present study shows that this GH-induced increase in kinase activity results from both an increase in affinity of GHR for Jak2 and an increase in Jak2 activity. Jak2 appears to bind directly to GHR, since only two proteins, migrating with sizes appropriate for Jak2 and GHR, are visualized when highly purified kinase-active GH-GHR complexes are isolated from GH-treated ³⁵ S-labeled 3T3-F442A fibroblasts by sequential immunoprecipitation using αPY and then either αGHR or αGH (Stred, S. E. et al., Endocrinol. 130:1626-1636 (1992)). The mechanism by which GH promotes association of Jak2 with GHR and Jak2 activation is likely to require dimerization of GHR, since GH-induced tyrosyl phosphorylation of cellular proteins appears to require dimerization of GHR (Silva, C. M. et a., Endocrinol. 32:101-108 (1993)). An important role for receptor dimerization in signaling via Jak2 is further suggested by work relating Jak2 activation to EPO receptor dimerization discussed in Example 2.

The results reported herein provide evidence that binding of GH by GHR results in the formation of a ligand-bound GHR dimer capable of binding Jak2. Recruitment of Jak2 leads to the formation of a GH-GHR-Jak2 complex, stimulation of Jak2 tyrosine kinase activity, and tyrosyl phosphorylation of Jak2, GHR, and presumably other proteins. Whether activated Jak2 is present only in a complex with GHR or can dissociate from GHR and phosphorylate proteins that are physically distant from GHR is currently being investigated. Also under investigation is the possibility that GHR can form complexes with kinases other than, or in addition to, Jak2. Obvious candidate kinases include other members of the Jak family. In 3T3-F442A and IM-9 cells, respectively, Jak1 and Tyk2 do not appear to associate with GHR to the same extent as Jak2. However, they or other as yet unidentified Jak kinases may do so in other cell types or under different physiological conditions.

In summary, the experiments presented here, in combination with the similar findings for the EPO receptor presented in Example 2 and other receptors for IL-3, GM-CSF, G-CSF, prolactin, and IFN-γ (see Example 1), indicate that the activation of Jak2 kinase activity by GH and EPO by a mechanism involving a Jak2-receptor complex is a prototype for signaling by many members of the cytokine/hematopoietin family receptors. The finding that GHR shares an important and early signaling molecule with other members of the cytokine/hematopoietin receptor family shows that GH, IL-3, EPO, prolactin, GM-CSF, G-CSF and IFN-γ are likely to share some signaling pathways. However, specificity could still be achieved, since phosphorylation of each receptor offers signaling capabilities unique to each ligand. The variable expression of individual receptors, the potential presence of only a subset of all possible signaling pathways in different cell types, and regulation of the signaling molecules in these pathways by other stimuli permits an additional level of specificity. This finding is likely to lead to the identification of new actions for GH as well as for these other cytokines.

Experimental Procedures

Materials

Stocks of 3τ3-F442A and CH04 cells were kind gifts of H. Green Harvard University, Cambridge, Mass.) and G. Norstedt (Karolinska Institute, Novum, Sweden), respectively. Recombinant human GH (hGH) was provided by Eli Lilly. Platelet-derived growth factor (recombinant human BB) and recombinant epidermal growth factor came from Collaborative Research. Recombinant insulin-like growth factor 1 was a gift of Kabl/PHARMACIA. Triton X-100 (SURFACT-AMPS X-100) came from Pierce Chemical Company, aprotinin and leupeptin from BOEHRINGER MANNHEIM, recombinant protein A-agarose from REPLIGAN, [γ-¹⁷ P]ATP (6000 Cl/mmol) from New England Nuclear Corporation, and the enhanced chemiluminescence detection system from Amersham Corporation.

Antibodies

αGH (NIDDK-anti-hGH-1C3, lot C11981) came from the National Institute of Diabetes and Digestive and Kidney Diseases/National Hormone and Pituitary Program, University of Maryland and School of Medicine (Baltimore). αPY-Shafer was a gift of Dr. J. A. Shafer (Merck, Sharp, and Dohme Research Laboratory, West Point, Pa.; Pang, D. T. et al., Arch. Biochem. Biophys. 242:176-186 (1985)), and αPY-41G10 was purchased from UBI. αJak2 was prepared in rabbits against a synthetic peptide corresponding to the hinge region between domains 1 and 2 of murine Jak2 (amino acids 758-776 (SEQ ID NO:5); see Example 1). αJak1 was prepared against a synthetic peptide to a corresponding region in murine Jak1 (amino acids 786-804; see Example 1). One αGHR (αGHR-C1) was prepared in rabbits against a fusion protein composed of glutathione S-transferase fused to the cytoplasmic domain of the cloned mouse liver GHR and affinity purified using immobilized GHR cytoplasmic domain. A second αGHR (αGHBP-poly), kindly provided by Dr. W. R. Baumbach (American Cyanamid, Princeton, N.J.), was produced in rabbits using Recombinant rat GH-binding protein produced in Escherichia coli (Sadeghi, H. et al., Mol. Endocrinol. 4:1799-1805 (1990)). αTyk2 was a gift of Dr. J. J. Krolewski (Columbia University, New York). αGLUT-1 was prepared in rabbits using band 4.5 purified from human erythrocytes. It recognizes both human and rodent GLUT-1 (Tal, P.-K. et al., J. Biol. Chem. 265:21828-21834 (1990)).

Immunoprecipitation and Western Blotting

Cells were grown to confluence and deprived of serum overnight as described previously (Wang, X. et al., J. Biol. Chem. 268:3573-3579 (1993)). Cells were incubated for the indicated times with hormone or growth factor as indicated at 37° C. in 95% air, 5% CO₂, rinsed with three changes of ice-cold 10 mM sodium phosphate (pH 7.4), 137 mM NaCl, 1 mM Na₃ VO₄, and scraped in lysis buffer (50 mM Tris (pH 7.5), 0.1% Triton X-100, 137 mM NaCl, 2 mM EGTA, 1 mM Na₃ VO₄, 1 mM phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin, and 10 μg/ml leupeptin) on ice. Cell lysates were centrifuged at 12,000×g for 10 min, and the resulting supernatants were incubated on ice 90 min with the indicated antibody. Immune complexes were collected on protein A-agarose during a 30-60 min. incubation at 8° C., washed three times with wash buffer (50 mM Tris (pH 7.5), 0.1% Triton X-100, 137 mM NaCl, 2 mM EGTA) and boiled for S min in a mire (80:20) of lysis buffer and (250 mM Tris [pH 6.8], 10% SDS, 10% β-mercaptoethanol, 40% glycerol). Unfractionated lysates were brought to the same final concentrations of Tris, SDS, β-mercaptoethanol, and glycerol and boiled for 5 min. The immunoprecipitates and lysates were subjected to SDS-PAGE followed by Western blot analysis with the indicated antibody (1:1000 to 1:5000 dilution used) using the enhanced chemiluminescence detection system (Campbell, G. S. et al., J. Biol. Chem. 268:7427-7434 (1993)). In some experiments, the proteins were dissociated from the immune complexes and then re-immunoprecipitated before analysis by Western blot.

Dissociation and Re-Immunoprecipitation of Immune Complexes

The immune complexes from the initial immunoprecipitation were washed once with 50 mM Tris, 137 mM NaCl (pH 7.5), brought to a final concentration of 0.75% SDS, 2% β-mercaptoethanol, 100 mM DTT, 100 μg/ml aprotinin, and 100 μg/ml leupeptin by addition of an equal volume of a 2×concentrated stock, and then boiled for 5 min.

The eluted proteins were diluted 10-fold with lysis buffer. A portion was removed, mixed (80:20) with SDS-PAGE sample buffer, and boiled for 5 min. The remaining sample was incubated with the second antiserum on ice for 60-90 min and with protein A-agarose at 8° C. for 1 hr. The immune complexes were washed three times with lysis buffer and boiled for 5 min in a mixture (80:20) of wash buffer and SDS-PAGE sample buffer.

Immunoprecipitation for Kinase Assays

Serum-deprived cells were incubated at 25° C. in the absence of presence of 30 ng/ml hGH for 60 min. The relatively long incubation period, low GH concentration, and low temperature were used to maximize the in vitro incorporation of ³² P into pp130 and GHR during the kinase assay. Cells were washed with phosphate-buffered saline, solubilized in 25 mM HEPES, 2 mM Na₂ CO₄, 0.1% Triton X-100, 0.5 mM DTT, 1 mM phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin, 10 μg/ml leupeptin (pH 7.4) (HVT), and centrifuged at 200,000×g for 1 hr at 4° C. Soluble proteins were incubated on ice for 1 hr with either αGH (1:10,000 dilution), αPY-Shafer (15 μg per plate of cells), or αJak2 (1:1,500 dilution) (Carter-Su., C. et al., J. Biol. Chem. 264:18654-18661 (1989)). Protein A-agarose was added for an additional 1 hr at 8° C. Immune complexes were washed three times with 50 mM HEPES, 150 mM NaCl, 0.1% Triton X-100, 0.5 mM DTT (pH 7.6) (NHT) and then once with 50 mM HEPES, 100 mM NaCl, 6.25 mM MnCl₃, 0.1% Triton X-100, 0.5 mM DTT (pH 7.6) (HNMT).

Sequential Immunoprecipitation With αPY and αJak

Proteins immobilized on αPY-protein A-agarose complexes were transferred to a small plastic column and equilibrated for 5 min with 10 mM p-nitrophenyl phosphate, 20 μg/ml aprotinin, 20 μg/ml leupeptin in HNMT (eluting buffer). Phosphoproteins were then eluted with 180 μl of eluting buffer, αJak2 (1:200 dilution) was added, and the mixture was incubated on ice for 1 hr. Protein A-agarose and 0.7 ml of HNMT containing 20 μg/ml aprotinin, 20 μg/ml leupeptin (phosphorylation buffer) was added, and incubation continued at 6° C. for 1 hr. Immune complexes were washed three times with NHT and once with phosphorylation buffer.

In Vitro Kinase Assay and Phosphoamino Acid Analysis

Proteins immobilized on αJak2 or αGH were mixed with 95 μl of phosphorylation buffer. [γ³² P]ATP was then added to yield a final concentration of 10 μM ATP and 5 mM MnCl₂. After 10 min at 30° C., the reaction was stopped with the addition of 10 mM EDTA in NHT. The immune complexes were washed three times with NHT and once with phosphorylation buffer. ³² P-labeled proteins were either subjected to a second immunoprecipitation or boiled for 5 min in SDS-PAGE sample buffer, resolved by SDS-PAGE, and visualized by autoradiography. The phosphoamino acid content of phosphorylated proteins was determined by limited acid hydrolysis using a modification of the procedure of Hunter and Selton (Hunter, T. and Selton, B. M., Proc. Natl. Acad. Sci. USA 77:1311-1315 (1980)) as described previously (Carter-Su., C. et al., J. Biol. Chem. 264:18654-18661 (1989); Stred, S. E., et al., Endocrinol. 127:2506-2516 (1990); Wang, X. et al., J. Biol. Chem. 267:17390-17396 (1992)).

SDS-PAGE and Densitometry

Proteins were separated by SDS-PAGE on 3%-10% gradient gels (30:0.05 acrylamide:bisacrylamide) as described previously (Carter-Su., C. et al., J. Biol. Chem. 264:18654-18661 (1989)). Densitometry was performed using a Bio-Med Instruments laser scanning densitometer attached to an Apple IIE computer (Bio-Med Instruments VIDEOPHORESIS II data analysis computer program).

EXAMPLE 4 Complementation of a Mutant Cell Line Defective in the Interferon-γ Signal Transduction Pathway by the Protein Tyrosine Kinase Jak2

Summary

The cell surface marker CD2 was placed under the control of the interferon-inducible 9-27 gene promoter and introduced into human HT1080 cells. A clone of cells showing a good response of CD2 to interferons-α, -β and -γ was selected and pools of mutagenized cells were screened for defective cell surface expression of CD2 and Class I HLAs in response to interferon-γ. Mutants in different complementation groups were isolated. Mutant γ-1 is deficient in the induction of all interferon-γ-inducible genes tested but retains a normal response to interferons-α and -β. Transfection of mutant γ-1 with protein tyrosine kinase Jak2 restored the wild-type phenotype. A role for Jak2 in the primary response to interferon-65 is indicated.

Introduction

The interferons (IFNs) confer an antiviral state on cells and can affect both cell growth and function (Pestka, S., et al., Annu. Rev. Biochem. 56:727-777 (1987)). There are three major antigenic types of human IFN: alpha (α), beta (β) and gamma (γ). Gene induction by IFNs-αβ and IFN-γ is through separate receptors. The existence of a minor IFN-β specific receptor cannot be excluded (Pelegrini, S., et al., Mol. Cell. Biol. 9:4605-4612 (1989)) and the multiplicity of IFN-α subtypes shows that the interaction of these with the IFN-αβ receptor(s) is likely to be complex.

The isolation of mutants affecting both the IFN-αβ and the IFN-γ signal transduction pathways has indicated that common factors are involved (John, J., et al., Mol Cell. Biol. 11:4189-4195 (1991); McKendry, R., et al., Proc. Natl. Acad. Sci. USA 88:11455-11459 (1991)). One such factor (p91, below and Example 4) has recently been identified (Schindler, C., et al., Science 258:1808-1812 (1992); Shuai, K., et al., Science 258:1808-1812 (1992)). IFN-binding components have been cloned for both major receptors (Aguet, M., et al., Cell 55:273-280 (1988); Uze, G., et al., Cell 60:225-234 (1990)). Signal transduction subunits have yet to be isolated, but the p48, p84, p91 and p113 polypeptide components of the primary transcription factor ISGF3, activated in response to IFNs-α and -β have been cloned and characterized (Veals, S. A., et al., Mol. Cell. Biol. 12:3315-3324 (1992); Schindler, C., et al., Proc. Natl. Acad. Sci. USA 89:7836-7839 (1992); Schindler, C., et al., Proc. Natl. Acad. Sci. USA 89:7840-7843 (1992)). There is rapid phosphorylation on tyrosine of p91, p84 and p113 in response to IFN-α and of p91 and p84 in response to IFN-γ (Shuai, K., et al., Science 258:1808-1812 (1992)). In addition, complementation of mutant U1A (11.1) which was isolated from cells expressing a drug-selectable marker under the control of the predominantly IFN-αβ-responsive 6-16 gene promoter, has revealed a role for the protein tyrosine kinase Tyk2 in the IFN-αβ response pathway (Velazquez, L., et al., Cell 70:313-322 (1992)). Here, using an alternative selection technique, complementation of a mutant in the IFN-γ response by Jak2, another member of the same family of protein tyrosine kinases (Wilks, A. F., et al., Mol. Cell. Biol. 11:2057-2065 (1991); Harpur, A. G., et al., Oncogene 7:1347-1353 (1992); Firmbach-Kraft, I., et al., Oncogene 5:1329-1336 (1990); Example 1), is reported.

Results

The 9-27 gene promoter is inducible by IFN-γ as well as IFNs-α and -β (Reid, L. E., et al., Proc. Natl. Acad. Sci. USA 86:840-844 (1989)). Significant constitutive expression from this promoter precluded a drug selection protocol. Accordingly a clone of cells (2C4) expressing the simple cell-surface marker CD2 (normally expressed only on T-cells) under the control of the 9-27 promoter was derived and the fluorescence activated cell sorter (FACS) used to screen for loss or gain of IFN-γ inducibility. IFN-inducible expression of endogenous Class I and II HLAs was also monitored. In 2C4 cells good induction of all three antigens by IFN-γ and of CD2 and Class I by IFN-α was observed.

Mutant γ-1 was isolated by mutagenesis of 2C4 and several rounds of sorting. To enhance the isolation of trans rather than cis mutants and of mutants in the primary rather than secondary IFN-γ response pathways, the final two sorts were on both CD2 and Class I. Mutant γ-1 is defective in the response to IFN-γ but not to IFN-α or IFN-β. Transfection of this mutant with a murine Jak2 expression construction (Example 1), however, restored the IFN-γ response of all three cell surface markers in an enriched population and clones of transfectants. Transfection with murine Jak1, in the same construct, was without effect.

The expression of a spectrum of IFN-γ-inducible mRNAs was also monitored by RNase protection. For all eight IFN-inducible mRNAs tested the positive IFN-α response (minimal for IRF1 and GBP) was the same for 2C4, mutant γ-1 and the γ-1/Jak2 transfectants, whereas for IFN-γ the response observed in 2C4 was lost in γ-1 but restored in the γ-1/Jak2 transfectants. A gamma activation sequence (GAS) motif has recently been identified as mediating the primary IFN-γ response of the GBP and ITF1 genes through p91 (see Example 1; Decker, T., et al., EMBO J. 10:927-932 (1991); Kanno, Y., et al., Mol. Cell. Biol. 13:3951-3963 (1993)). The DNA elements and/or factors governing the primary IFN-γ response of the remainder of the genes tested have yet to be rigorously established. The fact, however, that all of the genes tested are affected is consistent with the defect in mutant γ-1 being in the primary IFN-γ response pathway.

In all cases the IPN-γ response was restored by Jak2 and the IFN-γ dose response curves for the wild-type 2C4 and γ-1/Jak2 transfectants were essentially identical: a clear response was seen at 10 IU/ml and an approaching maximal response at 100 IU/ml. No restoration of IFN-γ response was observed on transfection of γ-1 cells with a functional Tyk2 expression clone and, in an inverse experiment, Jak2 did not complement the defect in Tyk2 in a U1 mutant.

The defect in mutant γ-1 cells does not reflect the absence of Jak2 protein since levels comparable to wild-type were observed on western transfer as was the case for Jak1 and Tyk2. The anti-peptide antibody used to immunoprecipitate Jak2 and to probe the western transfer was designed to distinguish between Jak1 and Jak2 and has high specificity for Jak2 (see Examples 1-2). The mutation in γ-1 may, therefore, reflect point or other minor mutations affecting the function but not the production of Jak2. Alternatively, the mutation could be in an upstream component which, once mutated, fails to interact productively with normal levels of endogenous human Jak2, but is rescued by high levels (see Example 5) of the transfected murine Jak2.

It will require substantial additional work before one can be certain of the precise nature of the mutation involved. The defect in mutant γ-1 is, however, without any apparent major effect on the biding of IFN-γ to its receptor. Essentially identical binding was reproducibly observed with wild-type 2C4 and mutant γ-1 cells. This is in contrast to the situation with mutant U1A (originally coded 11.1) in which the defect in Tyk2 results in loss of high affinity receptor binding for IFN-α (Pellegrini, S., et al., Mol. Cell. Biol. 9:4605-4612 (1989)). It will be of interest to determine whether this difference reflects the absence of Tyk2 but not Jak2 protein in U1A and γ-1 respectively, or a more fundamental difference in the presumptive interaction of the two kinases with their respective receptor complexes. The Jak2 protein, like Tyk2, does not appear to be significantly induced in response to IFNs γ or -α in the wild-type cells.

Discussion

Here it is shown that a mutant human cell line, defective in the IFN-γ response of all genes tested, is complemented by murine Jak2. Example 5 shows: (1) direct evidence that the defect in mutant γ-1 is early in the primary response pathway; (2) that Jak2 is rapidly phosphorylated on tyrosine in response to IFN-γ; and (3) results consistent with the rapid activation and (auto)phosphorylation of Jak2 in response to IFN-γ in wild-type but not mutant cells.

Irrespective of the precise nature of the mutation in γ-1, these data indicate an essential role for Jak2 in the primary IFN-γ response. The availability of antibody to Jak2 and of mutants in additional complementation groups in the IFN-γ response pathway should prove invaluable in determining the number and nature of the components involved in this response.

Methods and Materials

Cell surface expression of transfected CD2 and endogenous Class I and II HLAs in response to IFNs-α or -γ on wild-type 2C4, mutant γ-1 cells and mutant γ-1 cells stably transfected with a murine Jak2 cDNA expression construct. Data was generated for an enriched population and a clone of γ-1/Jak2 transfectants using FACSCAN (BECTON DICKINSON) analyses (3000 data points, Consort 30). Cells were plated at 5×10⁵ /10 cm dish and treated the following day with 10³ IU/ml of a highly purified mixture of α-IFNs (WELLFERON 1.5×10⁸ IU/mg protein, kindly supplied by WELLCOME RESEARCH. LABORATORIES, Beckenham, UK) or recombinant human IFN-γ (4×10⁷ IU/mg protein, obtained from Dr. Gunter Adolf, Ernst Boehringer Institut fur Arzneimittelforschung, Vienna, Austria, and commercially or readily available).

Cells (10⁶) were stained for 30 min at 0° C. with R-phycoerythrin-conjugated murine monoclonal antibody to human CD2 (DAKO-CD2 MT910, DAKO A/S Denmark) or HLA DRA (clone L243, Becton Dickinson), or FITC-conjugated murine monoclonal antibody to human HLA ABC (shared determinant, clone W6/32, SERALAB, UK) and fixed in 1% paraformaldehyde. Clone 2C4 was derived by stable co-transfection of human HT1080 cells with pDW9-27CD2 and pTKNco and FACSCAN analysis of G418-resistant clones. pDW9-27D2 is a modification of PJ3omega (Morgaenstern, J. P. et al., Nucl. Acids Res. 18: 1068 (1990)) in which the SV40 promoter was replaced by the 1.8 kb HindIII to BspMII promoter fragment of the 9-27 gene (Reid, L. E., et al., Proc. Nat. Acad. Sci. USA 86:840-844 (1989)) and which carries a fill length CD2 cDNA (Sewel, W. A., et al., Proc. Natl. Acad. Sci. USA 83:8718-8722 (1986)) in the EcoRI site of the polylinker.

Mutagenesis (five rounds) with ICR191 was as previously described (McKendry, R., et al., Proc. Natl. Acad. Sci. USA 88:11455-11459 (1991)). Cells not responsive to IFN-γ were "selected" using a FACSTAR Plus cell sorter (Becton Dickinson). 5×10⁷ mutagenized cells were treated with 500 IU/ml of recombinant human IFN-γ for 48 h, resuspended and stained with phycoerythrin-conjugated antibody to CD2 and (in the last two sorts) FITC-conjugated antibody to HLA Class I (above) and sorted immediately. The bottom 5% of fluorescing cells were collected.

After six rounds of sorting clone γ-1 was isolated by limiting dilution of the enriched population. It showed a novel IFN-γ⁻ -α⁺ -β⁺ phenotype distinct from other IFN-γ mutants previously described (Loh, J. E., et al., EMBO J. 11:1351-1363 (1992); Mao, C., et al., Proc. Natl. Acad. Sci. USA 90:2880-2884 (1993)). The phenotype was stable on continuous culture for at least three months.

Mutant γ-1 was complemented by transfection with a full length cDNA of murine Jak2 downstream of the CMV promoter in pRK5 in the presence of a puromycin-selectable marker plasmid. The puromycin-resistant population of stable transfectants were treated with recombinant IFN-γ, FACS sorted and the top 7% of responder cells were collected and analyzed. Clones of γ-1/Jak2 transfected cells, obtained by limiting dilution of the enriched population, were also analyzed, for which full restoration of the IFN-γ response was observed.

IFN-inducible gene expression in wild type 2C4, mutant γ-1 and mutant γ-1/Jak2 transfected cells: mRNA expression in response to IFNs-α or -γ was monitored by RNase protection using probes to detect the IFN-inducible mRNAs of: the 9-27, 6-16, 2-5A synthetase and ISGF3-γ genes and the p91 and p84 alternatively spliced products of the p91/84 ISGF3α gene and the IRF1 and GBP genes. The protection of γ-actin mRNA served as an internal loading control. Cytoplasmic RNA was prepared from monolayer cells by NP40 lysis and phenol/chloroform extraction (Porter, A. C. G., et al., EMBO J. 7:85-92 (1988)). RNase protection was with RNA probes labeled with ³² P UTP to 2-5×10⁸ cpm/μg of input DNA (Melton, D. A., et al., Nucl. Acids Res. 12:7035-7056 (1984)). One to 3×10⁵ cpm of each probe and 10 μg of RNA were used in each assay.

Expression of Jak2 in wild-type 2C4, mutant γ-1 cells and mutant γ-1 cells transfected with murine Jak2 (γ-1Jak2tr): Jak2 protein was immunoprecipitated from precleared whole cell extracts (10⁷ cells) with antiserum to Jak2 (Example 1) and protein A SEPHAROSE (PHARMACIA; John, J., et al., Mol. Cell. Biol. 11:4189-4195 (1991)) and analyzed by SDS-PAGE and western transfer using the antibody to Jak2 and the ECL detection system (Amersham International, UK). For the mutant γ-1 cell extracts immunoprecipitation was carried out in the absence (no peptide) or presence (30 μg/ml) of the Jak2 peptide to which the antiserum was raised (Jak2 pept) or, as a non-specific control, an unrelated Jak1 peptide (Jak1).

Binding of ¹²⁵ I-labeled IFN-γ to 2C4 and mutant γ-1 cells: ¹²⁵ I-IFN-γ (667 Ci/mMole, Amersham International, UK) treatment was of triplicate samples of 10⁶ cells for 90 min at 0° C. Non-specific binding was subtracted. It was determined in parallel in the presence of a 200 fold excess of unlabeled IFN-γ and represented approximately 40% of the total radioactivity bound. In a parallel antiviral assay versus EMC virus 1 fmole of ¹²⁵ I-IFN-γ was equivalent to 0.15 IU. Specific binding at the highest IFN-γ concentration here corresponded to about 6000 receptors per cell. On dilution of the IFN to a lower specific activity saturation binding was observed at approximately 10,000 receptors per cell.

EXAMPLE 5 Activation of the Protein Tyrosine Kinase Jak2 in Response to Interferon-γ

Summary

Mutant γ-1 cells respond normally to interferons-α and -β but are defective in the response of all genes tested to interferon -γ. The mutants can be complemented by the protein tyrosine kinase Jak2 (Example 4). In wild-type cells the transcription factor p91, which plays a central role in the primary interferon-γ signal transduction pathway, is rapidly phosphorylated on tyrosine in response to interferon-γ. No such phosphorylation occurs in mutant γ-1 cells, but it is restored on complementation of γ-1 cells with Jak2. Moreover, Jak2 is itself rapidly phosphorylated on tyrosine in response to interferon-γ in wild-type cells. Interferon-γ dependent phosphorylation of Jak2 is also observed in in vitro kinase assays of immunoprecipitates from human and mouse cells. No such phosphorylation is seen in mutant γ-1 cells or in response to interferon-α. These results indicate a role for Jak2 early in the primary interferon-γ signal transduction pathway.

Results

Interferons (IFNs) -α, -β and -γ induce overlapping sets of genes through distinct receptors (Pestka et al., Ann. Rev. Biochem. 56:727-777 (1987)). There has been rapid recent progress in the understanding of the signal transduction pathways involved. Central to this has been the realization that p91, a component of the complex IFN-αβ-inducible transcription factor ISGF3, plays a dual role in the IFN-αβ and -γ response pathways.

p91 is rapidly phosphorylated on tyrosine in response to either type of IFN (Schindler et al., Science 257:809-813 (1992); Shuai et al., Science 258:1808-1812 (1992)). Consistent with this, p91 is required for the IFN-γ response of a wide spectrum of genes. It appears to correspond to the gamma activation factor (GAP) which was first identified as being necessary for the activation of transcription of the GBP gene (Decker et al., EMBO J. 10:927-932 (1991)) and has since been implicated in the activation of a number of additional genes in response to IFN-γ through a common DNA motif (Shuai et al., Science 258:1808-1812 (1992); Pearse et al., Proc. Natl. Acad. Sci. USA 90:4314-4318 (1993); Kanno et al., Mol. Cell. Biol. 13:3951 (1993)). Mutant γ-1 was, therefore, assayed for phosphorylation of p91. Phosphorylation of p91, monitored by incorporation of ³² P_(i), occurs rapidly in wild-type 2C4 cells. No such phosphorylation was observed in mutant γ-1.

Phosphorylation of p91 did occur in γ-1 cells complemented by Jak2 as monitored by incorporation of ³² P_(i) or with antibodies to phosphotyrosine. Normal levels of p91 were present and, interestingly, phosphorylation of the p91 and p113 components of ISGF3α by IFN-α was normal in the mutant cells (Phosphorylation of the p84 component of ISGF3α in response to IFNs -α or γ is always lower and frequently difficult to detect (Schindler et al., Science 257:809-813 (1992); Shuai et al., Science 258:1808-1812 (1992)).

In addition, γ-1 cells are not complementable by a functional p91 expression construct. The defect in γ-1 cells is, therefore, upstream of p91.

Tyrosine phosphorylation of Jak2 was monitored by immunoprecipitation with specific antibody followed by western transfer analysis of the immune precipitates with antibody to phosphotyrosine. On this basis, Jak2 is rapidly phosphorylated on tyrosine in response to IFN-γ in wild-type but not in mutant γ-1 cells. No such phosphorylation of Jak2 was observed in response to IFN-α under conditions identical to those under which phosphorylation of Tyk2 by IFN-α is readily detected.

Tyrosine phosphorylation of p91 in response to IFN-γ and of p91 and p113 in response to IFN-α were monitored in parallel as internal controls both for IFN activity and detection of phosphotyrosine using a mixture of Py-20 and 4G10 antiphosphotyrosine antibodies. On reprobing the same transfer with antibody to Jak2, comparable levels of Jak2 protein were detected in wild-type and γ-1 mutant cells. The defect in γ-1 is, therefore, in the phosphorylation/function rather than the production of Jak2 (see Example 4).

A priori the apparent phosphorylation of Jak2 could be of an immunologically cross-reacting protein. The antiserum used, however, was raised against a Jak2 peptide which is not conserved in Jak1 and has high specificity for Jak2 (see Examples 1 and 2). Consistent with this, phosphorylated protein was not recovered when the immune precipitation was carried out in the presence of the appropriate competing peptide.

In γ-1/Jak2 transfectants there is a high "background" level of tyrosine phosphorylation of the overexpressed exogenous murine Jak2 even in the absence of IFN-γ treatment. The basis for this is not known. Against this background a variable increase in total tyrosine phosphorylation of Jak2 is seen in response to IFN-γ in the complemented cells. Interestingly, however, even in experiments in which no obvious increase in Jak2 phosphorylation was observed in the γ-1/Jak2 transfectants when assayed, a substantial response to IFN-γ was consistently observed in parallel in vitro kinase assays (see below). Transfected Jak2 can, therefore, be phosphorylated in response to IFN-γ. It is reasonable to conclude that the phosphorylation observed in wild-type cells in response to IFN-γ is due to Jak2.

Activation of protein tyrosine kinases in response to growth factors classically results in kinase activity which can be detected in an immune precipitate of the activated enzyme. Jak2, activated in response to IL3 (Example 1) and erythropoietin (Example 2), shows similar apparent in vitro kinase activity. This is also the case for Jak2 in response to IFN-γ. IFN-γ-dependent kinase activity was observed upon assay of Jak2 immunoprecipitates from wild-type 2C4 or mutant γ-1/Jak2 transfected cells. No such activity was observed in response to IFN-α or when the immunoprecipitates were prepared from mutant γ-1 cells or from wild-type cells in the presence of competing Jak2 peptide. Phosphorylation of Jak2 is not restricted to human HT1080 derived cells, and is also seen in response to IFN-γ but not -α in other human and a variety of mouse cell lines, including mouse L-cells.

Discussion

The results presented here together with those in Example 4 indicate that Jak2 is activated in response to IFN-γ and such activation plays a role early in the primary IFN-γ response pathway. Granted that p91 is phosphorylated at the same site (Tyr 701) in response to IFN-α and γ (Schindler et al., Science 257:809-813 (1992); Shuai et al., Science 258:1808-1812 (1992)), the normal phosphorylation of p91 in the γ-1 mutant in response to IFN-α is of interest in this regard. One can conclude either that Tyk2 or Jak2 can each carry out phosphorylation of the same tyrosine or, more intriguingly, that there is an additional kinase(s) involved.

Turning to the activation of Jak2, in the case of erythropoietin this appears to occur through direct interaction of Jak2 with the erythropoietin receptor (Example 2). It will obviously be of considerable interest if there is a similar interaction in the case of the IFN-γ pathway. The common activation of Jak2 by erythropoietin, IL3 and a number of other cytokines (see Examples 1-3) raises obvious questions. A major thrust of future work will be to identify the nature of the proteins interacting with Jak2 and the factors determining the specificity of the response.

Methods and Materials

Tyrosine phosphorylation of p91 in response to IFN-γ in normal and mutant γ-1 cells: Phosphorylation of p91 in response to IFN-γ in wild-type (2C4), mutant γ-1 and mutant γ-1 cells transfected with Jak2 (γ-Jak2tr) was monitored by incorporation of ³² P113_(i) or by western transfer with antibody to phosphotyrosine. p91 protein levels were monitored by western transfer as was tyrosine phosphorylation of the p91 and p113 components of ISGF3 in response to INF-α at 10³ IU/ml for 15-30 minutes. p91 was immunoprecipitated from precleaned whole cell extracts (10⁷ cells) with antiserum to p91 and protein A SEPHAROSE (PHARMACIA) as described previously (Schindler et al., Science 257:809-813 (1992); Shuai et al., Science 258:1808-1812 (1992)) and analyzed by SDS-PAGE and western transfer using a mixture of PY20 (ICN) and 4G10 (UBI) antiphosphotyrosine antibodies and, after stripping in 0.1M Tris HI pH 8.0, antibody to p91. p91 and p113 (complexed in IFN-α-activated ISGF3α) were co-immunoprecipitated with antibody to p113 (Schindler et al., Science 257:809-813 (1992)) and analyzed by SDS-PAGE and western transfer with antiphosphotyrosine antibodies as above. In the western transfers detection was by ECL (Amersham, UK) except for the p91 antibody screened transfer which was stained with diaminobenzidine (Amersham UK).

Tyrosine phosphorylation of Jak2 in response to IFN-γ but not -α in wild-type 2C4, mutant γ-1 and mutant γ-1/Jak2 transfected cells: Phosphorylation of Jak2, and of p91 and p113 as controls, were monitored by immunoprecipitation, SDS-PAGE and western transfer for phosphotyrosine using a mixture of Py-20 and 4G10 antiphosphotyrosine antibodies and detection by ECL (Amersham International). Extracts from INF-γ treated cells were immunoprecipitated with a mixture of antibodies to Jak2 and p113 (the latter co-precipitates 091 in IFN-α-activated ISGF3). The same blot was stripped (as described above) and reprobed with antibody to Jak2. Extracts from cells treated with INF-γ for 15 min were immunoprecipitated with antibody to Jak2 in the presence or absence, as indicated, of 0.1 mg/ml of the Jak2 peptide against which the antibody to Jak2 was raised (Example 1) or an unrelated Jak1 peptide. The immunoprecipitates were analyzed by SDS-PAGE and western transfer using antibodies to phosphotyrosine as above. Growth of the cells and treatment with 10³ IU/ml of highly purified IFN-γ or -α was as described above.

In vitro kinase assays: IFN-dependent phosphorylation of Jak2 was assayed in immunoprecipitates from (A) wild type (2C4) and mutant γ-1/Jak2 transfected cells, (B) wild type (2C4) and mutant γ-1 cells and (C) mouse L-cells. Treatment with IFN-γ or -α (500 IU/ml) as indicated was for 15 min. Immune precipitates on protein A SEPHAROSE (PHARMACIA) were washed in 50 mM NaCl, 5 mM MgCl₂, 5 mM MnCl2, 0.1 mM Na₃ VO₄, 10 mM HEPES pH 7.4 and incubated in the same buffer containing 0.25 mCi/ml of ³² P-γ-ATP for 30 min at room temperature (see Examples 1-2). After extensive washing proteins were eluted in sample buffer and analyzed by SDS-PAGE. Detection was by autoradiography or by western transfer for phosphotyrosine as described above. Growth and IFN treatment of human cells was as described above. Growth and IFN treatment of mouse L-cells was similar, but with recombinant murine IFN-γ (1-2×10⁷ IU/mg protein, a generous gift from Dr. Gunter Adolf, Ernest Boehringer Instant fur Arzneimittelforschung, Vienna, Austria) or recombinant human IFN-α A/D (Bgl), a hybrid highly active on mouse cells (2×10⁸ IU/mg protein kindly supplied by Dr. Sidney Pestka, Robert Wood Johnson Medical School, N.J., USA).

EXAMPLE 6 An Inhibitor of EPO Activity (Genestein) Inhibits Jak2 Kinase Activity

The biochemical activity of Jak2 may be demonstrated by use of an in vitro kinase assay. In this assay, purified Jak2 is precipitated from cell lysates using Jak2-specific antisera bound to protein A-sepharose. The immunoprecipitated Jak2 is then washed with kinase buffer (50 mM NaCl, 5 mM MgCl₂, 5 mM MnCl₂, 0.1 mM Na₃ VO₄, 10 mM HEPES pH 7.4) and subsequently incubated for 30 minutes at room temperature with an equal volume of kinase buffer containing 0.25 mCi/ml ³² P-gamma-ATP. After extensive washing, proteins are eluted with sample buffer for SDS-PAGE and separated on 7% gels. ³² P-containing proteins are then visualized by autoradiography.

Using this assay system, active Jak2 kinase has been demonstrated to be present only in mammalian cells which have been treated with an appropriate cytokine, such as erythropoietin (EPO) or interleukin-3 (IL-3). Thus, activation of the Jak2 catalytic activity is correlated with the biological activities of these cytokines.

This correlation is further supported by studies using the tyrosine kinase-specific inhibitor known as genestein. Genestein is known to inhibit the ability of EPO to stimulate cell growth.

Inclusion of genestein at 0.1 mM in the in vitro kinase assay described above results in a 2-fold reduction in the tyrosine kinase activity of Jak2. Thus, the inhibitory effect of genestein on EPO-induced cell proliferation can be explained by its inhibition of Jak2.

EXAMPLE 7 Production of a Constitutively Active Jak2 Kinase From Insect Cells

Since the active form of Jak2 may be isolated from mammalian cells only after stimulation with an appropriate cytokine, we have developed a system for the expression of catalytically active Jak2 which does not require cytokine stimulation. Specifically, when expressed at high levels in insect cells Jak2 is constitutively in an active state. This expression was accomplished by insertion of the Jak2 cDNA between the NotI and SmaI sites of the baculovirus transfer vector pVL1392 (PHARMINGEN, San Diego Calif.). This Jak2/vector construct then was co-transfected into insect cells with a defective baculovirus DNA (BACULOGOLD DNA, PHARMINGEN, San Diego, Calif.).

EXAMPLE 8 Cloning, Expression and Activity of Jak3

Many cytokines regulate growth and differentiation through interaction with receptors of the cytokine receptor superfamily. Although lacking catalytic domains, cytokine receptors couple ligand binding to induction of protein tyrosine phosphorylation. Recent studies have shown that one or more of the Janus kinase (Jak) family members associate with cytokine receptors and are tyrosine phosphorylated and activated following ligand binding. None of the reported Jak family members have yet been implicated in IL-2 or IL-4 signalling. Here we describe a new Jak family kinase, Jak3, and demonstrate that Jak3, and to a lesser extent Jak1, are tyrosine phosphorylated and Jak3 is activated in the responses to IL-2 and IL4 in T cells as well as in myeloid cells.

Janus kinase (Jaks) DNAs have identified by low stringency screening (Firmbach-Kraft, et al. Oncogene 5:1329-1336 (1990)) and by polymerase chain amplification (PCR) approaches (Wilks, A. F., Proc. Natl. Acad. Sci. U.S.A. 86:1603-1607 (1989); Partanen et al., Proc. Natl. Acad Sci. USA 87:8913-8917 (1990)). A variety of cytokines induce the tyrosine phosphorylation and activation of Jaks. Jak2 is activated by erythropoietin (EPO) (Witthuhn et al., Cell:227-236 (1993)), growth hormone (Artgetsinger et al., Cell 74:237-244 (1993)), prolactin hormone (Campbell et al., Proc. Natl Acad. Sci. USA in press, (1993)), granulocyte-specific colony stimulating factor (G-CSF), interleuk-3 (IL-3) (Silvennoinen, Proc. Nat. Acad. Sci. USA 90:8429-8433 (1993)) and granulocyte-macrophage colony stimulating factor (GM-CSF) (Quelle et al., Mol. Cell. Biol. submitted, (1994)). Interferon (IFN)-α/β responses activate and require Jak1 and another family member, Tyk2 (Velazques et al., Cell 70:313-322 (1992); Muller et al., Nature 366, 129-135 (1993)); while Jak1 and Jak2 are activated and required for the response to IFN-γ (Muller et al., Nature 366, 129-135 (1993); Watling et al., Nature 366, 166-170 (1993)). Lastly, cytokines that utilize a common gp130, or gp130 related subunit, including IL-6, oncostatin M, leukemia inhibitor factor (LIF) and ciliary neurotrophic factor (CNTF) activate Jak1 and Jak2 and to some extent Tyk2 (Stahl et al., Science 263:92-95 (1994); Narazaki et al., Proc. Natl. Acad. Sci. USA, in press, (1994)). Notably, no activation of Jak1, Jak2 or Tyk2 has been reported in the responses of IL-2 or IL4, which also utilize receptors of the cytokine receptor superfamily. We therefore looked for additional Jak family members that might be activated by IL-2 and IL-4.

Previously PCR approaches were used to identify protein tyrosine kinases in breast cancer cell lines (Cance et al., Int. J. Cancer 54:571-577 (1993)) from which a cDNA fragment was obtained that encoded a novel Jak family member. The same kinase was recently detected by PCR in rat hippocampal neurons (Sanchez et al., Proc. Natl. Acad. Sci. USA 91: 1819-1823 (1994)). Using the fragment from breast cancer cell lines, we obtained four overlapping cDNA clones from a murine B-cell cDNA library. The longest cDNA was 3.8 kb JAK3 Kinase Plasmid DNA in pBluescript SK+/-(pBSK) deposited at the American Type Culture Collection, Manassas VA on Feb. 7, 2000 and assigned number PTA-1338 and contained a long open reading frame which would encode a protein with 1099 amino acids and a predicted size of 122.6 kDa. The predicted sequence (FIGS. 6A-6C) is highly related to the Jaks and was termed Jak3. Murine Jak3 is 47%, 36% and 36% identical to amino acids in murine Jak2, murine Jak1 and human Tyk2 respectively. Jak3 contained a typical protein tyrosine kinase catalytic domain as well as an amino terminal kinase-like domain. In addition, there are blocks of similarity between Jak3 and the other Jak family members in the amino terminal region.

Translation of the Jak3 cDNA in vitro (FIGS. 7A-B) gave a 120 kDa product. Comparison of the in vitro translation products of cDNAs for murine Jak1, murine Jak2 and human Tyk2 demonstrated that each could be distinguished by size; Tyk2 migrates the slowest followed by Jak1, Jak2 and Jak3 consistent with their predicted sizes. The in vitro translated proteins were used to determine the specificity of anti-peptide antisera (FIG. 7B). Antiserum against a kinase domain peptide of Jak3 immunoprecipitated Jak3 (lane 2) but not Jak1, Jak2 or Tyk2. This precipitation was not seen with pre-immune serum (lane 1) and was competed by the immunizing peptide (lane 3) but not an irrelevant peptide (lane 4). Similarly, anti-peptide antisera against Jak1 or Jak2 (Silvennoinen, Proc. Natl. Acad. Sci. USA 90:8429-8433 (1993)) were specific and did not immunoprecipitate Jak3. Lastly, an anti-peptide antiserum against a region of Tyk2 from between the kinase domains was made. Unlike the others, this antiserum was cross-reactive and recognized Jak3 and Jak1 as well as Tyk2 but only weakly immunoprecipitated Jak2. However, a commercially available anti-peptide antiserum against Tyk2 (Santa CRUZ BIOTECHNOLOGY Inc.) was specific and did not cross-react with Jak1, Jak2 or Jak3.

Jak1, Jak2 and Tyk2 are ubiquitously expressed (Firmbach-Kraft, et al. Oncogene 5:1329-1336 (1990); Silvennoinen, Proc. Natl. Acad. Sci. USA 90:8429-8433 (1993); Harpur et al., Oncogene 7:1347-1353 (1992); Wilks et al., Mol. Cell Biol. 11:2057-2065 (1991)). To determine if Jak3 was similarly expressed, a series of cell lines and mouse tissues were examined for expression by Northern blot analysis. As illustrated in FIG. 8, the highest levels of transcripts were detected in an IL-2 dependent cytotoxic T-cell line (CTLL) which contained a single 4 kb transcript. A comparably sized transcript was detected at somewhat lower levels in IL-3 dependent myeloid cell lines. However, Jak3 transcripts were not detected in fibroblasts or a glioblastoma cell line. Among tissues, transcripts were detected at the highest levels in spleen and to lesser extent in liver, kidney, lungs and heart but were not detected in brain or testes. Consistent with the initial PCR amplification results (Cance et al., Int. J. Cancer 54:571-577 (1993)), Jak3 is also expressed breast tissue derived cell lines. Therefore, unlike other Jak family members, Jak3 expression is much more restricted and one of the sites of expression is the hematopoietic lineages.

To assess the role of Jak3 in signalling, the ability of several cytokines to induce Jak3 tyrosine phosphorylation was examined by immunoprecipitation and western blotting with a monoclonal antibody against phosphotyrosine. In a series of IL-3 dependent myeloid cell lines, no constitutive or inducible tyrosine phosphorylation of Jak3 was seen with EPO, IL-3, GM-CSF, G-CSF, IFN-α, IFN-γ or IL-6. However, Jak3 was tyrosine phosphorylated in IL-2 or IL4 stimulated CTLL cells (FIGS. 9A-D). In CTLL cells, IL-2 and IL-4 induced the tyrosine phosphorylation of several cellular proteins including a protein doublet of 120 and 130 kDa, consistent with recently published results (Kirken et al., J. Biol. Chem. 268:22765-22770 (1993)). As illustrated in FIG. 9A, IL-2 and EL-4 induced tyrosine phosphorylation of Jak3 (αJak3) which migrated at the position of the major 120 kDa substrate. IL-2 and IL-4 also induced tyrosine phosphorylation of Jak1 (αJak1) which co-migrated with the 130 kDa substrate. No tyrosine phosphorylation of Jak2 or Tyk2 was detected with Jak2 or Tyk2 specific antiserum. Lastly, the Jak3/Jak1 cross-reactive antiserum against Tyk2 did not precipitate a tyrosine phosphorylated protein of the size of Tyk2 but did immunoprecipitate tyrosine phosphorylated proteins that migrated at positions comparable to Jak1 and Jak3, consistent with the results with the specific antiserum. Phosphorylation of the Jaks in response to IL-2 or IL-4 was detectable within one minute following stimulation, peaked at 20-30 minutes and subsequently declined similar to the pattern seen in phosphorylation of Jak2 by growth hormone, IL-3 or EPO (Witthuhn et al., Cell:227-236 (1993); Artgetsinger et al., Cell 74:237-244 (1993); Silvennoinen, Proc. Natl. Acad. Sci. USA 90:8429-8433 (1993)).

Cytokine induced tyrosine phosphorylation of other Jaks activates their in vitro kinase activity (Witthuhn et al., Cell:227-236 (1993); Artgetsinger et al., Cell 74:237-244 (1993); Silvennoinen, Proc. Natl Acad. Sci. USA 90:8429-8433 (1993); Muller et al., Nature 366, 129-135 (1993); Stahl et al., Science 263:92-95 (1994)). We therefore examined the effects of IL-2 or IL-4 Jak1 or Jak3 kinase activity. The tyrosine phosphorylation of Jak1 was not associated with the activation of demonstrable kinase activity in immunoprecipitates comparable to the response seen to EPO (Witthuhn et al., Cell:227-236 (1993)). However, tyrosine phosphorylation of Jak1 in the response to IL-6 or CNTF is associated with activation of kinase activity (Stahl et al., Science 263:92-95 (1994); Narazaki et al., Proc. Natl. Acad. Sci. USA, in press, (1994)). Jak3 kinase activity was not detected in immunoprecipitates with the Jak3 specific anti-peptide antiserum. However, this antiserum is against a peptide (SEQ ID NO:15) containing the putative autophosphorylation site (KDYY) which may interfere with kinase activity as well as immunoprecipitation. We therefore assayed immunoprecipitates obtained with the Jak1/Jak3 cross-reactive antiserum against Tyk2. Activation of in vitro kinase activity was readily detectable in immunoprecipitates from cells stimulated with either IL-2 or IL-4 (FIG. 9B). Moreover, there was a single phosphorylated protein in the Jaks size range which co-migrated with Jak3. No detectable phosphorylation of a protein migrating at the position of Jak1 was seen, consistent with the results obtained with the Jak1 specific antiserum. Amino acid analysis of the in vitro phosphorylated protein indicated that phosphorylation occurred exclusively on tyrosine.

The cytoplasmic domains of the EPO receptor and the IL-β, chain have considerable homology D'Andrea, Cell 58:1023-1024 (1989)). We therefore assessed the specificity of the tyrosine phosphorylation of Jak3 in cells that expressed the EPO receptor. CTLL cells, transfected with the full-length, wild-type EPO receptor, express levels of high affinity EPO receptors comparable to transfected myeloid cells. Although the cells do not proliferate in response to EPO, EPO induces tyrosine phosphorylation of Jak2 (FIG. 9C). However, neither IL,2 nor IL-4 induced tyrosine phosphorylation of Jak2. Conversely, while IL-2 induced tyrosine phosphorylation of Jak3, EPO had no effect on Jak3 phosphorylation.

An IL-3 dependent cell line, 32Dc13(IL2Rβ), expressing the human IL-2 receptor 16 chain were also examined (FIG. 9D). These cells proliferate in response to human IL-2 comparable to IL-3. IL-3 induced the tyrosine phosphorylation of Jak2 but not Jak3. Nor was there detectable tyrosine phosphorylation of Jak1 or Tyk2 in IL-3 stimulated cells. Stimulation with IL-2 resulted in the tyrosine phosphorylation of Jak3 but no detectable tyrosine phosphorylation of Jak2 or Tyk2. Importantly, there was also no detectable tyrosine phosphorylation of Jak1. Thus, IL-2 and IL-4 cause the specific and consistent tyrosine phosphorylation of Jak3 but not of the other Jak family members. Previous studies have shown that the acidic region of the IL-2 receptor chain is required for association and activation of the p5611^(lck) (Hatakeyama et al., Cell 59:837-845 (1989)). We therefore examined 32Dc13 cells transfected with an IL-2 receptor β chain containing an internal, 70 amino acid deletion of the serine rich region. This mutant is the previously characterized A mutant which supports mitogenesis but not p56^(lck) activation (Hatakeyama et al., Science 252:1523-1528 (1991); Hatakeyama et al., Cell 59:837-845 (1989)). Stimulation of cells expressing this mutant resulted in induction of Jak3 tyrosine phosphorylation comparable to that seen in cells expressing the wild-type receptor.

The result demonstrate that, among the cytokines examined, Jak3 is specifically tyrosine phosphorylated and activated in the cellular responses to IL-2 and IL-4. IL-2 also increases the kinase activity of p56^(lck), p₅₉ ^(fyn), or p53/56^(lyn) (Taniguchi, T. & Minami, Y., Cell 73:5-8 (1993)). However, activation of the Src kinases requires the acidic domain of the IL-2 receptor β chain, which is dispensable for mitogenesis and for the activation of Jak3. Thus the role for activation of Src kinases has been unclear. In contrast, the membrane proximal, serine rich domain of the IL-2 P chain, which contains the box 1/box 2 motifs is required for mitogenesis. A similar region of the EPO receptor is required for association with Jak2 and for mitogenesis (Witthuhn et al., Cell:227-236 (1993)). Experiments are currently in progress to assess the requirement for this region for Jak3 activation.

IL-2 induces the tyrosine phosphorylation of a 116 kDa protein which could be cross-linked to the β chain (Kirken et al., J. Bol. Chem. 268:22765-22770 (1993)). These studies are similar to those which identified a 130 kDa phosphoprotein cross-linked to the EPO receptor (Yoshimura & Lodish, Mol. Cell Biol. 12:706-715 (1992)) which was subsequently shown to be Jak2 (Witthuhn et al., Cell:227-236 (1993)). Based on the role of the box 1 and box 2 regions in association of other receptors with Jaks, we would hypothesize that Jak3 associates with the IL-2 receptor β chain. Experiments are currently in progress to assess this hypothesis.

The activation of Jaks is often associated with the tyrosine phosphorylation and activation of the DNA binding activity of members of the signal transducers and activators of transcription (STAT) family. In particular, IFN-α activates STAT1 (p91) and STAT2 (p113), IFN-γ activates STAT1 (Pellegrin & Schindler, Trends in Biochemical Sciences 18:338-342 (1993)), IL-6 activates a new family member termed APRF or STAT3 (Akira et al., Cell in press, (1994)) and IL-3 activates a protein with properties of a novel STAT protein (Lamer et al., Science 261, 1730-1733 (1993)). In this regard, IL-4 induces the tyrosine phosphorylation of a DNA binding activity with properties of another novel STAT protein (Kotanides & Reich, Science 262:1265-1267 (1993)). A similar DNA binding activity is induced in CTLL cells by IL-2. It will be important to determine whether the IL-2/IL-4 induced STAT like proteins are members of the STAT family and constitute specific substrates of Jak3. Nevertheless, it can be hypothesized that cytokine induced activation of Jaks and STATs may be a very general mechanism by which cytokine binding is coupled to the regulation of gene expression.

Recombination events between the defective baculovirus DNA and the Jak2/vector DNA results in DNA encoding a viable baculovirus which will constitutively express Jak2. Infection of insect cells with this recombinant baculovius results in the high level expression of active Jak2 which may be purified by immunoprecipitation with Jak2-specific antisera. This source of active Jak2 will be useful in the study of biochemical properties of this enzyme, and can also be used in assays for inhibitors of Jak2 kinase activity based upon the in vitro Jak kinase assay described herein.

EXAMPLE 9 Activation of a Jak by IL-3 and IL-5 Demonstrated in huIL-5Rα Transfected Ba/F3 and FDCP-I Cells

Similarly as presented in the above examples, Ba/F3-huIL-5Rα and FDCP-I-huIL5Rα cells deprived of growth factor for 16 hrs were either unstimulated or stimulated with either IL3 or IL5 for 10 min. Cells were harvested and lysed for 20 minutes in 1 ml of ice cold lysis buffer. The lysates were incubated with anti-Jak2 sera and subjected to 7.5% SDS-PAGE. Gels were then transferred electrophoretically to nitrocellulose. When filters were probed with the 4G10 monoclonal antibody against phosphotyrosine, two bands that migrated at 130 kd and 150 kd were observed in cells stimulated with both IL3 and IL5. Comparable blots were probed with Jak2 sera showing that there are equivalent amounts of Jak2 in stimulated and unstimulated cells. IL3 and IL5 stimulation resulted in specific tyrosine phosphorylation of a band that co-migrates with Jak2. The tyrosine phosphorylated band above Jak2 is attributable to the association of Jak2 with the common beta subunit shared between IL3, GM-CSF and IL5.

EXAMPLE 10 Activation of Jak3 by IL-7 in the PreB-cell Line by IL-7

Similarly as presented in the above examples, D1F9 cells deprived of growth factor for 16 hrs were either unstimulated or stimulated with IL-7 for 10 min. Cells were harvested and lysed for 20 minutes in 1 ml of ice cold lysis buffer. The lysates were incubated with anti-Jak family sera and subjected to 7.5% SDS-PAGE. Gels were then transferred electrophoretically to nitrocellulose. When filters were probed with the 4G10 monoclonal antibody against phosphotyrosine two bands were observed in cells stimulated with IL7. The migration of the bands identified them as Jak1 and Jak3. These results are similar to those seen in cells stimulated with IL2 and IL4, which is expected as the IL2R-γ subunit is a component of the IL7 receptor.

EXAMPLE 11 Activation of a Jak by IL-9in Human M-07 Cells Recognized by muJak2 Sera

Similarly as presented in the above examples, M07 cells deprived of growth factor for 16 hrs were either unstimulated or stimulated with huIL3 and huIL9 for 10 min. Cells were harvested and lysed for 20 minutes in 1 ml of ice cold lysis buffer. The lysates were incubated with anti-Jak2 sera and subjected to 7.5% SDS-PAGE. Gels were then transferred electrophoretically to nitrocellulose. When filters were probed with the 4G10 monoclonal antibody against phosphotyrosine the expected band representing Jak2 in IL3 stimulated cells was observed. In the lane representing IL9 stimulation a single band that migrated faster than Jak2 was observed. The migration of this band shows that it is likely Jak3.

EXAMPLE 12 Activation of a Jak by IL-11 in the fibroblast Cell Line, 3T3-LI

Similarly as presented in the above examples, serum starved 3T3-LI cells were either unstimulated or stimulated with IL-11 for 10 min. Cells were harvested and lysed in 1 ml of ice cold lysis buffer. The lysates were incubated with anti-Jak1 or Jak2 sera and subjected to 7.5% SDS-PAGE. Gels were then transferred electrophoretically to nitrocellulose. When filters were probed with the 4G10 monoclonal antibody against phosphotyrosine a band representing Jak1 in IL-11 stimulated cells was observed. No comparable tyrosine phosphorylation of Jak2 was observed in response to IL-11. Comparable blots were probed with Jak2 sera and Jak1 sera showing that there are equivalent amounts of Jak2 and Jak1 in stimulated and unstimulated cells.

EXAMPLE 13 Activation of a Jak by G-CSF

Similarly as presented in the above examples, induction of tyrosine phosphorylation of Jak1 and Jak2 in NFS60, Ba/F3/G-CSFR, 32DC13/G-CSF and FDCP-I/G-CSF was performed. NFS60, Ba/F3/G-CSFR, 32DC13/G-CSF and FDCP-I/G-CSF cells deprived of growth factor for 16 hrs were either unstimulated or stimulated with G-CSF for 10 min. Cells were harvested and lysed for 20 minutes in 1 ml of ice cold lysis buffer. The lysates were incubated with anti-Jak2 and anti-Jak1 sera, subjected to 7.5% SDS-PAGE and transferred electrophoretically to nitrocellulose. When filters were probed with the 4G10 monoclonal antibody against phosphotyrosine a readily detectable band is evident in the G-CSF stimulated cells for Jak2 immunoprecipitation and a lesser intense band is seem in the Jak1 immunoprecipitated lysates. Comparable blots were probed with Jak2 sera and Jak1 sera showing that there are equivalent amounts of Jak2 and Jak1 in stimulated and unstimulated cells.

G-CSF receptor mutants characterized by their ability to support G-CSF dependent growth were utilized to examine whether a G-CSF dependent growth correlated with Jak activation as demonstrated in IL3 and Epo receptor mutants. Cells expressing G-CSF receptors and receptor mutants were examined. The ability to tyrosine phosphorylate Jak2 is correlated to a G-CSF dependence in all case with the exception of a Box I point mutation. In this case although the receptor supports G-CSF dependent growth Jak2 is not tyrosine phosphorylated.

Activation of kinase activity was examined by in vitro kinase assays on Jak1 and Jak2 immunoprecipitates of stimulated and unstimulated NFS-60 cells extracts. Jak1 immunoprecipitations showed no evidence of increased autophosphorylation in G-CSF stimulated NFS-60. No examination of Jak1 in vitro kinase activity has been preformed in Ba/F3/G-CSFR, 32DC13/G-CSF and FDCP-I/G-CSF where the Jak1 tyrosine phosphorylation appears to be increased in relationship to the NFS-60 cells. Jak2 immunoprecipitations have a major phosphorylated band that emigrates with Jak2 in response to G-CSF whereas no comparable band was detected in unstimulated cells.

EXAMPLE 14 Activation of a Jak by GM-CSF

Similarly as presented in the above examples, induction of tyrosine phosphorylation of Jak1 and Jak2 in cells expressing GM-CSF receptors is performed. GM-CSF receptor cells deprived of growth factor for 16 hrs are either unstimulated or stimulated with GM-CSF for 10 min. Cells are harvested and lysed for 20 minutes in 1 ml of ice cold lysis buffer. The lysates are incubated with anti-Jak2 and anti-Jak1 sera, subjected to 7.5% SDS-PAGE and transferred electrophoretically to nitrocellulose. When filters are probed with a monoclonal antibody against phosphotyrosine a readily detectable band is expected to be evident in the GM-CSF stimulated cells for Jak2 immunoprecipitation and a lesser intense band is seem in the Jak1 immunoprecipitated lysates. Comparable blots are probed with Jak2 sera and Jak1 sera showing that there are equivalent amounts of Jak2 and Jak1 in stimulated and unstimulated cells.

GM-CSF receptor mutants characterized by their ability to support GM-CSF dependent growth are utilized to examine whether a GM-CSF dependent growth correlated with Jak activation as is demonstrated in IL3 and Epo receptor mutants. Cells expressing GM-CSF receptors and receptor mutants are examined. The ability to tyrosine phosphorylate Jak2 is expected to correlated with a GM-CSF dependence in most cases.

Activation of kinase activity is examined by in vitro kinase assays on Jak1 and Jak2 immunoprecipitates of stimulated and unstimulated GM-CSF receptor containing cell extracts. Jak1 immunoprecipitations is expected to showed little evidence of increased autophosphorylation in GM-CSF stimulated cells. Jak1 tyrosine phosphorylation appears to be increased in relationship to the GM-CSFR cells. Jak2 immunoprecipitations are expected to have a major phosphorylated band that co-migrates with Jak2 in response to GM-CSF whereas no comparable band is expected to be detected in unstimulated cells.

EXAMPLE 15 The JAK Family of Kinases are Involved in Signal Transduction by the CNTF Family of Factors

Materials and Methods

Reagents

Antisera specific for LIFRβ (Stahl et al., J. Biol Chem. 268:7628-7631 (1993), gp130 (Davis et al., Science 260:1805-1808 (1993), Jak1 and Jak2 (Silvennoinen et al., Proc. Natl. Acad. Sci. USA, 1993 (in press) have been described. The rabbit antiserum against Tyk2 was raised and purified against a portion of Tyk2 expressed as a glutathione-S-transferase (GST) fusion protein (Velazquez et al., Cell 70:313-322 (1992)). Expression plasmids appropriate for COS expression of epitope-tagged LIFRβ and gp130 were previously described (Davis et al., Science 260:1805-1808 (1993), except that the LIFRβ coding sequence was modified to contain 3 successive copies of the myc epitope to improve selectability. Full length cDNA for murine Jak1 and Jak2 were provided in the plasmid pRK5.

Methods

Cell lines were passaged and maintained as previously described (Ip et al., Cell 69:1121-1132 (1992). COS cell transfections were carried out by a DEAE protocol (Davis et al., Science 260:1805-1808 (1993)). Plates of cells were starved in serum-free RPMI medium for 2-4 hours, then stimulated with 50 ng/ml of the indicated factor for 5 minutes. Cells were harvested and lysed as previously described (Stahl et al., J. Biol. Chem. 268:7628-7631 (1993)), except that 1% Brij 96 (Sigma) or 1% NP40 (Boehringer) was used as indicated. Immunoprecipitation, electrophoresis, and anti-phosphotyrosine immunoblotting with monoclonal antibody 4G10 (Upstate Biotechnology) and detection via enhanced chemiluminescence (Amersham) was carried out as previously described (Id). For in vitro kinase assays, the washed beads were incubated for 15 min at room temperature in 20 mM Hepes (pH 7.2), 10 mM MnCl2, 30 mM sodium orthovanadate and 10 MCi of (g-³² P)ATP (NEN DUPONT). Electrophoresis sample buffer was added and the samples were boiled, subjected to SDS PAGE, and electroblotted to PVDF. The membrane was then incubated in 1 M NaOH at 65° C. for 60 min to destroy serine and threonine phosphate before autoradiography.

Results

CNTF-Induced Responses are Associated with a 130 kDa Protein

Following addition of CNTF, a receptor complex forms that consists of CNTF, CNTFRα, gp130, and LIFRβ. Immunoprecipitation (IP) of the receptor complex with antibodies against LIFRβ or gp130 (not shown) following cell lysis in the detergent Brij 96 results in the co-purification of a 130 kDa protein that is tyrosine phosphorylated. LIF and OSM, which also bind to and heterodimerize gp130 and LIFRβ (Gearing et at., Science 260:1434-1437 (1992); Baumann et al., J. Biol. Chem. 268:8414-8417 (1993); Davis et al., Science 250:1805-1808 (1993)), also show association and tyrosine phosphorylation of a protein with an identical appearance. The purified receptor complex also shows associated protein tyrosine kinase activity in vitro giving rise to tyrosine phosphorylation of both gp130 and LIFRβ, as well as the associated 130 kDa protein. Tyrosine kinase activity is also associated with LIFRβ in the absence of CNTF, although the 130 kDa protein is either not present or not significantly phosphorylated in the absence of the factor. Other experiments showing that this in vitro kinase activity has the same sensitivity to staurosporine as that observed upon addition of CNTF to intact cells suggested that this associated tyrosine kinase activity is relevant to that which is required in the cell to mediate CNTF-induced responses. Furthermore, the 130 kDa protein appears to be a good candidate for this kinase since lysis of the cells in NP-40 does not give co-purification of either the 130 kDa protein or tyrosine kinase activity (not shown).

CNTF and Related Factors Induce Tyrosine Phosphorylation of Jak1, Jak2 and Tyk2

Experiments using specific antisera raised against portions of Jak1, Jak2, or Tyk2 reveal that all 3 of these kinases can become tyrosine phosphorylated following stimulation by CNTF, LIF, OSM, and IL6. CNTF induces tyrosine phosphorylation of both Jak1 and Jak2 in EW1 cells, and these proteins appear to co-migrate with 130 and 131 kDa proteins that co-purify with the receptor complex immunoprecipitated with a-LIFRβ. Furthermore, the addition of IL-6+sIL6Rα, as well as LIF and OSM (not shown) to EW-1 calls also results in phosphorylation of Jak1 and Jak2 but not Tyk2. In contrast, IL6 stimulated U266 cells give tyrosine phosphorylation of Tyk2 and Jak1 without apparent change in the phosphorylation status of Jak2. OSM treated SK-MES cells reveal tyrosine phosphorylation of primarily Jak2, with smaller changes in Tyk2 and Jak1. In each of these cases, tyrosine phosphorylation of the Jaks or Tyk2 is associated with an increase in their in vitro tyrosine kinase activity (not shown). These results stand in contrast to previous results showing that stimulation with GM-CSF, EPO, G-CSF, IFN-γ, or IL-3 only result in tyrosine phosphorylation of Jak2 ((Argetsinger et al., Cell 74:237-24 (1993); Silvennoinen et al., Proc. Natl. Acad. Sci. USA (in press; 1993); Witthuhn et al., Cell 74:227-236 (1993)). We conclude from these experiments that the CNTF family of factors can activate Jak1, Jak2, and Tyk2, although there is some variability in which Jak/Tyk family member is activated in a particular cell.

The Jaks Associate with CNTF β Receptor Components

Transient transfections in COS cells were used to determine whether the Jaks could associate with the β receptor components in the absence of factors. These experiments used carboxyl terminally epitope-tagged versions of LIFRβ containing the 10 amino acid portion of c-myc that is recognized by the monoclonal antibody 9E10 (Davis et al., Science 253:5963 (1991)). COS cells were co-transfected with appropriate expression vectors encoding full length versions of LIFRβ and Jak1 or Jak2, and Brij 96 lysates were immunoprecipitated with 9E10 and then blotted with the antisera against either Jak1 or Jak2. These experiments show that either Jak can associate with LIFRβ in the absence of any added ligand. Furthermore, a truncated version of LIFRβ which retains only the firm 76 amino acids of the cytoplasmic domain is fully capable of binding to Jak1 and Jak2 as well. This implicates the membrane proximal region of LIFRβ as the Jak binding domain, which is consistent with the homology between this region of the receptor with those in gp130 and EPOR that have been shown to be required for signal transduction upon factor binding (Murakami et al., Science 260:11349-11353 (1991); Witthuhn et al., Cell 74:227-236 (1993)).

Co-Transfection with Receptor β-Components and Jaks Results in Ligand Induced Functional Response

Further experiments in COS cells were undertaken to establish whether co-transfection of the receptor β-components with the Jaks could reconstruct a ligand-induced functional response. Epitope-tagged gp130FLAG and IL6 were chosen for these experiments, since gp130 homodimerizes and becomes tyrosine phosphorylated in response to IL6+ soluble IL6Rα obviating the need for cotransfection with LIFRβ (Murakami et al., Proc. Natl. Acad. Sci. USA 88:11349-11353 (1993); Davis et al., Science 260:1805-1808 (1993)). Following stimulation with IL6+sIL6Rα, neither mock transfected nor gp130FLAG transfected COS cells revealed substantial tyrosine phosphorylation of gp130 following immunoprecipitation with anti-FLAG and α-PTyr immunoblotting. In contrast, co-transfection with either Jak1, Jak2, or both Jak1 and Jak2 gives rise to a substantial increase in the induced tyrosine phosphorylation of gp130 upon stimulation with IL6+sIL-6Rα.

Discussion

Altogether, these results indicate that the Jaks can associate with the CNTF receptor β components, and become tyrosine phosphorylated in response to CNTF, LIF, IL6, or OSM, with concomitant activation of the tyrosine kinase. This most likely occurs through transphosphorylation as ligand-induced hetero- or homodimerization of the β components brings their bound Jaks into close apposition (Stahl and Yancopoulos, Cell 74:587-590 (1993)). The functional reconstruction in COS cells of ligand-induced tyrosine phosphorylation of gp130 upon co-transfection with either Jak1 or Jak2 is consistent with the notion that Jak1, Jak2, or Tyk2 can function as the first kinases activated inside the cell upon receptor β subunit dimerization, thus placing the Jak family of kinases as the most proximal intracellular step in mediating signal transduction of the CNTF family of factors.

All references cited herein, including journal articles or abstracts, published or corresponding U.S. or foreign patent applications, issued U.S. or foreign patents, or any other references, are entirely incorporated by reference herein, including all data, tables, figures, and text presented in the cited references. Additionally, the entire contents of the references cited within the references cited herein are also entirely incorporated by reference.

Reference to known method steps, conventional methods steps, known methods or conventional methods is not in any way an admission that any aspect, description or embodiment of the present invention is disclosed, taught or suggested in the relevant art.

The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying knowledge within the skill of the art (including the contents of the references cited herein), readily modify and/or adapt for various applications such specific embodiments, without undue experimentation, without departing from the general concept of the present invention. Therefore, such adaptations and modifications are intended to be within the meaning and range of equivalents of the disclosed embodiments, based on the teaching and guidance presented herein. It is to be understood that the phraseology or terminology herein is for the purpose of description and not of limitation, such that the terminology or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance presented herein, in combination with the knowledge of one of ordinary skill in the art.

    __________________________________________________________________________     #             SEQUENCE LISTING                                                    - -  - - (1) GENERAL INFORMATION:                                              - -    (iii) NUMBER OF SEQUENCES: 16                                           - -  - - (2) INFORMATION FOR SEQ ID NO:1:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 5 amino - #acids                                                   (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:                                - - Trp Ser Xaa Trp Ser                                                       1               5                                                               - -  - - (2) INFORMATION FOR SEQ ID NO:2:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 15 amino - #acids                                                  (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:                                - - Val Leu Pro Gln Asp Lys Glu Tyr Tyr Lys Va - #l Lys Glu Pro Gly          1               5   - #                10  - #                15                - -  - - (2) INFORMATION FOR SEQ ID NO:3:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 15 amino - #acids                                                  (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:                                - - Ala Ile Glu Thr Asp Lys Glu Tyr Tyr Thr Va - #l Lys Asp Asp Arg           1               5   - #                10  - #                15                - -  - - (2) INFORMATION FOR SEQ ID NO:4:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 15 amino - #acids                                                  (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:                                - - Ala Val Pro Glu Gly His Glu Tyr Tyr Arg Va - #l Arg Glu Asp Gly           1               5   - #                10  - #                15                - -  - - (2) INFORMATION FOR SEQ ID NO:5:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 19 amino - #acids                                                  (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:                                - - Asp Ser Gln Arg Lys Leu Gln Phe Tyr Glu As - #p Lys His Gln Leu Pro       1               5   - #                10  - #                15                - - Ala Pro Lys                                                                - -  - - (2) INFORMATION FOR SEQ ID NO:6:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 19 amino - #acids                                                  (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:                                - - Thr Leu Ile Glu Lys Glu Arg Phe Tyr Glu Se - #r Arg Cys Arg Pro Val       1               5   - #                10  - #                15                - - Thr Pro Ser                                                                - -  - - (2) INFORMATION FOR SEQ ID NO:7:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 19 amino - #acids                                                  (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:                                - - Ser Pro Ser Glu Lys Glu His Phe Tyr Gln Ar - #g Gln His Arg Leu Pro       1               5   - #                10  - #                15                - - Glu Pro Ser                                                                - -  - - (2) INFORMATION FOR SEQ ID NO:8:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 3629 base - #pairs                                                 (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ix) FEATURE:                                                                   (A) NAME/KEY: CDS                                                              (B) LOCATION: 94..3480                                                - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:                                - - CGGGGGAACA AGATGTGAAC TGTTTTCCCT CCCCAGAAGA AGAGGCCCTT TT -              #TTTCCCTC     60                                                                  - - CCGCGAAGGC CAATGTTCTG AAAAAAGCTC TAG ATG GGA ATG GC - #C TGC CTT        ACA     114                                                                                        - #                  - # Met Gly Met Ala Cys Leu Thr                          - #                  - #   1               - #5               - - ATG ACA GAA ATG GAG GCA ACC TCC ACA TCT CC - #T GTA CAT CAG AAT GGT           162                                                                        Met Thr Glu Met Glu Ala Thr Ser Thr Ser Pr - #o Val His Gln Asn Gly                     10         - #         15         - #         20                       - - GAT ATT CCT GGA AGT GCT AAT TCT GTG AAG CA - #G ATA GAG CCA GTC CTT           210                                                                        Asp Ile Pro Gly Ser Ala Asn Ser Val Lys Gl - #n Ile Glu Pro Val Leu                 25             - #     30             - #     35                           - - CAA GTG TAT CTG TAC CAT TCT CTT GGG CAA GC - #T GAA GGA GAG TAT CTG           258                                                                        Gln Val Tyr Leu Tyr His Ser Leu Gly Gln Al - #a Glu Gly Glu Tyr Leu             40                 - # 45                 - # 50                 - # 55        - - AAG TTT CCA AGT GGA GAG TAT GTT GCA GAA GA - #A ATT TGT GTG GCT GCT           306                                                                        Lys Phe Pro Ser Gly Glu Tyr Val Ala Glu Gl - #u Ile Cys Val Ala Ala                             60 - #                 65 - #                 70               - - TCT AAA GCT TGT GGT ATT ACG CCT GTG TAT CA - #T AAT ATG TTT GCG TTA           354                                                                        Ser Lys Ala Cys Gly Ile Thr Pro Val Tyr Hi - #s Asn Met Phe Ala Leu                         75     - #             80     - #             85                   - - ATG AGT GAA ACC GAA AGG ATC TGG TAC CCA CC - #C AAT CAT GTC TTC CAC           402                                                                        Met Ser Glu Thr Glu Arg Ile Trp Tyr Pro Pr - #o Asn His Val Phe His                     90         - #         95         - #        100                       - - ATA GAC GAG TCA ACC AGG CAT GAC ATA CTC TA - #C AGG ATA AGG TTC TAC           450                                                                        Ile Asp Glu Ser Thr Arg His Asp Ile Leu Ty - #r Arg Ile Arg Phe Tyr                105              - #   110              - #   115                           - - TTC CCT CAT TGG TAC TGT AGT GGC AGC AGC AG - #A ACC TAC AGA TAC GGA           498                                                                        Phe Pro His Trp Tyr Cys Ser Gly Ser Ser Ar - #g Thr Tyr Arg Tyr Gly            120                 1 - #25                 1 - #30                 1 -       #35                                                                               - - GTG TCC CGT GGG GCT GAA GCT CCT CTG CTT GA - #T GAC TTT GTC ATG         TCT      546                                                                     Val Ser Arg Gly Ala Glu Ala Pro Leu Leu As - #p Asp Phe Val Met Ser                           140  - #               145  - #               150               - - TAC CTT TTT GCT CAG TGG CGG CAT GAT TTT GT - #T CAC GGA TGG ATA AAA           594                                                                        Tyr Leu Phe Ala Gln Trp Arg His Asp Phe Va - #l His Gly Trp Ile Lys                        155      - #           160      - #           165                   - - GTA CCT GTG ACT CAT GAA ACT CAG GAA GAG TG - #T CTT GGG ATG GCG GTG           642                                                                        Val Pro Val Thr His Glu Thr Gln Glu Glu Cy - #s Leu Gly Met Ala Val                    170          - #       175          - #       180                       - - TTA GAC ATG ATG AGA ATA GCT AAG GAG AAA GA - #C CAG ACT CCA CTG GCT           690                                                                        Leu Asp Met Met Arg Ile Ala Lys Glu Lys As - #p Gln Thr Pro Leu Ala                185              - #   190              - #   195                           - - GTC TAT AAC TCT GTC AGC TAC AAG ACA TTC TT - #A CCA AAG TGC GTT CGA           738                                                                        Val Tyr Asn Ser Val Ser Tyr Lys Thr Phe Le - #u Pro Lys Cys Val Arg            200                 2 - #05                 2 - #10                 2 -       #15                                                                               - - GCG AAG ATC CAA GAC TAT CAC ATT TTA ACC CG - #G AAG CGA ATC AGG         TAC      786                                                                     Ala Lys Ile Gln Asp Tyr His Ile Leu Thr Ar - #g Lys Arg Ile Arg Tyr                           220  - #               225  - #               230               - - AGA TTT CGC AGA TTC ATT CAG CAA TTC AGT CA - #A TGT AAA GCC ACT GCC           834                                                                        Arg Phe Arg Arg Phe Ile Gln Gln Phe Ser Gl - #n Cys Lys Ala Thr Ala                        235      - #           240      - #           245                   - - AGG AAC CTA AAA CTT AAG TAT CTT ATA AAC CT - #G GAA ACC CTG CAG TCT           882                                                                        Arg Asn Leu Lys Leu Lys Tyr Leu Ile Asn Le - #u Glu Thr Leu Gln Ser                    250          - #       255          - #       260                       - - GCC TTC TAC ACA GAA CAG TTT GAA GTA AAA GA - #A TCT GCA AGA GGT CCT           930                                                                        Ala Phe Tyr Thr Glu Gln Phe Glu Val Lys Gl - #u Ser Ala Arg Gly Pro                265              - #   270              - #   275                           - - TCA GGT GAG GAG ATT TTT GCA ACC ATT ATA AT - #A ACT GGA AAC GGT GGA           978                                                                        Ser Gly Glu Glu Ile Phe Ala Thr Ile Ile Il - #e Thr Gly Asn Gly Gly            280                 2 - #85                 2 - #90                 2 -       #95                                                                               - - ATT CAG TGG TCA AGA GGG AAA CAT AAG GAA AG - #T GAG ACA CTG ACA         GAA     1026                                                                     Ile Gln Trp Ser Arg Gly Lys His Lys Glu Se - #r Glu Thr Leu Thr Glu                           300  - #               305  - #               310               - - CAG GAC GTA CAG TTA TAT TGT GAT TTC CCT GA - #T ATT ATT GAT GTC AGT          1074                                                                        Gln Asp Val Gln Leu Tyr Cys Asp Phe Pro As - #p Ile Ile Asp Val Ser                        315      - #           320      - #           325                   - - ATT AAG CAA GCA AAC CAG GAA TGC TCA AAT GA - #A AGT AGA ATT GTA ACT          1122                                                                        Ile Lys Gln Ala Asn Gln Glu Cys Ser Asn Gl - #u Ser Arg Ile Val Thr                    330          - #       335          - #       340                       - - GTC CAT AAA CAA GAT GGT AAA GTT TTG GAG AT - #A GAA CTT AGC TCA TTA          1170                                                                        Val His Lys Gln Asp Gly Lys Val Leu Glu Il - #e Glu Leu Ser Ser Leu                345              - #   350              - #   355                           - - AAA GAA GCC TTG TCA TTC GTG TCA TTA ATT GA - #C GGG TAT TAC AGA CTA          1218                                                                        Lys Glu Ala Leu Ser Phe Val Ser Leu Ile As - #p Gly Tyr Tyr Arg Leu            360                 3 - #65                 3 - #70                 3 -       #75                                                                               - - ACT GCG GAT GCG CAC CAT TAC CTC TGC AAA GA - #G GTG GCT CCC CCA         GCT     1266                                                                     Thr Ala Asp Ala His His Tyr Leu Cys Lys Gl - #u Val Ala Pro Pro Ala                           380  - #               385  - #               390               - - GTG CTC GAG AAC ATA CAC AGC AAC TGC CAC GG - #C CCA ATA TCA ATG GAT          1314                                                                        Val Leu Glu Asn Ile His Ser Asn Cys His Gl - #y Pro Ile Ser Met Asp                        395      - #           400      - #           405                   - - TTT GCC ATT AGC AAA CTA AAG AAG GCG GGT AA - #C CAG ACT GGA CTA TAT          1362                                                                        Phe Ala Ile Ser Lys Leu Lys Lys Ala Gly As - #n Gln Thr Gly Leu Tyr                    410          - #       415          - #       420                       - - GTG CTA CGA TGC AGC CCT AAG GAC TTC AAC AA - #A TAC TTT CTG ACC TTT          1410                                                                        Val Leu Arg Cys Ser Pro Lys Asp Phe Asn Ly - #s Tyr Phe Leu Thr Phe                425              - #   430              - #   435                           - - GCT GTT GAG CGA GAA AAT GTC ATT GAA TAT AA - #A CAC TGT TTG ATT ACG          1458                                                                        Ala Val Glu Arg Glu Asn Val Ile Glu Tyr Ly - #s His Cys Leu Ile Thr            440                 4 - #45                 4 - #50                 4 -       #55                                                                               - - AAG AAT GAG AAT GGA GAA TAC AAC CTC AGC GG - #G ACT AAG AGG AAC         TTC     1506                                                                     Lys Asn Glu Asn Gly Glu Tyr Asn Leu Ser Gl - #y Thr Lys Arg Asn Phe                           460  - #               465  - #               470               - - AGT AAC CTT AAG GAC CTT TTG AAT TGC TAC CA - #G ATG GAA ACT GTG CGC          1554                                                                        Ser Asn Leu Lys Asp Leu Leu Asn Cys Tyr Gl - #n Met Glu Thr Val Arg                        475      - #           480      - #           485                   - - TCA GAC AGT ATC ATC TTC CAG TTT ACC AAA TG - #C TGC CCC CCA AAG CCA          1602                                                                        Ser Asp Ser Ile Ile Phe Gln Phe Thr Lys Cy - #s Cys Pro Pro Lys Pro                    490          - #       495          - #       500                       - - AAA GAT AAA TCA AAC CTT CTC GTC TTC AGA AC - #A AAT GGT ATT TCT GAT          1650                                                                        Lys Asp Lys Ser Asn Leu Leu Val Phe Arg Th - #r Asn Gly Ile Ser Asp                505              - #   510              - #   515                           - - GTT CAG ATC TCA CCA ACA TTA CAG AGG CAT AA - #T AAT GTG AAT CAA ATG          1698                                                                        Val Gln Ile Ser Pro Thr Leu Gln Arg His As - #n Asn Val Asn Gln Met            520                 5 - #25                 5 - #30                 5 -       #35                                                                               - - GTG TTT CAC AAA ATC AGG AAT GAA GAT TTA AT - #A TTT AAT GAA AGT         CTT     1746                                                                     Val Phe His Lys Ile Arg Asn Glu Asp Leu Il - #e Phe Asn Glu Ser Leu                           540  - #               545  - #               550               - - GGC CAA GGT ACT TTT ACA AAA ATT TTT AAA GG - #T GTA AGA AGA GAA GTT          1794                                                                        Gly Gln Gly Thr Phe Thr Lys Ile Phe Lys Gl - #y Val Arg Arg Glu Val                        555      - #           560      - #           565                   - - GGA GAT TAT GGT CAA CTG CAC AAA ACG GAA GT - #T CTT TTG AAA GTC CTA          1842                                                                        Gly Asp Tyr Gly Gln Leu His Lys Thr Glu Va - #l Leu Leu Lys Val Leu                    570          - #       575          - #       580                       - - GAT AAA GCA CAT AGG AAC TAT TCA GAG TCT TT - #C TTC GAA GCA GCA AGC          1890                                                                        Asp Lys Ala His Arg Asn Tyr Ser Glu Ser Ph - #e Phe Glu Ala Ala Ser                585              - #   590              - #   595                           - - ATG ATG AGT CAG CTT TCT CAC AAG CAT TTG GT - #T TTG AAT TAT GGT GTC          1938                                                                        Met Met Ser Gln Leu Ser His Lys His Leu Va - #l Leu Asn Tyr Gly Val            600                 6 - #05                 6 - #10                 6 -       #15                                                                               - - TGT GTC TGT GGA GAG GAG AAC ATT CTG GTT CA - #A GAA TTT GTA AAA         TTT     1986                                                                     Cys Val Cys Gly Glu Glu Asn Ile Leu Val Gl - #n Glu Phe Val Lys Phe                           620  - #               625  - #               630               - - GGA TCA CTG GAT ACA TAC CTG AAG AAG AAC AA - #A AAT TCC ATA AAT ATA          2034                                                                        Gly Ser Leu Asp Thr Tyr Leu Lys Lys Asn Ly - #s Asn Ser Ile Asn Ile                        635      - #           640      - #           645                   - - TTA TGG AAA CTT GGA GTG GCT AAG CAG TTG GC - #A TGG GCC ATG CAT TTT          2082                                                                        Leu Trp Lys Leu Gly Val Ala Lys Gln Leu Al - #a Trp Ala Met His Phe                    650          - #       655          - #       660                       - - CTA GAA GAA AAA TCC CTT ATT CAT GGG AAT GT - #G TGT GCT AAA AAT ATC          2130                                                                        Leu Glu Glu Lys Ser Leu Ile His Gly Asn Va - #l Cys Ala Lys Asn Ile                665              - #   670              - #   675                           - - CTG CTT ATC AGA GAA GAA GAC AGG AGA ACG GG - #G AAC CCA CCT TTC ATC          2178                                                                        Leu Leu Ile Arg Glu Glu Asp Arg Arg Thr Gl - #y Asn Pro Pro Phe Ile            680                 6 - #85                 6 - #90                 6 -       #95                                                                               - - AAA CTT AGT GAT CCT GGC ATT AGC ATT ACA GT - #T CTA CCG AAG GAC         ATT     2226                                                                     Lys Leu Ser Asp Pro Gly Ile Ser Ile Thr Va - #l Leu Pro Lys Asp Ile                           700  - #               705  - #               710               - - CTT CAG GAG AGA ATA CCA TGG GTA CCT CCT GA - #A TGC ATT GAG AAT CCT          2274                                                                        Leu Gln Glu Arg Ile Pro Trp Val Pro Pro Gl - #u Cys Ile Glu Asn Pro                        715      - #           720      - #           725                   - - AAA AAT CTC AAT CTG GCA ACA GAC AAG TGG AG - #C TTC GGG ACC ACT CTG          2322                                                                        Lys Asn Leu Asn Leu Ala Thr Asp Lys Trp Se - #r Phe Gly Thr Thr Leu                    730          - #       735          - #       740                       - - TGG GAG ATC TGC AGT GGA GGA GAT AAG CCC CT - #G AGT GCT CTG GAT TCT          2370                                                                        Trp Glu Ile Cys Ser Gly Gly Asp Lys Pro Le - #u Ser Ala Leu Asp Ser                745              - #   750              - #   755                           - - CAA AGA AAG CTG CAG TTC TAT GAA GAT AAG CA - #T CAG CTT CCT GCA CCC          2418                                                                        Gln Arg Lys Leu Gln Phe Tyr Glu Asp Lys Hi - #s Gln Leu Pro Ala Pro            760                 7 - #65                 7 - #70                 7 -       #75                                                                               - - AAG TGG ACA GAG TTA GCA AAC CTT ATA AAT AA - #T TGC ATG GAC TAT         GAG     2466                                                                     Lys Trp Thr Glu Leu Ala Asn Leu Ile Asn As - #n Cys Met Asp Tyr Glu                           780  - #               785  - #               790               - - CCA GAT TTC AGG CCT GCT TTC AGA GCT GTC AT - #C CGT GAT CTT AAC AGC          2514                                                                        Pro Asp Phe Arg Pro Ala Phe Arg Ala Val Il - #e Arg Asp Leu Asn Ser                        795      - #           800      - #           805                   - - CTG TTT ACT CCA GAT TAT GAA CTA CTA ACA GA - #A AAT GAC ATG CTA CCA          2562                                                                        Leu Phe Thr Pro Asp Tyr Glu Leu Leu Thr Gl - #u Asn Asp Met Leu Pro                    810          - #       815          - #       820                       - - AAC ATG AGA ATA GGT GCC CTA GGG TTT TCT GG - #T GCT TTT GAA GAC AGG          2610                                                                        Asn Met Arg Ile Gly Ala Leu Gly Phe Ser Gl - #y Ala Phe Glu Asp Arg                825              - #   830              - #   835                           - - GAC CCT ACA CAG TTT GAA GAG AGA CAC TTG AA - #G TTT CTA CAG CAG CTT          2658                                                                        Asp Pro Thr Gln Phe Glu Glu Arg His Leu Ly - #s Phe Leu Gln Gln Leu            840                 8 - #45                 8 - #50                 8 -       #55                                                                               - - GGC AAA GGT AAC TTC GGG AGT GTG GAG ATG TG - #C CGC TAT GAC CCG         CTG     2706                                                                     Gly Lys Gly Asn Phe Gly Ser Val Glu Met Cy - #s Arg Tyr Asp Pro Leu                           860  - #               865  - #               870               - - CAG GAC AAC ACT GGC GAG GTG GTC GCT GTG AA - #G AAA CTC CAG CAC AGC          2754                                                                        Gln Asp Asn Thr Gly Glu Val Val Ala Val Ly - #s Lys Leu Gln His Ser                        875      - #           880      - #           885                   - - ACT GAA GAG CAC CTC CGA GAC TTT GAG AGG GA - #G ATC GAG ATC CTG AAA          2802                                                                        Thr Glu Glu His Leu Arg Asp Phe Glu Arg Gl - #u Ile Glu Ile Leu Lys                    890          - #       895          - #       900                       - - TCC TTG CAG CAT GAC AAC ATC GTC AAG TAC AA - #G GGA GTG TGC TAC AGT          2850                                                                        Ser Leu Gln His Asp Asn Ile Val Lys Tyr Ly - #s Gly Val Cys Tyr Ser                905              - #   910              - #   915                           - - GCG GGT CGG CGC AAC CTA AGA TTA ATT ATG GA - #A TAT TTA CCA TAT GGA          2898                                                                        Ala Gly Arg Arg Asn Leu Arg Leu Ile Met Gl - #u Tyr Leu Pro Tyr Gly            920                 9 - #25                 9 - #30                 9 -       #35                                                                               - - AGT TTA CGA GAC TAT CTC CAA AAA CAT AAA GA - #A CGG ATA GAT CAC         AAA     2946                                                                     Ser Leu Arg Asp Tyr Leu Gln Lys His Lys Gl - #u Arg Ile Asp His Lys                           940  - #               945  - #               950               - - AAA CTT CTT CAA TAC ACA TCT CAG ATA TGC AA - #G GGC ATG GAA TAT CTT          2994                                                                        Lys Leu Leu Gln Tyr Thr Ser Gln Ile Cys Ly - #s Gly Met Glu Tyr Leu                        955      - #           960      - #           965                   - - GGT ACA AAA AGG TAT ATC CAC AGG GAC CTG GC - #A ACA AGG AAC ATA TTG          3042                                                                        Gly Thr Lys Arg Tyr Ile His Arg Asp Leu Al - #a Thr Arg Asn Ile Leu                    970          - #       975          - #       980                       - - GTG GAA AAT GAG AAC AGG GTT AAA ATA GGA GA - #C TTC GGA TTA ACC AAA          3090                                                                        Val Glu Asn Glu Asn Arg Val Lys Ile Gly As - #p Phe Gly Leu Thr Lys                985              - #   990              - #   995                           - - GTC TTG CCG CAG GAC AAA GAA TAC TAC AAA GT - #A AAG GAG CCA GGG GAA          3138                                                                        Val Leu Pro Gln Asp Lys Glu Tyr Tyr Lys Va - #l Lys Glu Pro Gly Glu            1000                1005 - #                1010 - #               1015         - - AGC CCC ATA TTC TGG TAC GCA CCT GAA TCC TT - #G ACG GAG AGC AAG TTT          3186                                                                        Ser Pro Ile Phe Trp Tyr Ala Pro Glu Ser Le - #u Thr Glu Ser Lys Phe                            1020 - #               1025  - #              1030              - - TCT GTG GCC TCA GAT GTG TGG AGC TTT GGA GT - #G GTT CTA TAC GAA CTT          3234                                                                        Ser Val Ala Ser Asp Val Trp Ser Phe Gly Va - #l Val Leu Tyr Glu Leu                        1035     - #           1040      - #          1045                  - - TTC ACA TAC ATC GAG AAG AGT AAA AGT CCA CC - #C GTG GAA TTT ATG CGA          3282                                                                        Phe Thr Tyr Ile Glu Lys Ser Lys Ser Pro Pr - #o Val Glu Phe Met Arg                    1050         - #       1055          - #      1060                      - - ATG ATT GGC AAT GAT AAA CAA GGG CAA ATG AT - #T GTG TTC CAT TTG ATA          3330                                                                        Met Ile Gly Asn Asp Lys Gln Gly Gln Met Il - #e Val Phe His Leu Ile                1065             - #   1070              - #  1075                          - - GAG CTA CTG AAG AGC AAC GGA AGA TTG CCA AG - #G CCA GAA GGA TGC CCA          3378                                                                        Glu Leu Leu Lys Ser Asn Gly Arg Leu Pro Ar - #g Pro Glu Gly Cys Pro            1080                1085 - #                1090 - #               1095         - - GAT GAG ATT TAT GTG ATC ATG ACA GAG TGC TG - #G AAC AAC AAT GTG AGC          3426                                                                        Asp Glu Ile Tyr Val Ile Met Thr Glu Cys Tr - #p Asn Asn Asn Val Ser                            1100 - #               1105  - #              1110              - - CAG CGT CCC TCC TTC AGG GAC CTT TCG TTC GG - #G TGG ATC AAA TCC GGG          3474                                                                        Gln Arg Pro Ser Phe Arg Asp Leu Ser Phe Gl - #y Trp Ile Lys Ser Gly                        1115     - #           1120      - #          1125                  - - ACA GTA TAGCTGCGTG AAAGAGATGG CCTTCACTCA GAGACCAAGC AG - #ACTTCCAG           3530                                                                        Thr Val                                                                         - - AACCAGAACA AAGCTCTGTA GCCTTGTGTC TACACATCCT TATCATGATG CT -              #AGCTAGGC   3590                                                                  - - AGAAGAAACT GTGACGCCGT CTGCTCAAAG CTTTGCTTC      - #                       - #  3629                                                                      - -  - - (2) INFORMATION FOR SEQ ID NO:9:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 1129 amino - #acids                                                (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: protein                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:                                - - Met Gly Met Ala Cys Leu Thr Met Thr Glu Me - #t Glu Ala Thr Ser Thr         1               5 - #                 10 - #                 15               - - Ser Pro Val His Gln Asn Gly Asp Ile Pro Gl - #y Ser Ala Asn Ser Val                    20     - #             25     - #             30                   - - Lys Gln Ile Glu Pro Val Leu Gln Val Tyr Le - #u Tyr His Ser Leu Gly                35         - #         40         - #         45                       - - Gln Ala Glu Gly Glu Tyr Leu Lys Phe Pro Se - #r Gly Glu Tyr Val Ala            50             - #     55             - #     60                           - - Glu Glu Ile Cys Val Ala Ala Ser Lys Ala Cy - #s Gly Ile Thr Pro Val        65                 - # 70                 - # 75                 - # 80        - - Tyr His Asn Met Phe Ala Leu Met Ser Glu Th - #r Glu Arg Ile Trp Tyr                        85 - #                 90 - #                 95               - - Pro Pro Asn His Val Phe His Ile Asp Glu Se - #r Thr Arg His Asp Ile                   100      - #           105      - #           110                   - - Leu Tyr Arg Ile Arg Phe Tyr Phe Pro His Tr - #p Tyr Cys Ser Gly Ser               115          - #       120          - #       125                       - - Ser Arg Thr Tyr Arg Tyr Gly Val Ser Arg Gl - #y Ala Glu Ala Pro Leu           130              - #   135              - #   140                           - - Leu Asp Asp Phe Val Met Ser Tyr Leu Phe Al - #a Gln Trp Arg His Asp       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Phe Val His Gly Trp Ile Lys Val Pro Val Th - #r His Glu Thr Gln         Glu                                                                                              165  - #               170  - #               175              - - Glu Cys Leu Gly Met Ala Val Leu Asp Met Me - #t Arg Ile Ala Lys Glu                   180      - #           185      - #           190                   - - Lys Asp Gln Thr Pro Leu Ala Val Tyr Asn Se - #r Val Ser Tyr Lys Thr               195          - #       200          - #       205                       - - Phe Leu Pro Lys Cys Val Arg Ala Lys Ile Gl - #n Asp Tyr His Ile Leu           210              - #   215              - #   220                           - - Thr Arg Lys Arg Ile Arg Tyr Arg Phe Arg Ar - #g Phe Ile Gln Gln Phe       225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - Ser Gln Cys Lys Ala Thr Ala Arg Asn Leu Ly - #s Leu Lys Tyr Leu         Ile                                                                                              245  - #               250  - #               255              - - Asn Leu Glu Thr Leu Gln Ser Ala Phe Tyr Th - #r Glu Gln Phe Glu Val                   260      - #           265      - #           270                   - - Lys Glu Ser Ala Arg Gly Pro Ser Gly Glu Gl - #u Ile Phe Ala Thr Ile               275          - #       280          - #       285                       - - Ile Ile Thr Gly Asn Gly Gly Ile Gln Trp Se - #r Arg Gly Lys His Lys           290              - #   295              - #   300                           - - Glu Ser Glu Thr Leu Thr Glu Gln Asp Val Gl - #n Leu Tyr Cys Asp Phe       305                 3 - #10                 3 - #15                 3 -       #20                                                                               - - Pro Asp Ile Ile Asp Val Ser Ile Lys Gln Al - #a Asn Gln Glu Cys         Ser                                                                                              325  - #               330  - #               335              - - Asn Glu Ser Arg Ile Val Thr Val His Lys Gl - #n Asp Gly Lys Val Leu                   340      - #           345      - #           350                   - - Glu Ile Glu Leu Ser Ser Leu Lys Glu Ala Le - #u Ser Phe Val Ser Leu               355          - #       360          - #       365                       - - Ile Asp Gly Tyr Tyr Arg Leu Thr Ala Asp Al - #a His His Tyr Leu Cys           370              - #   375              - #   380                           - - Lys Glu Val Ala Pro Pro Ala Val Leu Glu As - #n Ile His Ser Asn Cys       385                 3 - #90                 3 - #95                 4 -       #00                                                                               - - His Gly Pro Ile Ser Met Asp Phe Ala Ile Se - #r Lys Leu Lys Lys         Ala                                                                                              405  - #               410  - #               415              - - Gly Asn Gln Thr Gly Leu Tyr Val Leu Arg Cy - #s Ser Pro Lys Asp Phe                   420      - #           425      - #           430                   - - Asn Lys Tyr Phe Leu Thr Phe Ala Val Glu Ar - #g Glu Asn Val Ile Glu               435          - #       440          - #       445                       - - Tyr Lys His Cys Leu Ile Thr Lys Asn Glu As - #n Gly Glu Tyr Asn Leu           450              - #   455              - #   460                           - - Ser Gly Thr Lys Arg Asn Phe Ser Asn Leu Ly - #s Asp Leu Leu Asn Cys       465                 4 - #70                 4 - #75                 4 -       #80                                                                               - - Tyr Gln Met Glu Thr Val Arg Ser Asp Ser Il - #e Ile Phe Gln Phe         Thr                                                                                              485  - #               490  - #               495              - - Lys Cys Cys Pro Pro Lys Pro Lys Asp Lys Se - #r Asn Leu Leu Val Phe                   500      - #           505      - #           510                   - - Arg Thr Asn Gly Ile Ser Asp Val Gln Ile Se - #r Pro Thr Leu Gln Arg               515          - #       520          - #       525                       - - His Asn Asn Val Asn Gln Met Val Phe His Ly - #s Ile Arg Asn Glu Asp           530              - #   535              - #   540                           - - Leu Ile Phe Asn Glu Ser Leu Gly Gln Gly Th - #r Phe Thr Lys Ile Phe       545                 5 - #50                 5 - #55                 5 -       #60                                                                               - - Lys Gly Val Arg Arg Glu Val Gly Asp Tyr Gl - #y Gln Leu His Lys         Thr                                                                                              565  - #               570  - #               575              - - Glu Val Leu Leu Lys Val Leu Asp Lys Ala Hi - #s Arg Asn Tyr Ser Glu                   580      - #           585      - #           590                   - - Ser Phe Phe Glu Ala Ala Ser Met Met Ser Gl - #n Leu Ser His Lys His               595          - #       600          - #       605                       - - Leu Val Leu Asn Tyr Gly Val Cys Val Cys Gl - #y Glu Glu Asn Ile Leu           610              - #   615              - #   620                           - - Val Gln Glu Phe Val Lys Phe Gly Ser Leu As - #p Thr Tyr Leu Lys Lys       625                 6 - #30                 6 - #35                 6 -       #40                                                                               - - Asn Lys Asn Ser Ile Asn Ile Leu Trp Lys Le - #u Gly Val Ala Lys         Gln                                                                                              645  - #               650  - #               655              - - Leu Ala Trp Ala Met His Phe Leu Glu Glu Ly - #s Ser Leu Ile His Gly                   660      - #           665      - #           670                   - - Asn Val Cys Ala Lys Asn Ile Leu Leu Ile Ar - #g Glu Glu Asp Arg Arg               675          - #       680          - #       685                       - - Thr Gly Asn Pro Pro Phe Ile Lys Leu Ser As - #p Pro Gly Ile Ser Ile           690              - #   695              - #   700                           - - Thr Val Leu Pro Lys Asp Ile Leu Gln Glu Ar - #g Ile Pro Trp Val Pro       705                 7 - #10                 7 - #15                 7 -       #20                                                                               - - Pro Glu Cys Ile Glu Asn Pro Lys Asn Leu As - #n Leu Ala Thr Asp         Lys                                                                                              725  - #               730  - #               735              - - Trp Ser Phe Gly Thr Thr Leu Trp Glu Ile Cy - #s Ser Gly Gly Asp Lys                   740      - #           745      - #           750                   - - Pro Leu Ser Ala Leu Asp Ser Gln Arg Lys Le - #u Gln Phe Tyr Glu Asp               755          - #       760          - #       765                       - - Lys His Gln Leu Pro Ala Pro Lys Trp Thr Gl - #u Leu Ala Asn Leu Ile           770              - #   775              - #   780                           - - Asn Asn Cys Met Asp Tyr Glu Pro Asp Phe Ar - #g Pro Ala Phe Arg Ala       785                 7 - #90                 7 - #95                 8 -       #00                                                                               - - Val Ile Arg Asp Leu Asn Ser Leu Phe Thr Pr - #o Asp Tyr Glu Leu         Leu                                                                                              805  - #               810  - #               815              - - Thr Glu Asn Asp Met Leu Pro Asn Met Arg Il - #e Gly Ala Leu Gly Phe                   820      - #           825      - #           830                   - - Ser Gly Ala Phe Glu Asp Arg Asp Pro Thr Gl - #n Phe Glu Glu Arg His               835          - #       840          - #       845                       - - Leu Lys Phe Leu Gln Gln Leu Gly Lys Gly As - #n Phe Gly Ser Val Glu           850              - #   855              - #   860                           - - Met Cys Arg Tyr Asp Pro Leu Gln Asp Asn Th - #r Gly Glu Val Val Ala       865                 8 - #70                 8 - #75                 8 -       #80                                                                               - - Val Lys Lys Leu Gln His Ser Thr Glu Glu Hi - #s Leu Arg Asp Phe         Glu                                                                                              885  - #               890  - #               895              - - Arg Glu Ile Glu Ile Leu Lys Ser Leu Gln Hi - #s Asp Asn Ile Val Lys                   900      - #           905      - #           910                   - - Tyr Lys Gly Val Cys Tyr Ser Ala Gly Arg Ar - #g Asn Leu Arg Leu Ile               915          - #       920          - #       925                       - - Met Glu Tyr Leu Pro Tyr Gly Ser Leu Arg As - #p Tyr Leu Gln Lys His           930              - #   935              - #   940                           - - Lys Glu Arg Ile Asp His Lys Lys Leu Leu Gl - #n Tyr Thr Ser Gln Ile       945                 9 - #50                 9 - #55                 9 -       #60                                                                               - - Cys Lys Gly Met Glu Tyr Leu Gly Thr Lys Ar - #g Tyr Ile His Arg         Asp                                                                                              965  - #               970  - #               975              - - Leu Ala Thr Arg Asn Ile Leu Val Glu Asn Gl - #u Asn Arg Val Lys Ile                   980      - #           985      - #           990                   - - Gly Asp Phe Gly Leu Thr Lys Val Leu Pro Gl - #n Asp Lys Glu Tyr Tyr               995          - #       1000          - #      1005                      - - Lys Val Lys Glu Pro Gly Glu Ser Pro Ile Ph - #e Trp Tyr Ala Pro Glu           1010             - #   1015              - #  1020                          - - Ser Leu Thr Glu Ser Lys Phe Ser Val Ala Se - #r Asp Val Trp Ser Phe       1025                1030 - #                1035 - #               1040         - - Gly Val Val Leu Tyr Glu Leu Phe Thr Tyr Il - #e Glu Lys Ser Lys Ser                       1045 - #               1050  - #              1055              - - Pro Pro Val Glu Phe Met Arg Met Ile Gly As - #n Asp Lys Gln Gly Gln                   1060     - #           1065      - #          1070                  - - Met Ile Val Phe His Leu Ile Glu Leu Leu Ly - #s Ser Asn Gly Arg Leu               1075         - #       1080          - #      1085                      - - Pro Arg Pro Glu Gly Cys Pro Asp Glu Ile Ty - #r Val Ile Met Thr Glu           1090             - #   1095              - #  1100                          - - Cys Trp Asn Asn Asn Val Ser Gln Arg Pro Se - #r Phe Arg Asp Leu Ser       1105                1110 - #                1115 - #               1120         - - Phe Gly Trp Ile Lys Ser Gly Thr Val                                                       1125                                                            - -  - - (2) INFORMATION FOR SEQ ID NO:10:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 3429 base - #pairs                                                 (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ix) FEATURE:                                                                   (A) NAME/KEY: CDS                                                              (B) LOCATION: 1..3426                                                 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:                               - - ATG GCT TTC TGT GCT AAA ATG AGG AGC TCC AA - #G AAG ACT GAG GTG AAC            48                                                                        Met Ala Phe Cys Ala Lys Met Arg Ser Ser Ly - #s Lys Thr Glu Val Asn              1               5 - #                 10 - #                 15               - - CTG GAG GCC CCT GAG CCA GGG GTG GAA GTG AT - #C TTC TAT CTG TCG GAC            96                                                                        Leu Glu Ala Pro Glu Pro Gly Val Glu Val Il - #e Phe Tyr Leu Ser Asp                         20     - #             25     - #             30                   - - AGG GAG CCC CTC CGG CTG GGC AGT GGA GAG TA - #C ACA GCA GAG GAA CTG           144                                                                        Arg Glu Pro Leu Arg Leu Gly Ser Gly Glu Ty - #r Thr Ala Glu Glu Leu                     35         - #         40         - #         45                       - - TGC ATC AGG GCT GCA CAG GCA TGC CGT ATC TC - #T CCT CTT TGT CAC AAC           192                                                                        Cys Ile Arg Ala Ala Gln Ala Cys Arg Ile Se - #r Pro Leu Cys His Asn                 50             - #     55             - #     60                           - - CTC TTT GCC CTG TAT GAC GAG AAC ACC AAG CT - #C TGG TAT GCT CCA AAT           240                                                                        Leu Phe Ala Leu Tyr Asp Glu Asn Thr Lys Le - #u Trp Tyr Ala Pro Asn             65                 - # 70                 - # 75                 - # 80        - - CGC ACC ATC ACC GTT GAT GAC AAG ATG TCC CT - #C CGG CTC CAC TAC CGG           288                                                                        Arg Thr Ile Thr Val Asp Asp Lys Met Ser Le - #u Arg Leu His Tyr Arg                             85 - #                 90 - #                 95               - - ATG AGG TTC TAT TTC ACC AAT TGG CAT GGA AC - #C AAC GAC AAT GAG CAG           336                                                                        Met Arg Phe Tyr Phe Thr Asn Trp His Gly Th - #r Asn Asp Asn Glu Gln                        100      - #           105      - #           110                   - - TCA GTG TGG CGT CAT TCT CCA AAG AAG CAG AA - #A AAT GGC TAC GAG AAA           384                                                                        Ser Val Trp Arg His Ser Pro Lys Lys Gln Ly - #s Asn Gly Tyr Glu Lys                    115          - #       120          - #       125                       - - AAA AAG ATT CCA GAT GCA ACC CCT CTC CTT GA - #T GCC AGC TCA CTG GAG           432                                                                        Lys Lys Ile Pro Asp Ala Thr Pro Leu Leu As - #p Ala Ser Ser Leu Glu                130              - #   135              - #   140                           - - TAT CTG TTT GCT CAG GGA CAG TAT GAT TTG GT - #G AAA TGC CTG GCT CCT           480                                                                        Tyr Leu Phe Ala Gln Gly Gln Tyr Asp Leu Va - #l Lys Cys Leu Ala Pro            145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - ATT CGA GAC CCC AAG ACC GAG CAG GAT GGA CA - #T GAT ATT GAG AAC         GAG      528                                                                     Ile Arg Asp Pro Lys Thr Glu Gln Asp Gly Hi - #s Asp Ile Glu Asn Glu                           165  - #               170  - #               175               - - TGT CTA GGG ATG GCT GTC CTG GCC ATC TCA CA - #C TAT GCC ATG ATG AAG           576                                                                        Cys Leu Gly Met Ala Val Leu Ala Ile Ser Hi - #s Tyr Ala Met Met Lys                        180      - #           185      - #           190                   - - AAG ATG CAG TTG CCA GAA CTG CCC AAG GAC AT - #C AGC TAC AAG CGA TAT           624                                                                        Lys Met Gln Leu Pro Glu Leu Pro Lys Asp Il - #e Ser Tyr Lys Arg Tyr                    195          - #       200          - #       205                       - - ATT CCA GAA ACA TTG AAT AAG TCC ATC AGA CA - #G AGG AAC CTT CTC ACC           672                                                                        Ile Pro Glu Thr Leu Asn Lys Ser Ile Arg Gl - #n Arg Asn Leu Leu Thr                210              - #   215              - #   220                           - - AGG ATG CGG ATA AAT AAT GTT TTC AAG GAT TT - #C CTA AAG GAA TTT AAC           720                                                                        Arg Met Arg Ile Asn Asn Val Phe Lys Asp Ph - #e Leu Lys Glu Phe Asn            225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - AAC AAG ACC ATT TGT GAC AGC AGC GTG TCC AC - #G CAT GAC CTG AAG         GTG      768                                                                     Asn Lys Thr Ile Cys Asp Ser Ser Val Ser Th - #r His Asp Leu Lys Val                           245  - #               250  - #               255               - - AAA TAC TTG GCT ACC TTG GAA ACT TTG ACA AA - #A CAT TAC GGT GCT GAA           816                                                                        Lys Tyr Leu Ala Thr Leu Glu Thr Leu Thr Ly - #s His Tyr Gly Ala Glu                        260      - #           265      - #           270                   - - ATA TTT GAG ACT TCC ATG TTA CTG ATT TCA TC - #A GAA AAT GAG ATG AAT           864                                                                        Ile Phe Glu Thr Ser Met Leu Leu Ile Ser Se - #r Glu Asn Glu Met Asn                    275          - #       280          - #       285                       - - TGG TTT CAT TCG AAT GAC GGT GGA AAC GTT CT - #C TAC TAC GAA GTG ATG           912                                                                        Trp Phe His Ser Asn Asp Gly Gly Asn Val Le - #u Tyr Tyr Glu Val Met                290              - #   295              - #   300                           - - GTG ACT GGG AAT CTT GGA ATC CAG TGG AGG CA - #T AAA CCA AAT GTT GTT           960                                                                        Val Thr Gly Asn Leu Gly Ile Gln Trp Arg Hi - #s Lys Pro Asn Val Val            305                 3 - #10                 3 - #15                 3 -       #20                                                                               - - TCT GTT GAA AAG GAA AAA AAT AAA CTG AAG CG - #G AAA AAA CTG GAA         AAT     1008                                                                     Ser Val Glu Lys Glu Lys Asn Lys Leu Lys Ar - #g Lys Lys Leu Glu Asn                           325  - #               330  - #               335               - - AAA GAC AAG AAG GAT GAG GAG AAA AAC AAG AT - #C CGG GAA GAG TGG AAC          1056                                                                        Lys Asp Lys Lys Asp Glu Glu Lys Asn Lys Il - #e Arg Glu Glu Trp Asn                        340      - #           345      - #           350                   - - AAT TTT TCA TTC TTC CCT GAA ATC ACT CAC AT - #T GTA ATA AAG GAG TCT          1104                                                                        Asn Phe Ser Phe Phe Pro Glu Ile Thr His Il - #e Val Ile Lys Glu Ser                    355          - #       360          - #       365                       - - GTG GTC AGC ATT AAC AAG CAG GAC AAC AAG AA - #A ATG GAA CTG AAG CTC          1152                                                                        Val Val Ser Ile Asn Lys Gln Asp Asn Lys Ly - #s Met Glu Leu Lys Leu                370              - #   375              - #   380                           - - TCT TCC CAC GAG GAG GCC TTG TCC TTT GTG TC - #C CTG GTA GAT GGC TAC          1200                                                                        Ser Ser His Glu Glu Ala Leu Ser Phe Val Se - #r Leu Val Asp Gly Tyr            385                 3 - #90                 3 - #95                 4 -       #00                                                                               - - TTC CGG CTC ACA GCA GAT GCC CAT CAT TAC CT - #C TGC ACC GAC GTG         GCC     1248                                                                     Phe Arg Leu Thr Ala Asp Ala His His Tyr Le - #u Cys Thr Asp Val Ala                           405  - #               410  - #               415               - - CCC CCG TTG ATC GTC CAC AAC ATA CAG AAT GG - #C TGT CAT GGT CCA ATC          1296                                                                        Pro Pro Leu Ile Val His Asn Ile Gln Asn Gl - #y Cys His Gly Pro Ile                        420      - #           425      - #           430                   - - TGT ACA GAA TAC GCC ATC AAT AAA TTG CGG CA - #A GAA GGA AGC GAG GAG          1344                                                                        Cys Thr Glu Tyr Ala Ile Asn Lys Leu Arg Gl - #n Glu Gly Ser Glu Glu                    435          - #       440          - #       445                       - - GGG ATG TAC GTG CTG AGG TGG AGC TGC ACC GA - #C TTT GAC AAC ATC CTC          1392                                                                        Gly Met Tyr Val Leu Arg Trp Ser Cys Thr As - #p Phe Asp Asn Ile Leu                450              - #   455              - #   460                           - - ATG ACC GTC ACC TGC TTT GAG AAG TCT GAG CA - #G GTG CAG GGT GCC CAG          1440                                                                        Met Thr Val Thr Cys Phe Glu Lys Ser Glu Gl - #n Val Gln Gly Ala Gln            465                 4 - #70                 4 - #75                 4 -       #80                                                                               - - AAG CAG TTC AAG AAC TTT CAG ATC GAG GTG CA - #G AAG GGC CGC TAC         AGT     1488                                                                     Lys Gln Phe Lys Asn Phe Gln Ile Glu Val Gl - #n Lys Gly Arg Tyr Ser                           485  - #               490  - #               495               - - CTG CAC GGT TCG GAC CGC AGC TTC CCC AGC TT - #G GGA GAC CTC ATG AGC          1536                                                                        Leu His Gly Ser Asp Arg Ser Phe Pro Ser Le - #u Gly Asp Leu Met Ser                        500      - #           505      - #           510                   - - CAC CTC AAG AAG CAG ATC CTG CGC ACG GAT AA - #C ATC AGC TTC ATG CTA          1584                                                                        His Leu Lys Lys Gln Ile Leu Arg Thr Asp As - #n Ile Ser Phe Met Leu                    515          - #       520          - #       525                       - - AAA CGC TGC TGC CAG CCC AAG CCC CGA GAA AT - #C TCC AAC CTG CTG GTG          1632                                                                        Lys Arg Cys Cys Gln Pro Lys Pro Arg Glu Il - #e Ser Asn Leu Leu Val                530              - #   535              - #   540                           - - GCT ACT AAG AAA GCC CAG GAG TGG CAG CCC GT - #C TAC CCC ATG AGC CAG          1680                                                                        Ala Thr Lys Lys Ala Gln Glu Trp Gln Pro Va - #l Tyr Pro Met Ser Gln            545                 5 - #50                 5 - #55                 5 -       #60                                                                               - - CTG AGT TTC GAT CGG ATC CTC AAG AAG GAT CT - #G GTG CAG GGC GAG         CAC     1728                                                                     Leu Ser Phe Asp Arg Ile Leu Lys Lys Asp Le - #u Val Gln Gly Glu His                           565  - #               570  - #               575               - - CTT GGG AGA GGC ACG AGA ACA CAC ATC TAT TC - #T GGG ACC CTG ATG GAT          1776                                                                        Leu Gly Arg Gly Thr Arg Thr His Ile Tyr Se - #r Gly Thr Leu Met Asp                        580      - #           585      - #           590                   - - TAC AAG GAT GAC GAA GGA ACT TCT GAA GAG AA - #G AAG ATA AAA GTG ATC          1824                                                                        Tyr Lys Asp Asp Glu Gly Thr Ser Glu Glu Ly - #s Lys Ile Lys Val Ile                    595          - #       600          - #       605                       - - CTC AAA GTC TTA GAC CCC AGC CAC AGG GAT AT - #T TCC CTG GCC TTC TTC          1872                                                                        Leu Lys Val Leu Asp Pro Ser His Arg Asp Il - #e Ser Leu Ala Phe Phe                610              - #   615              - #   620                           - - GAG GCA GCC AGC ATG ATG AGA CAG GTC TCC CA - #C AAA CAC ATC GTG TAC          1920                                                                        Glu Ala Ala Ser Met Met Arg Gln Val Ser Hi - #s Lys His Ile Val Tyr            625                 6 - #30                 6 - #35                 6 -       #40                                                                               - - CTC TAT GGC GTC TGT GTC CGC GAC GTG GAG AA - #T ATC ATG GTG GAA         GAG     1968                                                                     Leu Tyr Gly Val Cys Val Arg Asp Val Glu As - #n Ile Met Val Glu Glu                           645  - #               650  - #               655               - - TTT GTG GAA GGG GGT CCT CTG GAT CTC TTC AT - #G CAC CGG AAA AGT GAT          2016                                                                        Phe Val Glu Gly Gly Pro Leu Asp Leu Phe Me - #t His Arg Lys Ser Asp                        660      - #           665      - #           670                   - - GTC CTT ACC ACA CCA TGG AAA TTC AAA GTT GC - #C AAA CAG CTG GCC AGT          2064                                                                        Val Leu Thr Thr Pro Trp Lys Phe Lys Val Al - #a Lys Gln Leu Ala Ser                    675          - #       680          - #       685                       - - GCC CTG AGC TAC TTG GAG GAT AAA GAC CTG GT - #C CAT GGA AAT GTG TGT          2112                                                                        Ala Leu Ser Tyr Leu Glu Asp Lys Asp Leu Va - #l His Gly Asn Val Cys                690              - #   695              - #   700                           - - ACT AAA AAC CTC CTC CTG GCC CGT GAG GGA AT - #C GAC AGT GAG TGT GGC          2160                                                                        Thr Lys Asn Leu Leu Leu Ala Arg Glu Gly Il - #e Asp Ser Glu Cys Gly            705                 7 - #10                 7 - #15                 7 -       #20                                                                               - - CCA TTC ATC AAG CTC AGT GAC CCC GGC ATC CC - #C ATT ACG GTG CTG         TCT     2208                                                                     Pro Phe Ile Lys Leu Ser Asp Pro Gly Ile Pr - #o Ile Thr Val Leu Ser                           725  - #               730  - #               735               - - AGG CAA GAA TGC ATT GAA CGA ATC CCA TGG AT - #T GCT CCT GAG TGT GTT          2256                                                                        Arg Gln Glu Cys Ile Glu Arg Ile Pro Trp Il - #e Ala Pro Glu Cys Val                        740      - #           745      - #           750                   - - GAG GAC TCC AAG AAC CTG AGT GTG GCT GCT GA - #C AAG TGG AGC TTT GGA          2304                                                                        Glu Asp Ser Lys Asn Leu Ser Val Ala Ala As - #p Lys Trp Ser Phe Gly                    755          - #       760          - #       765                       - - ACC ACG CTC TGG GAA ATC TGC TAC AAT GGC GA - #G ATC CCC TTG AAA GAC          2352                                                                        Thr Thr Leu Trp Glu Ile Cys Tyr Asn Gly Gl - #u Ile Pro Leu Lys Asp                770              - #   775              - #   780                           - - AAG ACG CTG ATT GAG AAA GAG AGA TTC TAT GA - #A AGC CGG TGC AGG CCA          2400                                                                        Lys Thr Leu Ile Glu Lys Glu Arg Phe Tyr Gl - #u Ser Arg Cys Arg Pro            785                 7 - #90                 7 - #95                 8 -       #00                                                                               - - GTG ACA CCA TCA TGT AAG GAG CTG GCT GAC CT - #C ATG ACC CGC TGC         ATG     2448                                                                     Val Thr Pro Ser Cys Lys Glu Leu Ala Asp Le - #u Met Thr Arg Cys Met                           805  - #               810  - #               815               - - AAC TAT GAC CCC AAT CAG AGG CCT TTC TTC CG - #A GCC ATC ATG AGA GAC          2496                                                                        Asn Tyr Asp Pro Asn Gln Arg Pro Phe Phe Ar - #g Ala Ile Met Arg Asp                        820      - #           825      - #           830                   - - ATT AAT AAG CTT GAA GAG CAG AAT CCA GAT AT - #T GTT TCC AGA AAA AAA          2544                                                                        Ile Asn Lys Leu Glu Glu Gln Asn Pro Asp Il - #e Val Ser Arg Lys Lys                    835          - #       840          - #       845                       - - AAC CAG CCA ACT GAA GTG GAC CCC ACA CAT TT - #T GAG AAG CGC TTC CTA          2592                                                                        Asn Gln Pro Thr Glu Val Asp Pro Thr His Ph - #e Glu Lys Arg Phe Leu                850              - #   855              - #   860                           - - AAG AGG ATC CGT GAC TTG GGA GAG GGC CAC TT - #T GGG AAG GTT GAG CTC          2640                                                                        Lys Arg Ile Arg Asp Leu Gly Glu Gly His Ph - #e Gly Lys Val Glu Leu            865                 8 - #70                 8 - #75                 8 -       #80                                                                               - - TGC AGG TAT GAC CCC GAA GAC AAT ACA GGG GA - #G CAG GTG GCT GTT         AAA     2688                                                                     Cys Arg Tyr Asp Pro Glu Asp Asn Thr Gly Gl - #u Gln Val Ala Val Lys                           885  - #               890  - #               895               - - TCT CTG AAG CCT GAG AGT GGA GGT AAC CAC AT - #A GCT GAT CTG AAA AAG          2736                                                                        Ser Leu Lys Pro Glu Ser Gly Gly Asn His Il - #e Ala Asp Leu Lys Lys                        900      - #           905      - #           910                   - - GAA ATC GAG ATC TTA AGG AAC CTC TAT CAT GA - #G AAC ATT GTG AAG TAC          2784                                                                        Glu Ile Glu Ile Leu Arg Asn Leu Tyr His Gl - #u Asn Ile Val Lys Tyr                    915          - #       920          - #       925                       - - AAA GGA ATC TGC ACA GAA GAC GGA GGA AAT GG - #T ATT AAG CTC ATC ATG          2832                                                                        Lys Gly Ile Cys Thr Glu Asp Gly Gly Asn Gl - #y Ile Lys Leu Ile Met                930              - #   935              - #   940                           - - GAA TTT CTG CCT TCG GGA AGC CTT AAG GAA TA - #T CTT CCA AAG AAT AAG          2880                                                                        Glu Phe Leu Pro Ser Gly Ser Leu Lys Glu Ty - #r Leu Pro Lys Asn Lys            945                 9 - #50                 9 - #55                 9 -       #60                                                                               - - AAC AAA ATA AAC CTC AAA CAG CAG CTA AAA TA - #T GCC GTT CAG ATT         TGT     2928                                                                     Asn Lys Ile Asn Leu Lys Gln Gln Leu Lys Ty - #r Ala Val Gln Ile Cys                           965  - #               970  - #               975               - - AAG GGG ATG GAC TAT TTG GGT TCT CGG CAA TA - #C GTT CAC CGG GAC TTG          2976                                                                        Lys Gly Met Asp Tyr Leu Gly Ser Arg Gln Ty - #r Val His Arg Asp Leu                        980      - #           985      - #           990                   - - GCA GCA AGA AAT GTC CTT GTT GAG AGT GAA CA - #C CAA GTG AAA ATT GGA          3024                                                                        Ala Ala Arg Asn Val Leu Val Glu Ser Glu Hi - #s Gln Val Lys Ile Gly                    995          - #       1000          - #      1005                      - - GAC TTC GGT TTA ACC AAA GCA ATT GAA ACC GA - #T AAG GAG TAT TAC ACC          3072                                                                        Asp Phe Gly Leu Thr Lys Ala Ile Glu Thr As - #p Lys Glu Tyr Tyr Thr                1010             - #   1015              - #  1020                          - - GTC AAG GAT GAC CGG GAC AGC CCT GTG TTT TG - #G TAT GCT CCA GAA TGT          3120                                                                        Val Lys Asp Asp Arg Asp Ser Pro Val Phe Tr - #p Tyr Ala Pro Glu Cys            1025                1030 - #                1035 - #               1040         - - TTA ATG CAA TCT AAA TTT TAT ATT GCC TCT GA - #C GTC TGG TCT TTT GGA          3168                                                                        Leu Met Gln Ser Lys Phe Tyr Ile Ala Ser As - #p Val Trp Ser Phe Gly                            1045 - #               1050  - #              1055              - - GTC ACT CTG CAT GAG CTG CTG ACT TAC TGT GA - #T TCA GAT TCT AGT CCC          3216                                                                        Val Thr Leu His Glu Leu Leu Thr Tyr Cys As - #p Ser Asp Ser Ser Pro                        1060     - #           1065      - #          1070                  - - ATG GCT TTG TTC CTG AAA ATG ATA GGC CCA AC - #C CAT GGC CAG ATG ACA          3264                                                                        Met Ala Leu Phe Leu Lys Met Ile Gly Pro Th - #r His Gly Gln Met Thr                    1075         - #       1080          - #      1085                      - - GTC ACA AGA CTT GTG AAT ACG TTA AAA GAA GG - #A AAA CGC CTG CCG TGC          3312                                                                        Val Thr Arg Leu Val Asn Thr Leu Lys Glu Gl - #y Lys Arg Leu Pro Cys                1090             - #   1095              - #  1100                          - - CCA CCT AAC TGT CCA GAT GAG GTT TAT CAG CT - #T ATG AGA AAA TGC TGG          3360                                                                        Pro Pro Asn Cys Pro Asp Glu Val Tyr Gln Le - #u Met Arg Lys Cys Trp            1105                1110 - #                1115 - #               1120         - - GAA TTC CAA CCA TCC AAT CGG ACA AGC TTT CA - #G AAC CTT ATT GAA GGA          3408                                                                        Glu Phe Gln Pro Ser Asn Arg Thr Ser Phe Gl - #n Asn Leu Ile Glu Gly                            1125 - #               1130  - #              1135              - - TTT GAA GCA CTT TTA AAA TAA       - #                  - #                     3429                                                                      Phe Glu Ala Leu Leu Lys                                                                    1140                                                                - -  - - (2) INFORMATION FOR SEQ ID NO:11:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 1142 amino - #acids                                                (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: protein                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:                               - - Met Ala Phe Cys Ala Lys Met Arg Ser Ser Ly - #s Lys Thr Glu Val Asn         1               5 - #                 10 - #                 15               - - Leu Glu Ala Pro Glu Pro Gly Val Glu Val Il - #e Phe Tyr Leu Ser Asp                    20     - #             25     - #             30                   - - Arg Glu Pro Leu Arg Leu Gly Ser Gly Glu Ty - #r Thr Ala Glu Glu Leu                35         - #         40         - #         45                       - - Cys Ile Arg Ala Ala Gln Ala Cys Arg Ile Se - #r Pro Leu Cys His Asn            50             - #     55             - #     60                           - - Leu Phe Ala Leu Tyr Asp Glu Asn Thr Lys Le - #u Trp Tyr Ala Pro Asn        65                 - # 70                 - # 75                 - # 80        - - Arg Thr Ile Thr Val Asp Asp Lys Met Ser Le - #u Arg Leu His Tyr Arg                        85 - #                 90 - #                 95               - - Met Arg Phe Tyr Phe Thr Asn Trp His Gly Th - #r Asn Asp Asn Glu Gln                   100      - #           105      - #           110                   - - Ser Val Trp Arg His Ser Pro Lys Lys Gln Ly - #s Asn Gly Tyr Glu Lys               115          - #       120          - #       125                       - - Lys Lys Ile Pro Asp Ala Thr Pro Leu Leu As - #p Ala Ser Ser Leu Glu           130              - #   135              - #   140                           - - Tyr Leu Phe Ala Gln Gly Gln Tyr Asp Leu Va - #l Lys Cys Leu Ala Pro       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Ile Arg Asp Pro Lys Thr Glu Gln Asp Gly Hi - #s Asp Ile Glu Asn         Glu                                                                                              165  - #               170  - #               175              - - Cys Leu Gly Met Ala Val Leu Ala Ile Ser Hi - #s Tyr Ala Met Met Lys                   180      - #           185      - #           190                   - - Lys Met Gln Leu Pro Glu Leu Pro Lys Asp Il - #e Ser Tyr Lys Arg Tyr               195          - #       200          - #       205                       - - Ile Pro Glu Thr Leu Asn Lys Ser Ile Arg Gl - #n Arg Asn Leu Leu Thr           210              - #   215              - #   220                           - - Arg Met Arg Ile Asn Asn Val Phe Lys Asp Ph - #e Leu Lys Glu Phe Asn       225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - Asn Lys Thr Ile Cys Asp Ser Ser Val Ser Th - #r His Asp Leu Lys         Val                                                                                              245  - #               250  - #               255              - - Lys Tyr Leu Ala Thr Leu Glu Thr Leu Thr Ly - #s His Tyr Gly Ala Glu                   260      - #           265      - #           270                   - - Ile Phe Glu Thr Ser Met Leu Leu Ile Ser Se - #r Glu Asn Glu Met Asn               275          - #       280          - #       285                       - - Trp Phe His Ser Asn Asp Gly Gly Asn Val Le - #u Tyr Tyr Glu Val Met           290              - #   295              - #   300                           - - Val Thr Gly Asn Leu Gly Ile Gln Trp Arg Hi - #s Lys Pro Asn Val Val       305                 3 - #10                 3 - #15                 3 -       #20                                                                               - - Ser Val Glu Lys Glu Lys Asn Lys Leu Lys Ar - #g Lys Lys Leu Glu         Asn                                                                                              325  - #               330  - #               335              - - Lys Asp Lys Lys Asp Glu Glu Lys Asn Lys Il - #e Arg Glu Glu Trp Asn                   340      - #           345      - #           350                   - - Asn Phe Ser Phe Phe Pro Glu Ile Thr His Il - #e Val Ile Lys Glu Ser               355          - #       360          - #       365                       - - Val Val Ser Ile Asn Lys Gln Asp Asn Lys Ly - #s Met Glu Leu Lys Leu           370              - #   375              - #   380                           - - Ser Ser His Glu Glu Ala Leu Ser Phe Val Se - #r Leu Val Asp Gly Tyr       385                 3 - #90                 3 - #95                 4 -       #00                                                                               - - Phe Arg Leu Thr Ala Asp Ala His His Tyr Le - #u Cys Thr Asp Val         Ala                                                                                              405  - #               410  - #               415              - - Pro Pro Leu Ile Val His Asn Ile Gln Asn Gl - #y Cys His Gly Pro Ile                   420      - #           425      - #           430                   - - Cys Thr Glu Tyr Ala Ile Asn Lys Leu Arg Gl - #n Glu Gly Ser Glu Glu               435          - #       440          - #       445                       - - Gly Met Tyr Val Leu Arg Trp Ser Cys Thr As - #p Phe Asp Asn Ile Leu           450              - #   455              - #   460                           - - Met Thr Val Thr Cys Phe Glu Lys Ser Glu Gl - #n Val Gln Gly Ala Gln       465                 4 - #70                 4 - #75                 4 -       #80                                                                               - - Lys Gln Phe Lys Asn Phe Gln Ile Glu Val Gl - #n Lys Gly Arg Tyr         Ser                                                                                              485  - #               490  - #               495              - - Leu His Gly Ser Asp Arg Ser Phe Pro Ser Le - #u Gly Asp Leu Met Ser                   500      - #           505      - #           510                   - - His Leu Lys Lys Gln Ile Leu Arg Thr Asp As - #n Ile Ser Phe Met Leu               515          - #       520          - #       525                       - - Lys Arg Cys Cys Gln Pro Lys Pro Arg Glu Il - #e Ser Asn Leu Leu Val           530              - #   535              - #   540                           - - Ala Thr Lys Lys Ala Gln Glu Trp Gln Pro Va - #l Tyr Pro Met Ser Gln       545                 5 - #50                 5 - #55                 5 -       #60                                                                               - - Leu Ser Phe Asp Arg Ile Leu Lys Lys Asp Le - #u Val Gln Gly Glu         His                                                                                              565  - #               570  - #               575              - - Leu Gly Arg Gly Thr Arg Thr His Ile Tyr Se - #r Gly Thr Leu Met Asp                   580      - #           585      - #           590                   - - Tyr Lys Asp Asp Glu Gly Thr Ser Glu Glu Ly - #s Lys Ile Lys Val Ile               595          - #       600          - #       605                       - - Leu Lys Val Leu Asp Pro Ser His Arg Asp Il - #e Ser Leu Ala Phe Phe           610              - #   615              - #   620                           - - Glu Ala Ala Ser Met Met Arg Gln Val Ser Hi - #s Lys His Ile Val Tyr       625                 6 - #30                 6 - #35                 6 -       #40                                                                               - - Leu Tyr Gly Val Cys Val Arg Asp Val Glu As - #n Ile Met Val Glu         Glu                                                                                              645  - #               650  - #               655              - - Phe Val Glu Gly Gly Pro Leu Asp Leu Phe Me - #t His Arg Lys Ser Asp                   660      - #           665      - #           670                   - - Val Leu Thr Thr Pro Trp Lys Phe Lys Val Al - #a Lys Gln Leu Ala Ser               675          - #       680          - #       685                       - - Ala Leu Ser Tyr Leu Glu Asp Lys Asp Leu Va - #l His Gly Asn Val Cys           690              - #   695              - #   700                           - - Thr Lys Asn Leu Leu Leu Ala Arg Glu Gly Il - #e Asp Ser Glu Cys Gly       705                 7 - #10                 7 - #15                 7 -       #20                                                                               - - Pro Phe Ile Lys Leu Ser Asp Pro Gly Ile Pr - #o Ile Thr Val Leu         Ser                                                                                              725  - #               730  - #               735              - - Arg Gln Glu Cys Ile Glu Arg Ile Pro Trp Il - #e Ala Pro Glu Cys Val                   740      - #           745      - #           750                   - - Glu Asp Ser Lys Asn Leu Ser Val Ala Ala As - #p Lys Trp Ser Phe Gly               755          - #       760          - #       765                       - - Thr Thr Leu Trp Glu Ile Cys Tyr Asn Gly Gl - #u Ile Pro Leu Lys Asp           770              - #   775              - #   780                           - - Lys Thr Leu Ile Glu Lys Glu Arg Phe Tyr Gl - #u Ser Arg Cys Arg Pro       785                 7 - #90                 7 - #95                 8 -       #00                                                                               - - Val Thr Pro Ser Cys Lys Glu Leu Ala Asp Le - #u Met Thr Arg Cys         Met                                                                                              805  - #               810  - #               815              - - Asn Tyr Asp Pro Asn Gln Arg Pro Phe Phe Ar - #g Ala Ile Met Arg Asp                   820      - #           825      - #           830                   - - Ile Asn Lys Leu Glu Glu Gln Asn Pro Asp Il - #e Val Ser Arg Lys Lys               835          - #       840          - #       845                       - - Asn Gln Pro Thr Glu Val Asp Pro Thr His Ph - #e Glu Lys Arg Phe Leu           850              - #   855              - #   860                           - - Lys Arg Ile Arg Asp Leu Gly Glu Gly His Ph - #e Gly Lys Val Glu Leu       865                 8 - #70                 8 - #75                 8 -       #80                                                                               - - Cys Arg Tyr Asp Pro Glu Asp Asn Thr Gly Gl - #u Gln Val Ala Val         Lys                                                                                              885  - #               890  - #               895              - - Ser Leu Lys Pro Glu Ser Gly Gly Asn His Il - #e Ala Asp Leu Lys Lys                   900      - #           905      - #           910                   - - Glu Ile Glu Ile Leu Arg Asn Leu Tyr His Gl - #u Asn Ile Val Lys Tyr               915          - #       920          - #       925                       - - Lys Gly Ile Cys Thr Glu Asp Gly Gly Asn Gl - #y Ile Lys Leu Ile Met           930              - #   935              - #   940                           - - Glu Phe Leu Pro Ser Gly Ser Leu Lys Glu Ty - #r Leu Pro Lys Asn Lys       945                 9 - #50                 9 - #55                 9 -       #60                                                                               - - Asn Lys Ile Asn Leu Lys Gln Gln Leu Lys Ty - #r Ala Val Gln Ile         Cys                                                                                              965  - #               970  - #               975              - - Lys Gly Met Asp Tyr Leu Gly Ser Arg Gln Ty - #r Val His Arg Asp Leu                   980      - #           985      - #           990                   - - Ala Ala Arg Asn Val Leu Val Glu Ser Glu Hi - #s Gln Val Lys Ile Gly               995          - #       1000          - #      1005                      - - Asp Phe Gly Leu Thr Lys Ala Ile Glu Thr As - #p Lys Glu Tyr Tyr Thr           1010             - #   1015              - #  1020                          - - Val Lys Asp Asp Arg Asp Ser Pro Val Phe Tr - #p Tyr Ala Pro Glu Cys       1025                1030 - #                1035 - #               1040         - - Leu Met Gln Ser Lys Phe Tyr Ile Ala Ser As - #p Val Trp Ser Phe Gly                       1045 - #               1050  - #              1055              - - Val Thr Leu His Glu Leu Leu Thr Tyr Cys As - #p Ser Asp Ser Ser Pro                   1060     - #           1065      - #          1070                  - - Met Ala Leu Phe Leu Lys Met Ile Gly Pro Th - #r His Gly Gln Met Thr               1075         - #       1080          - #      1085                      - - Val Thr Arg Leu Val Asn Thr Leu Lys Glu Gl - #y Lys Arg Leu Pro Cys           1090             - #   1095              - #  1100                          - - Pro Pro Asn Cys Pro Asp Glu Val Tyr Gln Le - #u Met Arg Lys Cys Trp       1105                1110 - #                1115 - #               1120         - - Glu Phe Gln Pro Ser Asn Arg Thr Ser Phe Gl - #n Asn Leu Ile Glu Gly                       1125 - #               1130  - #              1135              - - Phe Glu Ala Leu Leu Lys                                                               1140                                                                - -  - - (2) INFORMATION FOR SEQ ID NO:12:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 3561 base - #pairs                                                 (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ix) FEATURE:                                                                   (A) NAME/KEY: CDS                                                              (B) LOCATION: 1..3561                                                 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:                               - - ATG CCT CTG CGC CAC TGG GGG ATG GCC AGG GG - #C AGT AAG CCC GTT GGG            48                                                                        Met Pro Leu Arg His Trp Gly Met Ala Arg Gl - #y Ser Lys Pro Val Gly              1               5 - #                 10 - #                 15               - - GAT GGA GCC CAG CCC ATG GCT GCC ATG GGA GG - #C CTG AAG GTG CTT CTG            96                                                                        Asp Gly Ala Gln Pro Met Ala Ala Met Gly Gl - #y Leu Lys Val Leu Leu                         20     - #             25     - #             30                   - - CAC TGG GCT GGT CCA GGC GGC GGG GAG CCC TG - #G GTC ACT TTC AGT GAG           144                                                                        His Trp Ala Gly Pro Gly Gly Gly Glu Pro Tr - #p Val Thr Phe Ser Glu                     35         - #         40         - #         45                       - - TCA TCG CTG ACA GCT GAG GAA GTC TGC ATC CA - #C ATT GCA CAT AAA GTT           192                                                                        Ser Ser Leu Thr Ala Glu Glu Val Cys Ile Hi - #s Ile Ala His Lys Val                 50             - #     55             - #     60                           - - GGT ATC ACT CCT CCT TGC TTC AAT CTC TTT GC - #C CTC TTC GAT GCT CAG           240                                                                        Gly Ile Thr Pro Pro Cys Phe Asn Leu Phe Al - #a Leu Phe Asp Ala Gln             65                 - # 70                 - # 75                 - # 80        - - GCC CAA GTC TGG TTG CCC CCA AAC CAC ATC CT - #A GAG ATC CCC AGA GAT           288                                                                        Ala Gln Val Trp Leu Pro Pro Asn His Ile Le - #u Glu Ile Pro Arg Asp                             85 - #                 90 - #                 95               - - GCA AGC CTG ATG CTA TAT TTC CGC ATA AGG TT - #T TAT TTC CGG AAC TGG           336                                                                        Ala Ser Leu Met Leu Tyr Phe Arg Ile Arg Ph - #e Tyr Phe Arg Asn Trp                        100      - #           105      - #           110                   - - CAT GGC ATG AAT CCT CGG GAA CCG GCT GTG TA - #C CGT TGT GGG CCC CCA           384                                                                        His Gly Met Asn Pro Arg Glu Pro Ala Val Ty - #r Arg Cys Gly Pro Pro                    115          - #       120          - #       125                       - - GGA ACC GAG GCA TCC TCA GAT CAG ACA GCA CA - #G GGG ATG CAA CTC CTG           432                                                                        Gly Thr Glu Ala Ser Ser Asp Gln Thr Ala Gl - #n Gly Met Gln Leu Leu                130              - #   135              - #   140                           - - GAC CCA GCC TCA TTT GAG TAC CTC TTT GAG CA - #G GGC AAG CAT GAG TTT           480                                                                        Asp Pro Ala Ser Phe Glu Tyr Leu Phe Glu Gl - #n Gly Lys His Glu Phe            145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - GTG AAT GAC GTG GCA TCA CTG TGG GAG CTG TC - #G ACC GAG GAG GAG         ATC      528                                                                     Val Asn Asp Val Ala Ser Leu Trp Glu Leu Se - #r Thr Glu Glu Glu Ile                           165  - #               170  - #               175               - - CAC CAC TTT AAG AAT GAG AGC CTG GGC ATG GC - #C TTT CTG CAC CTC TGT           576                                                                        His His Phe Lys Asn Glu Ser Leu Gly Met Al - #a Phe Leu His Leu Cys                        180      - #           185      - #           190                   - - CAC CTC GCT CTC CGC CAT GGC ATC CCC CTG GA - #G GAG GTG GCC AAG AAG           624                                                                        His Leu Ala Leu Arg His Gly Ile Pro Leu Gl - #u Glu Val Ala Lys Lys                    195          - #       200          - #       205                       - - ACC AGC TTC AAG GAC TGC ATC CCG CGC TCC TT - #C CGC CGG CAT ATC CGG           672                                                                        Thr Ser Phe Lys Asp Cys Ile Pro Arg Ser Ph - #e Arg Arg His Ile Arg                210              - #   215              - #   220                           - - CAG CAC AGC GCC CTG ACC CGG CTG CGC CTT CG - #G AAC GTC TTC CGC AGG           720                                                                        Gln His Ser Ala Leu Thr Arg Leu Arg Leu Ar - #g Asn Val Phe Arg Arg            225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - TTC CTG CGG GAC TTC CAG CCG GGC CGA CTC TC - #C CAG CAG ATG GTC         ATG      768                                                                     Phe Leu Arg Asp Phe Gln Pro Gly Arg Leu Se - #r Gln Gln Met Val Met                           245  - #               250  - #               255               - - GTC AAA TAC CTA GCC ACA CTC GAG CGG CTG GC - #A CCC CGC TTC GGC ACA           816                                                                        Val Lys Tyr Leu Ala Thr Leu Glu Arg Leu Al - #a Pro Arg Phe Gly Thr                        260      - #           265      - #           270                   - - GAG CGT GTG CCC GTG TGC CAC CTG AGG CTG CT - #G GCC CAG GCC GAG GGG           864                                                                        Glu Arg Val Pro Val Cys His Leu Arg Leu Le - #u Ala Gln Ala Glu Gly                    275          - #       280          - #       285                       - - GAG CCC TGC TAC ATC CGG GAC AGT GGG GTG GC - #C CCT ACA GAC CCT GGC           912                                                                        Glu Pro Cys Tyr Ile Arg Asp Ser Gly Val Al - #a Pro Thr Asp Pro Gly                290              - #   295              - #   300                           - - CCT GAG TCT GCT GCT GGG CCC CCA ACC CAC GA - #G GTG CTG GTG ACA GGC           960                                                                        Pro Glu Ser Ala Ala Gly Pro Pro Thr His Gl - #u Val Leu Val Thr Gly            305                 3 - #10                 3 - #15                 3 -       #20                                                                               - - ACT GGT GGC ATC CAG TGG TGG CCA GTA GAG GA - #G GAG GTG AAC AAG         GAG     1008                                                                     Thr Gly Gly Ile Gln Trp Trp Pro Val Glu Gl - #u Glu Val Asn Lys Glu                           325  - #               330  - #               335               - - GAG GGT TCT AGT GGC AGC AGT GGC AGG AAC CC - #C CAA GCC AGC CTG TTT          1056                                                                        Glu Gly Ser Ser Gly Ser Ser Gly Arg Asn Pr - #o Gln Ala Ser Leu Phe                        340      - #           345      - #           350                   - - GGG AAG AAG GCC AAG GCT CAC AAG GCA TTC GG - #C CAG CCG GCA GAC AGG          1104                                                                        Gly Lys Lys Ala Lys Ala His Lys Ala Phe Gl - #y Gln Pro Ala Asp Arg                    355          - #       360          - #       365                       - - CCG CGG GAG CCA CTG TGG GCC TAC TTC TGT GA - #C TTC CGG GAC ATC ACC          1152                                                                        Pro Arg Glu Pro Leu Trp Ala Tyr Phe Cys As - #p Phe Arg Asp Ile Thr                370              - #   375              - #   380                           - - CAC GTG GTG CTG AAA GAG CAC TGT GTC AGC AT - #C CAC CGG CAG GAC AAC          1200                                                                        His Val Val Leu Lys Glu His Cys Val Ser Il - #e His Arg Gln Asp Asn            385                 3 - #90                 3 - #95                 4 -       #00                                                                               - - AAG TGC CTG GAG CTG AGC TTG CCT TCC CGG GC - #T GCG GCG CTG TCC         TTC     1248                                                                     Lys Cys Leu Glu Leu Ser Leu Pro Ser Arg Al - #a Ala Ala Leu Ser Phe                           405  - #               410  - #               415               - - GTG TCG CTG GTG GAC GGC TAT TTC CGC CTG AC - #G GCC GAC TCC AGC CAC          1296                                                                        Val Ser Leu Val Asp Gly Tyr Phe Arg Leu Th - #r Ala Asp Ser Ser His                        420      - #           425      - #           430                   - - TAC CTG TGC CAC GAG GTG GCT CCC CCA CGG CT - #G GTG ATG AGC ATC CGG          1344                                                                        Tyr Leu Cys His Glu Val Ala Pro Pro Arg Le - #u Val Met Ser Ile Arg                    435          - #       440          - #       445                       - - GAT GGG ATC CAC GGA CCC CTG CTG GAG CCA TT - #T GTG CAG GCC AAG CTG          1392                                                                        Asp Gly Ile His Gly Pro Leu Leu Glu Pro Ph - #e Val Gln Ala Lys Leu                450              - #   455              - #   460                           - - CGG CCC GAG GAC GGC CTG TAC CTC ATT CAC TG - #G AGC ACC AGC CAC CCC          1440                                                                        Arg Pro Glu Asp Gly Leu Tyr Leu Ile His Tr - #p Ser Thr Ser His Pro            465                 4 - #70                 4 - #75                 4 -       #80                                                                               - - TAC CGC CTG ATC CTC ACA GTG GCC CAG CGT AG - #C CAG GCA CCA GAC         GGC     1488                                                                     Tyr Arg Leu Ile Leu Thr Val Ala Gln Arg Se - #r Gln Ala Pro Asp Gly                           485  - #               490  - #               495               - - ATG CAG AGC TTG CGG CTC CGA AAG TTC CCC AT - #T GAG CAG CAG GAC GGG          1536                                                                        Met Gln Ser Leu Arg Leu Arg Lys Phe Pro Il - #e Glu Gln Gln Asp Gly                        500      - #           505      - #           510                   - - GCC TTC GTG CTG GAG GGC TGG GGC CGG TCC TT - #C CCC AGC GTT CGG GAA          1584                                                                        Ala Phe Val Leu Glu Gly Trp Gly Arg Ser Ph - #e Pro Ser Val Arg Glu                    515          - #       520          - #       525                       - - CTT GGG GCT GCC TTG CAG GGC TGC TTG CTG AG - #G GCC GGG GAT GAC TGC          1632                                                                        Leu Gly Ala Ala Leu Gln Gly Cys Leu Leu Ar - #g Ala Gly Asp Asp Cys                530              - #   535              - #   540                           - - TTC TCT CTG CGT CGC TGT TGC CTG CCC CAA CC - #A GGA GAA ACC TCC AAT          1680                                                                        Phe Ser Leu Arg Arg Cys Cys Leu Pro Gln Pr - #o Gly Glu Thr Ser Asn            545                 5 - #50                 5 - #55                 5 -       #60                                                                               - - CTC ATC ATC ATG CGG GGG GCT CGG GCC AGC CC - #C AGG ACA CTC AAC         CTC     1728                                                                     Leu Ile Ile Met Arg Gly Ala Arg Ala Ser Pr - #o Arg Thr Leu Asn Leu                           565  - #               570  - #               575               - - AGC CAG CTC AGC TTC CAC CGG GTT GAC CAG AA - #G GAG ATC ACC CAG CTG          1776                                                                        Ser Gln Leu Ser Phe His Arg Val Asp Gln Ly - #s Glu Ile Thr Gln Leu                        580      - #           585      - #           590                   - - TCC CAC TTG GGC CAG GGC ACA AGG ACC AAC GT - #G TAT GAG GGC CGC CTG          1824                                                                        Ser His Leu Gly Gln Gly Thr Arg Thr Asn Va - #l Tyr Glu Gly Arg Leu                    595          - #       600          - #       605                       - - CGA GTG GAG GGC AGC GGG GAC CCT GAG GAG GG - #C AAG ATG GAT GAC GAG          1872                                                                        Arg Val Glu Gly Ser Gly Asp Pro Glu Glu Gl - #y Lys Met Asp Asp Glu                610              - #   615              - #   620                           - - GAC CCC CTC GTG CCT GGC AGG GAC CGT GGG CA - #G GAG CTA CGA GTG GTG          1920                                                                        Asp Pro Leu Val Pro Gly Arg Asp Arg Gly Gl - #n Glu Leu Arg Val Val            625                 6 - #30                 6 - #35                 6 -       #40                                                                               - - CTC AAA GTG CTG GAC CCT AGT CAC CAT GAC AT - #C GCC CTG GCC TTC         TAC     1968                                                                     Leu Lys Val Leu Asp Pro Ser His His Asp Il - #e Ala Leu Ala Phe Tyr                           645  - #               650  - #               655               - - GAG ACA GCC AGC CTC ATG AGC CAG GTC TCC CA - #C ACG CAC CTG GCC TTC          2016                                                                        Glu Thr Ala Ser Leu Met Ser Gln Val Ser Hi - #s Thr His Leu Ala Phe                        660      - #           665      - #           670                   - - GTG CAT GGC GTC TGT GTG CGC GGC CCT GAA AA - #T AGC ATG GTG ACA GAG          2064                                                                        Val His Gly Val Cys Val Arg Gly Pro Glu As - #n Ser Met Val Thr Glu                    675          - #       680          - #       685                       - - TAC GTG GAG CAC GGA CCC CTG GAT GTG TGG CT - #G CGG AGG GAG CGG GGC          2112                                                                        Tyr Val Glu His Gly Pro Leu Asp Val Trp Le - #u Arg Arg Glu Arg Gly                690              - #   695              - #   700                           - - CAT GTG CCC ATG GCT TGG AAG ATG GTG GTG GC - #C CAG CAG CTG GCC AGC          2160                                                                        His Val Pro Met Ala Trp Lys Met Val Val Al - #a Gln Gln Leu Ala Ser            705                 7 - #10                 7 - #15                 7 -       #20                                                                               - - GCC CTC AGC TAC CTG GAG AAC AAG AAC CTG GT - #T CAT GGT AAT GTG         TGT     2208                                                                     Ala Leu Ser Tyr Leu Glu Asn Lys Asn Leu Va - #l His Gly Asn Val Cys                           725  - #               730  - #               735               - - GGC CGG AAC ATC CTG CTG GCC CGG CTG GGG TT - #G GCA GAG GGC ACC AGC          2256                                                                        Gly Arg Asn Ile Leu Leu Ala Arg Leu Gly Le - #u Ala Glu Gly Thr Ser                        740      - #           745      - #           750                   - - CCC TTC ATC AAG CTG AGT GAT CCT GGC GTG GG - #C CTG GGC GCC CTC TCC          2304                                                                        Pro Phe Ile Lys Leu Ser Asp Pro Gly Val Gl - #y Leu Gly Ala Leu Ser                    755          - #       760          - #       765                       - - AGG GAG GAG CGG GTG GAG AGG ATC CCC TGG CT - #G GCC CCC GAA TGC CTA          2352                                                                        Arg Glu Glu Arg Val Glu Arg Ile Pro Trp Le - #u Ala Pro Glu Cys Leu                770              - #   775              - #   780                           - - CCA GGT GGG GCC AAC AGC CTA AGC ACC GCC AT - #G GAC AAG TGG GGG TTT          2400                                                                        Pro Gly Gly Ala Asn Ser Leu Ser Thr Ala Me - #t Asp Lys Trp Gly Phe            785                 7 - #90                 7 - #95                 8 -       #00                                                                               - - GGC GCC ACC CTC CTG GAG ATC TGC TTT GAC GG - #A GAG GCC CCT CTG         CAG     2448                                                                     Gly Ala Thr Leu Leu Glu Ile Cys Phe Asp Gl - #y Glu Ala Pro Leu Gln                           805  - #               810  - #               815               - - AGC CGC AGT CCC TCC GAG AAG GAG CAT TTC TA - #C CAG AGG CAG CAC CGG          2496                                                                        Ser Arg Ser Pro Ser Glu Lys Glu His Phe Ty - #r Gln Arg Gln His Arg                        820      - #           825      - #           830                   - - CTG CCC GAG CCC TCC TGC CCA CAG CTG GCC AC - #A CTC ACC AGC CAG TGT          2544                                                                        Leu Pro Glu Pro Ser Cys Pro Gln Leu Ala Th - #r Leu Thr Ser Gln Cys                    835          - #       840          - #       845                       - - CTG ACC TAT GAG CCA ACC CAG AGG CCA TCA TT - #C CGC ACC ATC CTG CGT          2592                                                                        Leu Thr Tyr Glu Pro Thr Gln Arg Pro Ser Ph - #e Arg Thr Ile Leu Arg                850              - #   855              - #   860                           - - GAC CTC ACC CGC GTG CAG CCC CAC AAT CTT GC - #T GAC GTC TTG ACT GTG          2640                                                                        Asp Leu Thr Arg Val Gln Pro His Asn Leu Al - #a Asp Val Leu Thr Val            865                 8 - #70                 8 - #75                 8 -       #80                                                                               - - AAC CGG GAC TCA CCG GCC GTC GGA CCT ACT AC - #T TTC CAC AAG CGC         TAT     2688                                                                     Asn Arg Asp Ser Pro Ala Val Gly Pro Thr Th - #r Phe His Lys Arg Tyr                           885  - #               890  - #               895               - - TTG AAA AAG ATC CGA GAT CTG GGC GAG GGT CA - #C TTC GGC AAG GTC AGC          2736                                                                        Leu Lys Lys Ile Arg Asp Leu Gly Glu Gly Hi - #s Phe Gly Lys Val Ser                        900      - #           905      - #           910                   - - TTG TAC TGC TAC GAT CCG ACC AAC GAC GGC AC - #T GGC GAG ATG GTG GCG          2784                                                                        Leu Tyr Cys Tyr Asp Pro Thr Asn Asp Gly Th - #r Gly Glu Met Val Ala                    915          - #       920          - #       925                       - - GTG AAA GCC CTC AAG GCA GAC TGC GGC CCC CA - #G CAC CGC TCG GGC TGG          2832                                                                        Val Lys Ala Leu Lys Ala Asp Cys Gly Pro Gl - #n His Arg Ser Gly Trp                930              - #   935              - #   940                           - - AAG CAG GAG ATT GAC ATT CTG CGC ACG CTC TA - #C CAC GAG CAC ATC ATC          2880                                                                        Lys Gln Glu Ile Asp Ile Leu Arg Thr Leu Ty - #r His Glu His Ile Ile            945                 9 - #50                 9 - #55                 9 -       #60                                                                               - - AAG TAC AAG GGC TGC TGC GAG GAC CAA GGC GA - #G AAG TCG CTG CAG         CTG     2928                                                                     Lys Tyr Lys Gly Cys Cys Glu Asp Gln Gly Gl - #u Lys Ser Leu Gln Leu                           965  - #               970  - #               975               - - GTC ATG GAG TAC GTG CCC CTG GGC AGC CTC CG - #A GAC TAC CTG CCC CGG          2976                                                                        Val Met Glu Tyr Val Pro Leu Gly Ser Leu Ar - #g Asp Tyr Leu Pro Arg                        980      - #           985      - #           990                   - - CAC AGC ATC GGG CTG GCC CAG CTG CTG CTC TT - #C GCC CAG CAG ATC TGC          3024                                                                        His Ser Ile Gly Leu Ala Gln Leu Leu Leu Ph - #e Ala Gln Gln Ile Cys                    995          - #       1000          - #      1005                      - - GAG GGC ATG GCC TAT CTG CAC GCG CAC GAC TA - #C ATC CAC CGA GAC CTA          3072                                                                        Glu Gly Met Ala Tyr Leu His Ala His Asp Ty - #r Ile His Arg Asp Leu                1010             - #   1015              - #  1020                          - - GCC GCG CGC AAC GTG CTG CTG GAC AAC GAC AG - #G CTG GTC AAG ATC GGG          3120                                                                        Ala Ala Arg Asn Val Leu Leu Asp Asn Asp Ar - #g Leu Val Lys Ile Gly            1025                1030 - #                1035 - #               1040         - - GAC TTT GGC CTA GCC AAG GCC GTG CCC GAA GG - #C CAC GAG TAC TAC CGC          3168                                                                        Asp Phe Gly Leu Ala Lys Ala Val Pro Glu Gl - #y His Glu Tyr Tyr Arg                            1045 - #               1050  - #              1055              - - GTG CGC GAG GAT GGG GAC AGC CCC GTG TTC TG - #G TAT GCC CCA GAG TGC          3216                                                                        Val Arg Glu Asp Gly Asp Ser Pro Val Phe Tr - #p Tyr Ala Pro Glu Cys                        1060     - #           1065      - #          1070                  - - CTG AAG GAG TAT AAG TTC TAC TAT GCG TCA GA - #T GTC TGG TCC TTC GGG          3264                                                                        Leu Lys Glu Tyr Lys Phe Tyr Tyr Ala Ser As - #p Val Trp Ser Phe Gly                    1075         - #       1080          - #      1085                      - - GTG ACC CTG TAT GAG CTG CTG ACG CAC TGT GA - #C TCC AGC CAG AGC CCC          3312                                                                        Val Thr Leu Tyr Glu Leu Leu Thr His Cys As - #p Ser Ser Gln Ser Pro                1090             - #   1095              - #  1100                          - - CCC ACG AAA TTC CTT GAG CTC ATA GGC ATT GC - #T CAG GGT CAG ATG ACA          3360                                                                        Pro Thr Lys Phe Leu Glu Leu Ile Gly Ile Al - #a Gln Gly Gln Met Thr            1105                1110 - #                1115 - #               1120         - - GTT CTG AGA CTC ACT GAG TTG CTG GAA CGA GG - #G GAG AGG CTG CCA CGG          3408                                                                        Val Leu Arg Leu Thr Glu Leu Leu Glu Arg Gl - #y Glu Arg Leu Pro Arg                            1125 - #               1130  - #              1135              - - CCC GAC AAA TGT CCC TGT GAG GTC TAT CAT CT - #C ATG AAG AAC TGC TGG          3456                                                                        Pro Asp Lys Cys Pro Cys Glu Val Tyr His Le - #u Met Lys Asn Cys Trp                        1140     - #           1145      - #          1150                  - - GAG ACA GAG GCG TCC TTT CGC CCA ACC TTC GA - #G AAC CTC ATA CCC ATT          3504                                                                        Glu Thr Glu Ala Ser Phe Arg Pro Thr Phe Gl - #u Asn Leu Ile Pro Ile                    1155         - #       1160          - #      1165                      - - CTG AAG ACA GTC CAT GAG AAG TAC CAA GGC CA - #G GCC CCT TCA GTG TTC          3552                                                                        Leu Lys Thr Val His Glu Lys Tyr Gln Gly Gl - #n Ala Pro Ser Val Phe                1170             - #   1175              - #  1180                          - - AGC GTG TGC              - #                  - #                        - #       3561                                                                   Ser Val Cys                                                                    1185                                                                            - -  - - (2) INFORMATION FOR SEQ ID NO:13:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 1187 amino - #acids                                                (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: protein                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:                               - - Met Pro Leu Arg His Trp Gly Met Ala Arg Gl - #y Ser Lys Pro Val         Gly                                                                                1               5 - #                 10 - #                 15              - - Asp Gly Ala Gln Pro Met Ala Ala Met Gly Gl - #y Leu Lys Val Leu Leu                    20     - #             25     - #             30                   - - His Trp Ala Gly Pro Gly Gly Gly Glu Pro Tr - #p Val Thr Phe Ser Glu                35         - #         40         - #         45                       - - Ser Ser Leu Thr Ala Glu Glu Val Cys Ile Hi - #s Ile Ala His Lys Val            50             - #     55             - #     60                           - - Gly Ile Thr Pro Pro Cys Phe Asn Leu Phe Al - #a Leu Phe Asp Ala Gln        65                 - # 70                 - # 75                 - # 80        - - Ala Gln Val Trp Leu Pro Pro Asn His Ile Le - #u Glu Ile Pro Arg Asp                        85 - #                 90 - #                 95               - - Ala Ser Leu Met Leu Tyr Phe Arg Ile Arg Ph - #e Tyr Phe Arg Asn Trp                   100      - #           105      - #           110                   - - His Gly Met Asn Pro Arg Glu Pro Ala Val Ty - #r Arg Cys Gly Pro Pro               115          - #       120          - #       125                       - - Gly Thr Glu Ala Ser Ser Asp Gln Thr Ala Gl - #n Gly Met Gln Leu Leu           130              - #   135              - #   140                           - - Asp Pro Ala Ser Phe Glu Tyr Leu Phe Glu Gl - #n Gly Lys His Glu Phe       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Val Asn Asp Val Ala Ser Leu Trp Glu Leu Se - #r Thr Glu Glu Glu         Ile                                                                                              165  - #               170  - #               175              - - His His Phe Lys Asn Glu Ser Leu Gly Met Al - #a Phe Leu His Leu Cys                   180      - #           185      - #           190                   - - His Leu Ala Leu Arg His Gly Ile Pro Leu Gl - #u Glu Val Ala Lys Lys               195          - #       200          - #       205                       - - Thr Ser Phe Lys Asp Cys Ile Pro Arg Ser Ph - #e Arg Arg His Ile Arg           210              - #   215              - #   220                           - - Gln His Ser Ala Leu Thr Arg Leu Arg Leu Ar - #g Asn Val Phe Arg Arg       225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - Phe Leu Arg Asp Phe Gln Pro Gly Arg Leu Se - #r Gln Gln Met Val         Met                                                                                              245  - #               250  - #               255              - - Val Lys Tyr Leu Ala Thr Leu Glu Arg Leu Al - #a Pro Arg Phe Gly Thr                   260      - #           265      - #           270                   - - Glu Arg Val Pro Val Cys His Leu Arg Leu Le - #u Ala Gln Ala Glu Gly               275          - #       280          - #       285                       - - Glu Pro Cys Tyr Ile Arg Asp Ser Gly Val Al - #a Pro Thr Asp Pro Gly           290              - #   295              - #   300                           - - Pro Glu Ser Ala Ala Gly Pro Pro Thr His Gl - #u Val Leu Val Thr Gly       305                 3 - #10                 3 - #15                 3 -       #20                                                                               - - Thr Gly Gly Ile Gln Trp Trp Pro Val Glu Gl - #u Glu Val Asn Lys         Glu                                                                                              325  - #               330  - #               335              - - Glu Gly Ser Ser Gly Ser Ser Gly Arg Asn Pr - #o Gln Ala Ser Leu Phe                   340      - #           345      - #           350                   - - Gly Lys Lys Ala Lys Ala His Lys Ala Phe Gl - #y Gln Pro Ala Asp Arg               355          - #       360          - #       365                       - - Pro Arg Glu Pro Leu Trp Ala Tyr Phe Cys As - #p Phe Arg Asp Ile Thr           370              - #   375              - #   380                           - - His Val Val Leu Lys Glu His Cys Val Ser Il - #e His Arg Gln Asp Asn       385                 3 - #90                 3 - #95                 4 -       #00                                                                               - - Lys Cys Leu Glu Leu Ser Leu Pro Ser Arg Al - #a Ala Ala Leu Ser         Phe                                                                                              405  - #               410  - #               415              - - Val Ser Leu Val Asp Gly Tyr Phe Arg Leu Th - #r Ala Asp Ser Ser His                   420      - #           425      - #           430                   - - Tyr Leu Cys His Glu Val Ala Pro Pro Arg Le - #u Val Met Ser Ile Arg               435          - #       440          - #       445                       - - Asp Gly Ile His Gly Pro Leu Leu Glu Pro Ph - #e Val Gln Ala Lys Leu           450              - #   455              - #   460                           - - Arg Pro Glu Asp Gly Leu Tyr Leu Ile His Tr - #p Ser Thr Ser His Pro       465                 4 - #70                 4 - #75                 4 -       #80                                                                               - - Tyr Arg Leu Ile Leu Thr Val Ala Gln Arg Se - #r Gln Ala Pro Asp         Gly                                                                                              485  - #               490  - #               495              - - Met Gln Ser Leu Arg Leu Arg Lys Phe Pro Il - #e Glu Gln Gln Asp Gly                   500      - #           505      - #           510                   - - Ala Phe Val Leu Glu Gly Trp Gly Arg Ser Ph - #e Pro Ser Val Arg Glu               515          - #       520          - #       525                       - - Leu Gly Ala Ala Leu Gln Gly Cys Leu Leu Ar - #g Ala Gly Asp Asp Cys           530              - #   535              - #   540                           - - Phe Ser Leu Arg Arg Cys Cys Leu Pro Gln Pr - #o Gly Glu Thr Ser Asn       545                 5 - #50                 5 - #55                 5 -       #60                                                                               - - Leu Ile Ile Met Arg Gly Ala Arg Ala Ser Pr - #o Arg Thr Leu Asn         Leu                                                                                              565  - #               570  - #               575              - - Ser Gln Leu Ser Phe His Arg Val Asp Gln Ly - #s Glu Ile Thr Gln Leu                   580      - #           585      - #           590                   - - Ser His Leu Gly Gln Gly Thr Arg Thr Asn Va - #l Tyr Glu Gly Arg Leu               595          - #       600          - #       605                       - - Arg Val Glu Gly Ser Gly Asp Pro Glu Glu Gl - #y Lys Met Asp Asp Glu           610              - #   615              - #   620                           - - Asp Pro Leu Val Pro Gly Arg Asp Arg Gly Gl - #n Glu Leu Arg Val Val       625                 6 - #30                 6 - #35                 6 -       #40                                                                               - - Leu Lys Val Leu Asp Pro Ser His His Asp Il - #e Ala Leu Ala Phe         Tyr                                                                                              645  - #               650  - #               655              - - Glu Thr Ala Ser Leu Met Ser Gln Val Ser Hi - #s Thr His Leu Ala Phe                   660      - #           665      - #           670                   - - Val His Gly Val Cys Val Arg Gly Pro Glu As - #n Ser Met Val Thr Glu               675          - #       680          - #       685                       - - Tyr Val Glu His Gly Pro Leu Asp Val Trp Le - #u Arg Arg Glu Arg Gly           690              - #   695              - #   700                           - - His Val Pro Met Ala Trp Lys Met Val Val Al - #a Gln Gln Leu Ala Ser       705                 7 - #10                 7 - #15                 7 -       #20                                                                               - - Ala Leu Ser Tyr Leu Glu Asn Lys Asn Leu Va - #l His Gly Asn Val         Cys                                                                                              725  - #               730  - #               735              - - Gly Arg Asn Ile Leu Leu Ala Arg Leu Gly Le - #u Ala Glu Gly Thr Ser                   740      - #           745      - #           750                   - - Pro Phe Ile Lys Leu Ser Asp Pro Gly Val Gl - #y Leu Gly Ala Leu Ser               755          - #       760          - #       765                       - - Arg Glu Glu Arg Val Glu Arg Ile Pro Trp Le - #u Ala Pro Glu Cys Leu           770              - #   775              - #   780                           - - Pro Gly Gly Ala Asn Ser Leu Ser Thr Ala Me - #t Asp Lys Trp Gly Phe       785                 7 - #90                 7 - #95                 8 -       #00                                                                               - - Gly Ala Thr Leu Leu Glu Ile Cys Phe Asp Gl - #y Glu Ala Pro Leu         Gln                                                                                              805  - #               810  - #               815              - - Ser Arg Ser Pro Ser Glu Lys Glu His Phe Ty - #r Gln Arg Gln His Arg                   820      - #           825      - #           830                   - - Leu Pro Glu Pro Ser Cys Pro Gln Leu Ala Th - #r Leu Thr Ser Gln Cys               835          - #       840          - #       845                       - - Leu Thr Tyr Glu Pro Thr Gln Arg Pro Ser Ph - #e Arg Thr Ile Leu Arg           850              - #   855              - #   860                           - - Asp Leu Thr Arg Val Gln Pro His Asn Leu Al - #a Asp Val Leu Thr Val       865                 8 - #70                 8 - #75                 8 -       #80                                                                               - - Asn Arg Asp Ser Pro Ala Val Gly Pro Thr Th - #r Phe His Lys Arg         Tyr                                                                                              885  - #               890  - #               895              - - Leu Lys Lys Ile Arg Asp Leu Gly Glu Gly Hi - #s Phe Gly Lys Val Ser                   900      - #           905      - #           910                   - - Leu Tyr Cys Tyr Asp Pro Thr Asn Asp Gly Th - #r Gly Glu Met Val Ala               915          - #       920          - #       925                       - - Val Lys Ala Leu Lys Ala Asp Cys Gly Pro Gl - #n His Arg Ser Gly Trp           930              - #   935              - #   940                           - - Lys Gln Glu Ile Asp Ile Leu Arg Thr Leu Ty - #r His Glu His Ile Ile       945                 9 - #50                 9 - #55                 9 -       #60                                                                               - - Lys Tyr Lys Gly Cys Cys Glu Asp Gln Gly Gl - #u Lys Ser Leu Gln         Leu                                                                                              965  - #               970  - #               975              - - Val Met Glu Tyr Val Pro Leu Gly Ser Leu Ar - #g Asp Tyr Leu Pro Arg                   980      - #           985      - #           990                   - - His Ser Ile Gly Leu Ala Gln Leu Leu Leu Ph - #e Ala Gln Gln Ile Cys               995          - #       1000          - #      1005                      - - Glu Gly Met Ala Tyr Leu His Ala His Asp Ty - #r Ile His Arg Asp Leu           1010             - #   1015              - #  1020                          - - Ala Ala Arg Asn Val Leu Leu Asp Asn Asp Ar - #g Leu Val Lys Ile Gly       1025                1030 - #                1035 - #               1040         - - Asp Phe Gly Leu Ala Lys Ala Val Pro Glu Gl - #y His Glu Tyr Tyr Arg                       1045 - #               1050  - #              1055              - - Val Arg Glu Asp Gly Asp Ser Pro Val Phe Tr - #p Tyr Ala Pro Glu Cys                   1060     - #           1065      - #          1070                  - - Leu Lys Glu Tyr Lys Phe Tyr Tyr Ala Ser As - #p Val Trp Ser Phe Gly               1075         - #       1080          - #      1085                      - - Val Thr Leu Tyr Glu Leu Leu Thr His Cys As - #p Ser Ser Gln Ser Pro           1090             - #   1095              - #  1100                          - - Pro Thr Lys Phe Leu Glu Leu Ile Gly Ile Al - #a Gln Gly Gln Met Thr       1105                1110 - #                1115 - #               1120         - - Val Leu Arg Leu Thr Glu Leu Leu Glu Arg Gl - #y Glu Arg Leu Pro Arg                       1125 - #               1130  - #              1135              - - Pro Asp Lys Cys Pro Cys Glu Val Tyr His Le - #u Met Lys Asn Cys Trp                   1140     - #           1145      - #          1150                  - - Glu Thr Glu Ala Ser Phe Arg Pro Thr Phe Gl - #u Asn Leu Ile Pro Ile               1155         - #       1160          - #      1165                      - - Leu Lys Thr Val His Glu Lys Tyr Gln Gly Gl - #n Ala Pro Ser Val Phe           1170             - #   1175              - #  1180                          - - Ser Val Cys                                                               1185                                                                            - -  - - (2) INFORMATION FOR SEQ ID NO:14:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 1153 amino - #acids                                                (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: protein                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:                               - - Met Gln Tyr Leu Asn Ile Lys Glu Asp Cys As - #n Ala Met Ala Phe Cys       1               5   - #                10  - #                15                - - Ala Lys Met Arg Ser Phe Lys Lys Thr Glu Va - #l Lys Gln Val Val Pro                   20      - #            25      - #            30                    - - Glu Pro Gly Val Glu Val Thr Phe Tyr Leu Se - #r Asp Arg Glu Pro Leu               35          - #        40          - #        45                        - - Arg Leu Gly Ser Gly Glu Tyr Thr Ala Glu Gl - #u Leu Cys Ile Arg Ala           50              - #    55              - #    60                            - - Ala Gln Glu Cys Ser Ile Ser Pro Leu Cys Hi - #s Asn Leu Phe Ala Leu       65                  - #70                  - #75                  - #80         - - Tyr Asp Glu Ser Thr Lys Leu Trp Tyr Ala Pr - #o Asn Arg Ile Ile Thr                       85  - #                90  - #                95                - - Val Asp Asp Lys Thr Ser Leu Arg Leu His Ty - #r Arg Met Arg Phe Tyr                   100      - #           105      - #           110                   - - Phe Thr Asn Trp His Gly Thr Asn Asp Asn Gl - #u Gln Ser Val Trp Arg               115          - #       120          - #       125                       - - His Ser Pro Lys Lys Gln Lys Asn Gly Tyr Gl - #u Lys Lys Arg Val Pro           130              - #   135              - #   140                           - - Glu Ala Thr Pro Leu Leu Asp Ala Ser Ser Le - #u Glu Tyr Leu Phe Ala       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Gln Gly Gln Tyr Asp Leu Ile Lys Phe Leu Al - #a Pro Ile Arg Asp         Pro                                                                                              165  - #               170  - #               175              - - Lys Thr Glu Gln Asp Gly His Asp Ile Glu As - #n Glu Cys Leu Gly Met                   180      - #           185      - #           190                   - - Ala Val Leu Ala Ile Ser His Tyr Ala Met Me - #t Lys Lys Met Gln Leu               195          - #       200          - #       205                       - - Pro Glu Leu Pro Lys Asp Ile Ser Tyr Lys Ar - #g Tyr Ile Pro Glu Thr           210              - #   215              - #   220                           - - Leu Asn Lys Ser Ile Arg Gln Arg Asn Leu Le - #u Thr Arg Met Arg Ile       225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - Asn Asn Val Phe Lys Asp Phe Leu Lys Glu Ph - #e Asn Asn Lys Thr         Ile                                                                                              245  - #               250  - #               255              - - Cys Asp Ser Ser Val Ser Thr His Asp Leu Ly - #s Val Lys Tyr Leu Ala                   260      - #           265      - #           270                   - - Thr Leu Glu Thr Leu Thr Lys His Tyr Gly Al - #a Glu Ile Phe Glu Thr               275          - #       280          - #       285                       - - Ser Met Leu Leu Ile Ser Ser Glu Asn Glu Le - #u Ser Arg Cys His Ser           290              - #   295              - #   300                           - - Asn Asp Ser Gly Asn Val Leu Tyr Glu Val Me - #t Val Thr Gly Asn Leu       305                 3 - #10                 3 - #15                 3 -       #20                                                                               - - Gly Ile Gln Trp Arg Gln Lys Pro Asn Val Va - #l Pro Val Glu Lys         Glu                                                                                              325  - #               330  - #               335              - - Lys Asn Lys Leu Lys Arg Lys Lys Leu Glu Ty - #r Asn Lys His Lys Lys                   340      - #           345      - #           350                   - - Asp Asp Glu Arg Asn Lys Leu Arg Glu Glu Tr - #p Asn Asn Phe Ser Tyr               355          - #       360          - #       365                       - - Phe Pro Glu Ile Thr His Ile Val Ile Lys Gl - #u Ser Val Val Ser Ile           370              - #   375              - #   380                           - - Asn Lys Gln Asp Asn Lys Asn Met Glu Leu Ly - #s Leu Ser Ser Arg Glu       385                 3 - #90                 3 - #95                 4 -       #00                                                                               - - Glu Ala Leu Ser Phe Val Ser Leu Val Asp Gl - #y Tyr Phe Arg Leu         Thr                                                                                              405  - #               410  - #               415              - - Ala Asp Ala His His Tyr Leu Cys Thr Asp Va - #l Ala Pro Pro Leu Ile                   420      - #           425      - #           430                   - - Val His Asn Ile Gln Asn Gly Cys His Gly Pr - #o Ile Cys Thr Glu Tyr               435          - #       440          - #       445                       - - Ala Ile Asn Lys Leu Arg Gln Glu Gly Ser Gl - #u Glu Gly Met Tyr Val           450              - #   455              - #   460                           - - Leu Arg Trp Ser Cys Thr Asp Phe Asp Asn Il - #e Leu Met Thr Val Thr       465                 4 - #70                 4 - #75                 4 -       #80                                                                               - - Cys Phe Glu Lys Ser Glu Val Leu Gly Gly Gl - #n Lys Gln Phe Lys         Asn                                                                                              485  - #               490  - #               495              - - Phe Gln Ile Glu Val Gln Lys Gly Arg Tyr Se - #r Leu His Gly Ser Met                   500      - #           505      - #           510                   - - Asp His Phe Pro Ser Leu Arg Asp Leu Met As - #n His Leu Lys Lys Gln               515          - #       520          - #       525                       - - Ile Leu Arg Thr Asp Asn Ile Ser Phe Val Le - #u Lys Arg Cys Cys Gln           530              - #   535              - #   540                           - - Pro Lys Pro Arg Glu Ile Ser Asn Leu Leu Va - #l Ala Thr Lys Lys Ala       545                 5 - #50                 5 - #55                 5 -       #60                                                                               - - Gln Glu Trp Gln Pro Val Tyr Ser Met Ser Gl - #n Leu Ser Phe Asp         Arg                                                                                              565  - #               570  - #               575              - - Ile Leu Lys Lys Asp Ile Ile Gln Gly Glu Hi - #s Leu Gly Arg Gly Thr                   580      - #           585      - #           590                   - - Arg Thr His Ile Tyr Ser Gly Thr Leu Leu As - #p Tyr Lys Asp Glu Glu               595          - #       600          - #       605                       - - Gly Ile Ala Glu Glu Lys Lys Ile Lys Val Il - #e Leu Lys Val Leu Asp           610              - #   615              - #   620                           - - Pro Ser His Arg Asp Ile Ser Leu Ala Phe Ph - #e Glu Ala Ala Ser Met       625                 6 - #30                 6 - #35                 6 -       #40                                                                               - - Met Arg Gln Val Ser His Lys His Ile Val Ty - #r Leu Tyr Gly Val         Cys                                                                                              645  - #               650  - #               655              - - Val Arg Asp Val Glu Asn Ile Met Val Glu Gl - #u Phe Val Glu Gly Gly                   660      - #           665      - #           670                   - - Pro Leu Asp Leu Phe Met His Arg Lys Ser As - #p Ala Leu Thr Thr Pro               675          - #       680          - #       685                       - - Trp Lys Phe Lys Val Ala Lys Gln Leu Ala Se - #r Ala Leu Ser Tyr Leu           690              - #   695              - #   700                           - - Glu Asp Lys Asp Leu Val His Gly Asn Val Cy - #s Thr Lys Asn Leu Leu       705                 7 - #10                 7 - #15                 7 -       #20                                                                               - - Leu Ala Arg Glu Gly Ile Asp Ser Asp Ile Gl - #y Pro Phe Ile Lys         Leu                                                                                              725  - #               730  - #               735              - - Ser Asp Pro Gly Ile Pro Val Ser Val Leu Th - #r Arg Gln Glu Cys Ile                   740      - #           745      - #           750                   - - Glu Arg Ile Pro Trp Ile Ala Pro Glu Cys Va - #l Glu Asp Ser Lys Asn               755          - #       760          - #       765                       - - Leu Ser Val Ala Ala Asp Lys Trp Ser Phe Gl - #y Thr Thr Leu Trp Glu           770              - #   775              - #   780                           - - Ile Cys Tyr Asn Gly Glu Ile Pro Leu Lys As - #p Lys Thr Leu Ile Glu       785                 7 - #90                 7 - #95                 8 -       #00                                                                               - - Lys Glu Arg Phe Tyr Glu Ser Arg Cys Arg Pr - #o Val Thr Pro Ser         Cys                                                                                              805  - #               810  - #               815              - - Lys Glu Leu Ala Asp Leu Met Thr Arg Cys Me - #t Asn Tyr Asp Pro Asn                   820      - #           825      - #           830                   - - Gln Arg Pro Phe Phe Arg Ala Ile Met Arg As - #p Ile Asn Lys Leu Glu               835          - #       840          - #       845                       - - Glu Gln Asn Pro Asp Ile Val Ser Glu Lys Gl - #n Pro Thr Thr Glu Val           850              - #   855              - #   860                           - - Asp Pro Thr His Phe Glu Lys Arg Phe Leu Ly - #s Arg Ile Arg Asp Leu       865                 8 - #70                 8 - #75                 8 -       #80                                                                               - - Gly Glu Gly His Phe Gly Lys Val Glu Leu Cy - #s Arg Tyr Asp Pro         Glu                                                                                              885  - #               890  - #               895              - - Gly Asp Asn Thr Gly Glu Gln Val Ala Val Ly - #s Ser Leu Lys Pro Glu                   900      - #           905      - #           910                   - - Ser Gly Gly Asn His Ile Ala Asp Leu Lys Ly - #s Glu Ile Glu Ile Leu               915          - #       920          - #       925                       - - Arg Asn Leu Tyr His Glu Asn Ile Val Lys Ty - #r Lys Gly Ile Cys Met           930              - #   935              - #   940                           - - Glu Asp Gly Gly Asn Gly Ile Lys Leu Ile Me - #t Glu Phe Leu Pro Ser       945                 9 - #50                 9 - #55                 9 -       #60                                                                               - - Gly Ser Leu Lys Glu Tyr Leu Pro Lys Asn Ly - #s Asn Lys Ile Asn         Leu                                                                                              965  - #               970  - #               975              - - Lys Gln Gln Leu Lys Tyr Ala Ile Gln Ile Cy - #s Lys Gly Met Asp Tyr                   980      - #           985      - #           990                   - - Leu Gly Ser Arg Gln Tyr Val His Arg Asp Le - #u Ala Ala Arg Asn Val               995          - #       1000          - #      1005                      - - Leu Val Glu Ser Glu His Gln Val Lys Ile Gl - #y Asp Phe Gly Leu Thr           1010             - #   1015              - #  1020                          - - Lys Ala Ile Glu Thr Asp Lys Glu Tyr Tyr Th - #r Val Lys Asp Asp Arg       1025                1030 - #                1035 - #               1040         - - Asp Ser Pro Val Phe Trp Tyr Ala Pro Glu Cy - #s Leu Ile Gln Cys Lys                       1045 - #               1050  - #              1055              - - Phe Tyr Ile Ala Ser Asp Val Trp Ser Phe Gl - #y Val Thr Leu His Glu                   1060     - #           1065      - #          1070                  - - Leu Leu Thr Tyr Cys Asp Ser Asp Ser Phe Pr - #o Met Ala Leu Phe Leu               1075         - #       1080          - #      1085                      - - Lys Met Ile Gly Pro Thr His Gly Gln Met Th - #r Val Thr Arg Leu Val           1090             - #   1095              - #  1100                          - - Asn Thr Leu Lys Glu Gly Lys Arg Leu Pro Cy - #s Pro Pro Asn Cys Pro       1105                1110 - #                1115 - #               1120         - - Asp Glu Val Tyr Gln Leu Met Arg Lys Cys Tr - #p Glu Phe Gln Pro Ser                       1125 - #               1130  - #              1135              - - Asn Arg Thr Thr Phe Gln Asn Leu Ile Glu Gl - #y Phe Glu Ala Leu Leu                   1140     - #           1145      - #          1150                  - - Lys                                                                        - -  - - (2) INFORMATION FOR SEQ ID NO:15:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 17 amino - #acids                                                  (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:                               - - Ala Lys Leu Leu Pro Leu Asp Lys Asp Tyr Ty - #r Val Val Arg Glu Pro         1               5 - #                 10 - #                 15               - - Gly                                                                        - -  - - (2) INFORMATION FOR SEQ ID NO:16:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 1099 amino - #acids                                                (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: protein                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:                               - - Met Ala Pro Pro Ser Glu Glu Thr Pro Leu Il - #e Pro Gln Arg Ser Cys       1               5   - #                10  - #                15                - - Ser Leu Ser Ser Ser Glu Ala Gly Ala Leu Hi - #s Val Leu Leu Pro Pro                   20      - #            25      - #            30                    - - Arg Gly Pro Gly Pro Pro Gln Arg Leu Ser Ph - #e Ser Phe Gly Asp Tyr               35          - #        40          - #        45                        - - Leu Ala Glu Asp Leu Cys Val Arg Ala Ala Ly - #s Ala Cys Gly Ile Leu           50              - #    55              - #    60                            - - Pro Val Tyr His Ser Leu Phe Ala Leu Ala Th - #r Glu Asp Phe Ser Cys       65                  - #70                  - #75                  - #80         - - Trp Phe Pro Pro Ser His Ile Phe Cys Ile Gl - #u Asp Val Asp Thr Gln                       85  - #                90  - #                95                - - Val Leu Val Tyr Arg Leu Arg Phe Tyr Phe Pr - #o Asp Trp Phe Gly Leu                   100      - #           105      - #           110                   - - Glu Thr Cys His Arg Phe Gly Leu Arg Lys As - #p Leu Thr Ser Ala Ile               115          - #       120          - #       125                       - - Leu Asp Leu His Val Leu Glu His Leu Phe Al - #a Gln His Arg Ser Asp           130              - #   135              - #   140                           - - Leu Val Ser Gly Arg Leu Pro Val Gly Leu Se - #r Met Lys Glu Gln Gly       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Glu Phe Leu Ser Leu Ala Val Leu Asp Leu Al - #a Gln Met Ala Arg         Glu                                                                                              165  - #               170  - #               175              - - Gln Ala Gln Arg Pro Gly Glu Leu Leu Lys Th - #r Val Ser Tyr Lys Ala                   180      - #           185      - #           190                   - - Cys Leu Pro Pro Ser Leu Arg Asp Val Ile Gl - #n Gly Gln Asn Phe Val               195          - #       200          - #       205                       - - Thr Arg Arg Arg Ile Arg Arg Thr Val Val Le - #u Ala Leu Leu Pro Cys           210              - #   215              - #   220                           - - Gly Arg Leu Pro Gly Arg Pro Tyr Ala Leu Me - #t Ala Lys Tyr Ile Leu       225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - Asp Leu Glu Arg Leu His Pro Ala Ala Thr Th - #r Glu Thr Phe Arg         Val                                                                                              245  - #               250  - #               255              - - Gly Leu Pro Gly Ala Gln Glu Glu Pro Gly Le - #u Leu Arg Val Ala Gly                   260      - #           265      - #           270                   - - Asp Asn Gly Ile Pro Trp Ser Ser Asn Asp Gl - #u Leu Phe Gln Thr Phe               275          - #       280          - #       285                       - - Cys Asp Phe Pro Glu Ile Val Asp Val Ser Il - #e Asn Gln Ala Pro Arg           290              - #   295              - #   300                           - - Val Gly Pro Ala Gly Glu His Arg Leu Val Th - #r Val Thr Arg Met Asp       305                 3 - #10                 3 - #15                 3 -       #20                                                                               - - Gly His Ile Leu Glu Ala Glu Phe Pro Gly Le - #u Pro Glu Ala Leu         Ser                                                                                              325  - #               330  - #               335              - - Phe Val Ala Leu Val Asp Gly Tyr Phe Arg Le - #u Ile Cys Asp Ser Arg                   340      - #           345      - #           350                   - - His Tyr Phe Cys Lys Glu Val Ala Pro Pro Ar - #g Leu Leu Glu Glu Glu               355          - #       360          - #       365                       - - Ala Asp Val Cys His Gly Pro Ile Thr Leu As - #p Phe Ala Ile His Lys           370              - #   375              - #   380                           - - Leu Lys Ala Ala Gly Ser Leu Pro Gly Thr Ty - #r Ile Leu Arg Arg Ser       385                 3 - #90                 3 - #95                 4 -       #00                                                                               - - Pro Gln Asp Tyr Asp Ser Phe Leu Leu Thr Al - #a Cys Val Gln Thr         Pro                                                                                              405  - #               410  - #               415              - - Leu Gly Pro Asp Tyr Lys Gly Cys Leu Ile Ar - #g Gln Asp Pro Ser Gly                   420      - #           425      - #           430                   - - Ala Phe Ser Leu Val Gly Leu Ser Gln Pro Hi - #s Arg Ser Leu Arg Glu               435          - #       440          - #       445                       - - Leu Leu Ala Ala Cys Trp Asn Ser Gly Leu Ar - #g Val Asp Gly Ala Ala           450              - #   455              - #   460                           - - Leu Tyr Leu Thr Ser Cys Cys Ala Pro Arg Pr - #o Lys Glu Lys Ser Asn       465                 4 - #70                 4 - #75                 4 -       #80                                                                               - - Leu Ile Val Val Arg Arg Gly Cys Asn Pro Al - #a Pro Ala Pro Gly         Cys                                                                                              485  - #               490  - #               495              - - Ser Pro Ser Cys Cys Ala Leu Thr Gln Leu Se - #r Phe His Thr Ile Pro                   500      - #           505      - #           510                   - - Thr Asp Ser Leu Glu Trp His Glu Asn Leu Gl - #y His Gly Ser Phe Thr               515          - #       520          - #       525                       - - Lys Ile Phe Arg Gly Ser Arg Arg Glu Val Va - #l Asp Gly Glu Thr His           530              - #   535              - #   540                           - - Asp Ser Glu Val Leu Leu Lys Val Met Asp Se - #r Arg His Arg Asn Cys       545                 5 - #50                 5 - #55                 5 -       #60                                                                               - - Met Glu Ser Phe Leu Glu Ala Ala Ser Leu Me - #t Ser Gln Val Ser         Tyr                                                                                              565  - #               570  - #               575              - - Pro His Leu Val Leu Leu His Gly Val Cys Me - #t Ala Gly Asp Ser Ile                   580      - #           585      - #           590                   - - Met Val Gln Glu Phe Val Tyr Leu Gly Ala Il - #e Asp Met Tyr Leu Arg               595          - #       600          - #       605                       - - Lys Arg Gly His Leu Val Ser Ala Ser Trp Ly - #s Leu Gln Val Thr Lys           610              - #   615              - #   620                           - - Gln Leu Ala Tyr Ala Leu Asn Tyr Leu Glu As - #p Lys Gly Leu Pro His       625                 6 - #30                 6 - #35                 6 -       #40                                                                               - - Gly Asn Val Ser Ala Arg Lys Val Leu Leu Al - #a Arg Glu Gly Gly         Asp                                                                                              645  - #               650  - #               655              - - Gly Asn Pro Pro Phe Ile Lys Leu Ser Asp Pr - #o Gly Val Ser Pro Thr                   660      - #           665      - #           670                   - - Val Leu Ser Leu Glu Met Leu Thr Asp Arg Il - #e Pro Trp Val Ala Pro               675          - #       680          - #       685                       - - Glu Cys Leu Gln Glu Ala Gln Thr Leu Cys Le - #u Glu Ala Asp Lys Trp           690              - #   695              - #   700                           - - Gly Phe Gly Ala Thr Thr Trp Glu Val Phe Gl - #n Arg Gly Pro Ala His       705                 7 - #10                 7 - #15                 7 -       #20                                                                               - - Ile Thr Ser Leu Glu Pro Ala Lys Lys Leu Ly - #s Phe Tyr Glu Asp         Gln                                                                                              725  - #               730  - #               735              - - Gly Gln Leu Pro Ala Leu Lys Trp Thr Glu Le - #u Ala Gly Leu Ile Thr                   740      - #           745      - #           750                   - - Gln Cys Met Ala Tyr Asp Pro Gly Arg Arg Pr - #o Ser Phe Arg Ala Ile               755          - #       760          - #       765                       - - Leu Arg Asp Leu Asn Gly Leu Ile Thr Ser As - #p Tyr Glu Leu Leu Ser           770              - #   775              - #   780                           - - Asp Pro Thr Pro Gly Ile Pro Ser Pro Arg As - #p Glu Leu Cys Val Ala       785                 7 - #90                 7 - #95                 8 -       #00                                                                               - - Gly Ala Gln Leu Tyr Ala Cys Gln Asp Pro Al - #a Ile Phe Glu Glu         Arg                                                                                              805  - #               810  - #               815              - - His Leu Lys Tyr Ile Ser Leu Leu Gly Lys Gl - #y Asn Phe Gly Ser Val                   820      - #           825      - #           830                   - - Glu Leu Cys Arg Tyr Asp Pro Leu Gly Asp As - #n Thr Gly Pro Leu Val               835          - #       840          - #       845                       - - Ala Val Lys Gln Leu Gln His Ser Val Pro As - #p Gln Gln Arg Asp Phe           850              - #   855              - #   860                           - - Gln Arg Glu Ile Gln Ile Leu Lys Ala Leu Hi - #s Ser Asp Phe Ile Val       865                 8 - #70                 8 - #75                 8 -       #80                                                                               - - Lys Tyr Arg Gly Val Ser Tyr Gly Pro Gly Ar - #g Gln Ser Leu Arg         Leu                                                                                              885  - #               890  - #               895              - - Val Met Glu Tyr Leu Pro Ser Gly Cys Leu Ar - #g Asp Leu Leu Gln Arg                   900      - #           905      - #           910                   - - His Arg Gly Leu His Thr Asp Arg Leu Leu Le - #u Phe Ala Trp Gln Ile               915          - #       920          - #       925                       - - Cys Lys Gly Met Glu Tyr Leu Gly Ala Arg Ar - #g Cys Val His Arg Asp           930              - #   935              - #   940                           - - Leu Ala Ala Arg Asn Ile Leu Val Glu Ser Gl - #u Ala His Val Lys Ile       945                 9 - #50                 9 - #55                 9 -       #60                                                                               - - Ala Asp Phe Gly Leu Ala Lys Leu Leu Pro Le - #u Gly Lys Asp Tyr         Tyr                                                                                              965  - #               970  - #               975              - - Val Val Arg Glu Pro Gly Gln Ser Pro Ile Ph - #e Trp Tyr Ala Pro Glu                   980      - #           985      - #           990                   - - Ser Leu Ser Asp Asn Ile Phe Ser Arg Gln Se - #r Asp Val Trp Ser Phe               995          - #       1000          - #      1005                      - - Gly Val Val Leu Tyr Glu Leu Phe Thr Tyr Cy - #s Asp Lys Ser Cys Ser           1010             - #   1015              - #  1020                          - - Pro Ser Ala Glu Phe Leu Arg Met Met Gly Pr - #o Glu Arg Glu Gly Pro       1025                1030 - #                1035 - #               1040         - - Pro Leu Cys Arg Leu Leu Glu Leu Leu Ala Gl - #u Gly Arg Arg Leu Pro                       1045 - #               1050  - #              1055              - - Pro Pro Pro Thr Cys Pro Thr Glu Val Gln Gl - #u Leu Met Gln Leu Cys                   1060     - #           1065      - #          1070                  - - Trp Ala Pro Glu Pro His Asp Arg Pro Ala Ph - #e Ala Thr Leu Ser Pro               1075         - #       1080          - #      1085                      - - Gln Leu Asp Pro Leu Trp Arg Gly Arg Pro Gl - #y                               1090             - #   1095                                               __________________________________________________________________________ 

What is claimed is:
 1. An isolated DNA molecule comprising a DNA sequence encoding the Jak 3 kinase amino acid sequence of FIG. 6 (SEQ ID NO:16).
 2. An isolated DNA molecule comprising a DNA sequence encoding an amino acid sequence corresponding to Jak3 kinase wherein there is one conservative amino acid substitution of the amino acid sequence of SEQ ID NO:16.
 3. An isolated DNA molecule wherein said molecule encodes a Jak3 kinase that is at least 80% homologous to the amino acid sequence of SEQ ID NO:
 16. 4. An isolated DNA molecule wherein said molecule encodes a Jak3 kinase that is at least 80-99% homologous to the amino acid sequence of SEQ ID NO:16.
 5. The isolated DNA molecule of claim 4, wherein said molecule encodes a Jak3 kinase that is at least 95% homologous to the amino acid sequence of SEQ ID NO:
 16. 6. The isolated DNA molecule of claim 4, wherein said molecule encodes a Jak3 kinase that is at least 99% homologous to the amino acid sequence of SEQ ID NO:
 16. 7. An expression vector, comprising the isolated DNA molecule of any one of claims 1, 3, 4, 5, or 6 wherein said vector expresses said Jak3 kinase in a host cell.
 8. An isolated host cell comprising an expression vector of claim
 7. 